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1. Both biological and practical considerations favor fluorescence in situ hybridization 
(FISH) as the preferable technique for targeted detection of translocations in mature 
B cell lymphomas (this thesis). 
2. The application of FISH on routinely processed paraffin tissue samples represents a 
considerable advance in the application of molecular biology in clinical pathology (this 
thesis). 
3. Chromosomal breakpoints in MYC gene are highly associated with Burkitt lymphoma, 
however they are not a disease specific marker (this thesis). 
4. In adult patients, B cell lymphomas with Burkitt-like morphology may often represent 
transformed NHL (this thesis). 
5. Cyclin D1deregulation is an essential oncogenic event in multiple myeloma patients 
that is triggered by t(11 ;14)(q13;q32), but also by a yet unknown mechanism often 
associated with chromosome 11 trisomy (this thesis). 
6. Deregulation of essential oncogenes often represents a functional endpoint of various 
genetic lesions (development). 
7. Chromosomal translocations are a hallmark of most B cell lymphomas, however 
additional genetic and epigenetic events are indispensable in lymphomagenesis 
( development). 
8. I have never let my schooling interfere with my education. Mark Twain 
9. No one can make you feel inferior without your consent. Eleanor Roosevelt 
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B cell development and classification and B cell neoplasms 
B cell neoplasms represent a clonal proliferation of B cells and in many respect appear to 
recapitulate stages of normal 8-cell development, ranging from precursor B cells to mature plasma cells. 1 •2•3 
The capability of B cells to respond specifically to an ultimate variety of antigenic stimuli depends on the 
expression of an immunoglobulin (lg) molecule on the cell surface that serves as a B cell antigen receptor 
(BCR).3 Therefore, the formation and expression of BCR is a critically important event in the differentiation 
and maturation of B cells. Apart from BCR expression, this process involves changes in cytomorphology and 
homing that are correlated to many changes in gene mRNA and protein expression. 3·4 The development of 
B cell begins within the bone marrow with formation of the hypervariable regions of heavy chain and li�ht 
chain lg genes that potentially can recognize foreign antigens by a process called V(D)J recombination. 3• •6•7 
The variable region genes of heavy chain (lgH) are assembled from variable (V), diversity (D) and joining (J) 
elements and those of the light chain (K or J.) by V and J elements. In the germline configuration there are 
many different V, D and J elements (for the lgH gene, respectively 40-46 VH, 25 DH and 6 JH elements). 
Upon rearrangement in precursor ·a-cells there is an almost random assembly of these elements with 
deletion of the DNA located between them, and additional nucleotide insertion, resulting is an almost 
indefinitive number of possibilities, for all lg loci estimated at >1012 . Each precursor B cell generates a 
particular set of genes that encodes a distinct lg molecule. Only these B cells that acquire heavy- and light 
chain variable regions genes that can be translated into protein (dependent on a correct reading frame) 
survive, leave the bone marrow and form mature narve B cells. Cells with out-of-frame rearrangement die by 
programmed cell death. 8-cells, expressing auto-reactive receptors either are also eventually removed by 
apoptosis or undergo secondary V(D)J rearrangements. Na"ive circulating B cells can be recruited into the 
germinal centers (GC) of secondary lymphoid organs8, i.e. lymph nodes, the spleen, and mucosa associated 
lymphoid tissue (MALT), where during the course of a T cell dependent immune response they undergo 
further genomic modification of their BCR by somatic hypermutation and class switch recombination (CSR). 
Somatic hypermutation is a process by which mutations (mainly single nucleotide exchanyes, but also 
deletions and duplication) are inserted into (mainly) the variable region of the lg genes.9•1 0• 1 As a result, 
antibody variants with different affinities to the antigen are generated, and cells expressing BCR with a 
relatively high affinity to the respective antigen are positively selected. GC B cells undergo several rounds of 
proliferation and selection, and eventually the cells expressing favorable mutants leave the GC and 
differentiate into long lived plasma cells or memory B cells. However, by far most GC B cells acquire 
unfavorable mutations and undergo apoptosis, a process which is facilitated by the temporary 
downregulation of the anti-apoptotic bcl-2 protein. Besides this process of affinity maturation, a fraction of GC 
B cells is submitted to immunoglobulin class switch recombination with respective changes of the isotype of 
the expressed BCR (from lgM/lgD to lgG, lgA or lgE). CSR results in different effector functions of the 
antibody for instance because of the different complement binding characteristics of the isotypes.12• 13 At the 
molecular level, Cµ and Cl> genes that are originally expressed by all narve B cells are replaced by a Cy, Ca 
or CE gene a recombination event that deletes the DNA between repeated sequences (called switch regions) 
located upstream of each constant gene. In consequence, both the mutation status of the variable heavy 
chain genes as well as the isotype expression of the lymphoma cells represent useful markers of the 
different stages of B cell development 3•5 : the presence of 'ongoing' mutations that vary between lymphoma 
cells but are clonally related, indicates a GC origin, a homogeneous mutational status of the variable heavy­
chain region denotes a post-Ge origin, and the lack of any mutations assumes a pre-GC stage of the tumor 
(see Figure 1 ). 
The recently published World Health Organization (WHO) classification of non Hodgkin's lymphoma (NHL) 
represents a significant advance in our ability to understand, identify and therefore, treat different specific 
lymphoma entities. It is based on the concept of the clinicopathologic entities in which histology, 
immunophenotype, (molecular) genetic data as well as clinical features are integrated, but also taking into 
account the putative cell of origin of different NHL.1 
7 






















Schematic representation of different 
stages of B cell development. 
Corresponding lymphoma subtypes 
are listed below the arrowed line. 
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An excellent example of this successful approach is the current diagnosis and classification of 
mantle cell lymphoma (MCL} with a morphology and immunophenotype corresponding to its origin of narve 
B-cells of the follicular mantle zone.1•1�·15 The translocation t(11;14}(q13;q32} that results in cyclin 01 
expression represents a genetic hallmark and the disease. The median age of patients is about 65 years with 
a marked male preponderance and a poor clinical outcome with a median overall survival of 3.0 to 3.5 years. 
In spite of all recent research in the field, the normal cell counterpart of some entities remains to be 
defined- e.g. the corresponding putative cell of origin of hairy cell leukemia (HCL} has not been identified, 
although most data suggest a late postgerminal center derivation of the tumor cells. 16• 17 These investigations 
also revealed some unexpected findings, for instance recent reports indicate that about 50% of the B-cell 
chronic lymphocytic leukemia (B-CLL} cases carry unmutated lgV genes and derive from narve B cells, while 
the rest of the CLL cases resemble memory B cells with mutated lgV genes. Gene expression profiling of 
CLL indicates a rather homogeneous phenotype related to memory B-cells, however, with some essential 
differences in BCR signaling between the two subtx.ges. Importantly, patients with mutated and unmutated 
CLL have a significantly different clinical outcome. 1 • 2 
Diffuse large B-cell lymphoma (DLBCL} is also a heterogeneous entity not only in morphology, 
immunophenotype and genetics, but also in respect to the gene expression profile and the presumptive cell 
of origin. There are at least 2 and possibly more, molecular subtypes: lymphomas with a germinal center B 
cell-like profile of gene expression (GCB profile), that resemble reactive germinal center cells, and 
lymphomas that express genes more related to activated B-cells (ABC profile} of post germinal center 
origin.23-26 
Chromosomal translocations in B-non-Hodgkin's lymphoma 
During the past decade, extensive data have been collected indicating the association of certain 
recurrent, sometimes entity defining genetic abnormalities with different hematopoietic neoplasias. 1• 5• 27•31 
Many of these abnormalities include chromosomal translocations, deletions, amplifications and mutations 
which are involved in the pathogenesis of the disease through mechanisms including activation of a proto­
oncogene, disruption of a tumor suppressor gene or generation of a fusion gene with "gain of function" pro­
oncogenic activity. In most mature B-cell neoplasms chromosomal translocations result in the transcriptional 
deregulation of an oncogene by juxtaposing it to regulatory sequences of genes that are constitutively 
expressed in mature B cells, most often the lg genes (Table 2, Figure 2).5• 27• 31 
The important oncogenes described up to date include BCL 1/CCND1 at 11q13 involved in mantle 
cell lymphoma (MCL} and some multiple myelomas (MM), BCL2 at 18q21 rearranged in almost all follicular 
lymphoma (FL) and some DLBCL, c-MYC at 8q24 involved in almost all Burkitt's lymphoma (BL), few 
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DLBCL, and rare cases of (transformed) FL as well as clinical accelerated MM, BCL6 at 3q27 involved in 
more than on third of DLBCL and few FL, MAL T1 on 18q21, rearranged in variable percenlaf1e of MALT 
lymphomas, CCDN3 on 6p21, FGFR3/MMSET on 4p16, c- maf in 16q23 rearranged in MM 31• 2• ss-a, (see 
Table 1). 
Table 1 Non-random chromosomal translocatlons in mature B neoplasms 
Chromosomal Gene function B-NHL frequency references 
translocation subcategory 
t(14;18)(q32;q21) BCL2 anti-apoptotic protein FL 80-90% 1,35-37 
and variants DLBCL 20-30% 
CLL <1% 
1(1 ;22)(q22;q11) FCGR2B low affinity lg Fe receptor FL, DLBCL <1% 62-64 
t(8;14)(q24;q32) MYC transcription factor BL -100% 1,31,32,35,3 
and variants DLBCL 5-10% 7-46 
FL <1% 
MM 
t(3;14)(q27;q32) BCL6 transcriptional repressor DLBCL 40% 1,35,50-55 
and variants FL ?% 
t(11;14)(q13;q32) CCND1 G1 eye/in MCL >95% 1,14,31,32 
MM -20% 
t(9;14)(p13;q32) PAX5 transcription factor variant SLL not 49 
established 
t(11;18)(q21;q21) APl2/MALT1 anti-apoptosis protein MALT -30%* 56-58 
t(14;15)(q32;q11-13) BCL8 DLBCL -4% 65 
1(1 ;14)(q21 ;q32) MUC1 cell surface receptors DLBCL <1% 66 
tf1;141(o22;a32) BCL10 aoootosis regu/atoN orotein MALT 67 
t(14;18)(q32;q21) MALT1 MALT -20%* co 
t(14;19Ua32;a13) BCL3 IKB CWSLL <5% 69 
t(4;14)(p16;q32) FGFR3/MMSET MM 15-20% 59 
t(14;16)(q32;q23) c-maf transcription factor MM 2-10% 60 
and variant 
t(6;14)(p21 ;q32) CyclinD3 Cell cycle protein MM 3-4% 61 
t(6;14)(p25;q32) MUM1//RF-4 interferon regulatory factor MM not 70 
established 
der7q21 CDK6 cell cycle kinase splenic MZL 60-70% 71,72 
FL - Follicular lymphoma; DLBCL - diffuse large B cell lymphoma; CLL - chronic lymphocytic leukemia; BL - Burkitt lymphoma; MM -
multiple myeloma; MALT - mucosa-associated lymphoid tissue lymphoma; SLL - small lymphocytic lymphoma; MZL - marginal zone 
lymphoma 
Three enhancers are known to regulate lgH expression in B cells and subsequently are involved in a 
translocation event leading to oncogene deregulation: the intronic enhancer (Eµ) located in the intron 
between the JH and switch µ sequences and the two 3' lgH enhancers downstream of the alpha genes (Ea1 
and Ea2). In case of a break in the lgH locus, these enhancers become differently positioned: in case of a 
breakpoint in the V,D or J elements, all three enhancers are juxtaposed to the oncogene; in case of a 
breakpoint in Sµ both Ea1 and Ea2 are juxtaposed and in case of a break in many downstream constant 
genes only Ea2 is juxtaposed to the gene. Thus, in case of a reciprocal translocation within a switch region 
these enhancers become dissociated on each derivative chromosome, therefore (onco)genes on both alleles 
may become deregulated by such a translocation event.5• 73•74 Similarly to the lgH enhancers, lg K and A light 
chain genes are also involved in chromosomal translocations, although with a relatively low frequency. 
Translocations resulting in the generation of a fusion gene are more common in leukemias and in T cell 
lymphomas 75 with two exceptions in mature B cell lyml)homa: the 1(11 ;18)(q21 ;q21) with an 
API/MAL T158and t(2;17)(p23;q23) with clathrin/ALK fusion product 76(Figure 2). 
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Figure 2 illustrated two models of 
chromosomal translocation. Most 
commonly in mature B cell neoplasm the 
coding sequences of one gene are 
juxtaposed and subsequently 
deregulated by the regulatory sequences 
of the translocation partner. Another 
option is a generation of a fusion gene 
from the coding sequences of both 
tr==i.n�lnr-.idinn n�rtnFu·� 
Transcriptional deregulation Fusion protein 
The pathogenetic role of chromosomal translocations is demonstrated by in vitro transformation 
studies and experiments in transgenic animal model. 77•52 These experimental models indicate that 
chromosomal translocations contribute to lymphoma development, however, are not sufficient to cause it, 
which is consistent with the general requirement of multiple genetic lesions in tumorigenesis. In line with this 
view, some of the most common translocations in B cell lymphoma have also been detected as rare 
somatically acquired events in healthy volunteers. 83 The mechanisms by which chromosomal translocations 
occur are poorly understood, although with respect to the lg loci, they appear to be associated with a 
dysfunction of the genetic remodeling mechanisms operating in normal lymphoid cells, including the lg gene 
rearrangements (VDJ and class switch recombination) and somatic hypermutation.5 Correspondingly, 
different chromosomal translocations occur at different stages of B-cell development. For example, the 
breakpoints of the t(14;18) in FL, t(11;14) in MCL and t(1;14) in MALT show structural features suggesting a 
generation from an aberrant VDJ recombination attempt in bone marrow precursor B cells.5·84-86 Breakpoints 
in most lgH translocations in MM, 3q27 translocations in DLBCL and t(8;14) in sporadic BL are located within 
lg switch regions, therefore, they likely have been generated by aberrant isotype switching 5•31 •4 1 • 49• 97•92 in 
germinal center B cells. The location of certain translocation breakpoints {e.g. t(8;14 ) in endemic BL, some 
t(3;14) in DLBCL 5• 41 } in already rearranged VDJ genes that contain somatic hypermutations, suggests that 
they are mediated by an aberrant somatic hypermutation machinery during the germinal center reaction. 
Detection of the chromosomal translocation 
Conventional cytogenetic analysis represents a "gold standard" for detection of recurrent genetic 
lesions and in addition provides an overview on the complete karyotype.36• 93• 94 However, it is laborious and 
time consuming and requires viable, dividing cells from fresh tissue samples. Its rate of success largely 
varies depending on the availability of proliferating tumor cells and the quality and number of the metaphase 
chromosomes. Of note, there may be a selective growth advantage of residual normal cells in the culture 
which may dilute out the clone and hence the relevant karyotypic abnormality. In addition, many tumors have 
numerous and complex chromosomal rearrangements, including non-reciprocal rearrangements that 
complicate the identification of specific chromosomes and diagnostic abnormalities. Often rearrangements 
involve chromosomal bands of similar size and staining patterns (e.g. t(12;21 )(p12;q21) in pediatic acute 
lymphoblastic leukemia)95 or that are poorly stained (e.g. subtelomeric regions) and therefore invisible by 
standard G-banding. Thus, some important recurrent translocations were selectively overlooked in 
conventional karyotypes, for instance the t(4;14)/FGFR3/MUMSET and t(14;16)/c-maf in MM,56•60•62 as well 
as many 3q27/BCL6 translocations in DLBCL and FL.55 
Molecular methods as Southern blot and the polymerase chain reaction (PCR) represent important 
tools for detection of chromosomal translocations in B-NHL.32•96-99 PCR has the advantage of speed and 
sensitivity, and needs very little patient's material. At the genomic level it can be performed if both 
chromosomal partners are known and the breakpoints are clustered. In case of a fusion transcript like the 
t(11;18) in MALT lymphomas, the translocation can be much easier detected at the RNA level by RT-PCR. 
PCR detection at the genomic level is severely hampered by the lack of local clustering in many NHL 
translocations (e.g. the BCL 1/ CCND1 and MYC translocation breakpoints are dispersed over regions of 
10 
more than 300 kbj100-1 05and by the fact that some genes involved in translocations (e.g. BCL6) can be 
juxtaposed to multiple translocation partners. 1 06• 1 07 Therefore, to reach a detection rate that is acceptable for 
dia�nostic settings, multiple primer pairs and more sophisticated long distance PCR protocols are needed. 
42• 
9 1 • Many clustered breakpoints are relatively easy to detect by Southern blot analysis and restriction length 
analysis (e.g. MBR/8Cl6 breakpoints in DLBCL), however others (e.g. MYC breakpoints in most endemic 
Burkitt lymphomas) 1 02• 1 03 extend beyond the length of the DNA fragments generated by the restriction 
enzymes and labeled by the genomic probes. Therefore, the use PCR and Southern blot analysis for regular 
detection of the translocations in B cell neoplasia is difficult and complex in the majority of the cases. As an 
alternative, pulsed-field gel electrophoresis (PFGE) has been used to detect breakpoints, however, this 
technically demanding method is not applicable in a diagnostic setting. 
In some instances, an abnormal expression pattern of the RNA or protein product strongly correlates 
with the presence of an underlying genetic lesion. Aberrant gene expression on the RNA level may then be 
quantified by real-time PCR or microarray gene expression studies. 1 08•1 09 An example is the detection of 
cyclin D1 by RT-PCR in leukemic cells of mantle cell lymphoma, used as a diagnostic tool by especially 
hematoloaists. Overexpression of the gene product can be detected by conventional immunohistochemistry 
as well.1 1 0' 
This latter approach as used by most pathologists has the major advantage that is easily applicable 
in a routine pathology setting and that it also provides information about the tissue distribution, as well as the 
cellular and subcellular localization of the oncogenic proteins. Some conditions facilitate the use of these 
assays: it is especially useful in cases where the gene involved in the chromosomal rearrangement is not 
expressed by the normal haematopoietic cells. This is the case for cyclin D1 and ALK. 1 1 1  Other proteins 
have a restricted expression pattern in normal cells (e.g. BCL2 labels mantle zone B cells and T cells but not 
the normal germinal centres) and in consequence their abnormal distribution may indicate the presence of a 
genetic lesion and malignancy (e.g. BCL2 labeling of the neoplastic follicles of FL).1 12"1 1 3 In other cases an 
altered subcellular localization of the gene product might hint to a specific translocation: wild type BLC10 is 
localized in the cytoplasm but aberrant nuclear BCL 10 expression in MALT lymphomas 1 14 is associated with 
t(1;14) and t(11;18) translocations, both resulting in NF-KB activation. Similarly, different patterns of ALK 
protein expression in the tumor cells (cytoplasmic and nuclear, versus ftranular, membranous or an other 
localization) hint at the involvement of specific fusion partners of ALK 1 In contrast, immunocytochemical 
studies of widely expressed gene products (e.g. MYC)1 1 0  generally have little clinical value. Thus, in some 
diseases there is a strong correlation between the underlying genetic lesion and aberrant gene expression 
(e.g. cyclin D1 expression and t(11;14) in MCL) 1 1 6•1 1 7  making the method valuable in regular diagnostic 
practice, in other diseases the use is restricted to certain considerations of differential diagnoses (e.g. BCL2 
expression and t(14;18) in FL versus follicular hyperplasia) 1 •33• 1 1 3, while there is no such correlation in many 
other diseases such as DLBCL. Therefore, breakpoint analysis can be complemented but not simply 
replaced by RT-PCR or immunohistochemistry for the respective oncogene products and gene expression 
should be interpreted in the context of the individual malignancy. Although BCL2 expression is not directly 
correlated with t(14;18) in DLBCL, recent data indicate that the genetic lesions and the expression of the 
respective protein and RNA might be of interest for their prognostic value. Thus, BCL2 expression in the 
context of a 1(14;18) in DLBCL confers a germinal center B cell-like profile of gene expression (GCB profile) 
and correspondingly a favorable outcome, while BCL2 expression without a t(14;18) is more related to NF-kB 
activation in activated 8-cells (ABC profile) and a poor survival. 35• 1 1 11-120 
Fluorescence in situ hybridization - general principles and application 
Fluorescence in situ hybridization (FISH) is a relatively simple technique that allows targeted 
detection of both numerical and defined structural chromosomal abnormalities and the technique also 
provides information at the single-cell leve1.121 •124 FISH is based on the same principle as Southern blot 
analysis, namely the ability of single-stranded test DNA to anneal to complementary target DNA sequences. 
The test DNA, referred to as a probe, is labeled through incorporation of reporter molecules and the reaction 
is 'in situ' visualized and localized by direct or indirect immunofluorescence. FISH can be applied on intact 
chromosomes of metaphase cell preparations, interphase nuclei obtained from imprints, cell suspensions, 
frozen tissue or paraffin tissue blocks, on already cut paraffin tissue sections, or on isolated DNA molecules, 
the latter mostly called DNA fibre FISH. 
As a cytogenetic method, FISH is performed on metaphase preparations supplementary to banding 
analysis with a superior sensitivity for detection of both numerical and structural aberrations. Different types 
of probes can be used, i.e. whole chromosome probes (chromosome painting), centromeric probes or locus 
specific probes. Due to the high degree of DNA condensation, the resolution of metaphase FISH is 2-3 Mb 
and small size probes can be used with acceptable efficiency. Multicolor metaphase FISH (M-FISH/SKY) 
1 25'126 utilizes differentially labeled whole chromosome probes for each individual chromosome or each 
chromosomal arm and thereby provides simultaneous information over the complete karyotype. This method 
dramatically improves the sensitivity of the conventional banding analysis. It is valuable for identification of 
structural abnormalities that are too small to be detected by conventional cytogenetics such as insertions and 
characterization of marker chromosomes and/or complex karyotypes. However, the method shares all 
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limitations of the banding analysis, e.g. the need of viable dividing target cells and their possible selection 
due to a growth disadvantage, and the method also needs well stretched chromosomes to allow a 
reasonable resolution. 
Fibre FISH is a molecular method applied on mechanically stretched DNA molecules that are 
isolated from fresh or frozen cell and/or tissue samples and immobilized on glass object slides.127• 128 The 
method is useful for fine mapping of the deletions, insertions and chromosomal translocations at a level of 5 
to several hundreds kilobases, but due to the technical difficulties the method is not useful as a diagnostic 
tool in daily practice. 
lnterphase FISH provides a unique possibility for targeted detection and quantification of defined 
numerical and structural aberrations in non-dividing or terminally differentiated cells. Since the technique is 
relatively rapid and straightforward, with a high sensitivity and specificity, different interphase FISH strategies 
have been developed and extensively applied on nuclear suspensions of fresh or frozen cell and/or tissue 
samples and cytological imprints. 121 -124 The regular use on routine paraffin embedded tissue samples is 
impaired by technical problems (e.g. weak or /and inconsistent hybridization signal, low signal to noise ratio, 
ambiguities in interpreting the results), and therefore, its use has mostly been restricted to the detection of 
numerical chromosomal aberrations in solid cancer. The variable success rates may be related to a 
combination of factors including the small size of the targets, their degradation and / or masking during 
fixation and the further processing of the sample as well as the use of a relatively insensitive detection 
systems and fluorescence microscope equipment. More recently, we and other groups reported on the 
successful aoplication of this method on nuclei isolated from paraffin tissue blocks and/or paraffin tissue 
sections.129•1 :ls 
lnterphase FISH on formalin fixed, paraffin tissue samples - technical and methodological 
considerations 
The introduction of the interphase FISH protocols for paraffin tissue samples offers an important tool 
for detection of chromosomal aberrations, since these methods allow the use of samples that are not 
selected by the restricted availability of fresh or frozen tissue. This refers to biopsy samples from distant and/ 
or small laboratories where storage and transportation of frozen tissue is difficult, retrospective and 
multicentre studies, referral cases, serial samples from relatively rare disorders, and the increasing number 
of small biopsies (endoscopic, needle, stereotactic) that are entirely fixed for diagnostic purpose. 
To obtain consistent, reproducible hybridization signals on fixed, paraffin embedded tissue samples 
various FISH approaches have been used. One option is the implementation of �robes annealing to large 
repetitive DNA sequences, resulting in strong and easily detectable signals.1 30•1 3 1 • 1 3•1 37•1 38 Indeed, probes for 
repetitive a -satellite peri-centromeric DNA targets have been extensively used for the detection of numerical 
aberrations on archived samples, but also in combination with a locus specific probe to detect chromosomal 
breakpoints.1 30• 1 3 1 •1 38 Alternatively, large insert clones such as multi-yeast artificial chromosome (YAC) 
constructs (with a total length of hundreds of kb's to one or more Mb) have been applied as locus specific 
probes.1 33• 1 37 Both the use of peri-centromeric probes and large multi-YAC probes have important 
disadvantages. The pericentromeric regions are mostly far away from the breakpoint under study, resulting in 
considerable distances between the signal and studied target in the relatively decondensed DNA of 
interphase nuclei. YAC probes cover large regions of DNA that contain much "junk" DNA full of partially 
repetitive DNA sequences. These sequences cause a high background upon hybridization, while if 
appropriately blocked reduce the intensity of the specific signal. 
In general, various factors such the physical distance between the probes, degree of chromatin 
condensation and molecular structure of the region will be of influence on the FISH signals, and especially 
will determine whether FISH signals generated by two probes will co-localize or segregate in interphase 
nuclei. Thus, segregation and co-localization of distant probes as mentioned above might be relatively 
fortuitous in interphase nuclei and give rise to ambiguities in the interpretation of the results.1 38 Furthermore, 
neither of these approaches do allow exact localization of the breakpoint, which is increasingly important 
since some genomic areas contain a high density of genes that all might be involved in a translocation. A 
different option to the use of these probes annealing to large DNA targets, is the development of optimized 
FISH protocols for fixed, paraffin embedded tissue samples that integrate different pre-treatment and 
denaturation steps, in combination with sensitive detection systems and software. This approach allows the 
use of relatively small probes devoid of repetitive sequences that directly target the region of interest. 
For detection of translocation breakpoints in interphase nuclei, various FISH strategies have been 
used 123 as schematically represented in Figure 3. Single probes spanning the entire breakpoint region that 
split in case of a translocation breakage and, therefore, generate an additional signal have been used.1 39 
However, this approach always needs to exclude polysomy. Furthermore, the size of the additional signal 
generated by the break depends on the exact position of the breakpoint and in some instances it can be very 
small and difficult to visualize. Finally, in approximately 10-20% of all translocations, the breakpoint is 
accompanied by deletion of the telomeric part, �enerating false negative results. 
Two color FISH breakpoint analysis 1 0•124 can be performed using a so-called co-localization or 
segregation assay. The co-localization assay makes use of probes that are specific for the two different loci 
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that are randomly local ized in normal nuclei but co-local ize upon a translocation event and juxtaposition of 
the two loci (Figure 3). The segregation assay makes use of two breakpoint flanking signals that co-local ize 
in normal nuclei but segregate upon chromosomal breakage (Figure 3). 
Both practical and biological considerations are in favor of the segregation assay over the co­
localization assay. First, due to the fortuitous overlap of signals in normal cel ls, the cut-off levels are 
generally much higher in F ISH co-local ization assays than in segregation assays. 1 40 Secondly, some authors 
described a non-random d istribution of the genes/loci that are involved in translocations in n ormal nuclei 
further increasing the chance of co-localization in normal cel ls. 141-1 43 Third ly· many target genes involved i n  
translocation (e.g .  MYC, BCL6) 41 · 1 06• 1 07 have variable translocation partners and in case of a co-localization 
assay probes for all possible partners should be applied . Final ly, in tissue sections both the cutting artifacts 
as wel l  as the overlap of nuclei generate loss as well as an increase of signals, the latter by accidental 
overlap. I n  case of a co-local ization assay and/or the use of breakpoint spanning probes, these patterns are 
d ifficult to recognize and interpret. This complexity is even increased in case of additional  numerical 
abnormal ities such as trisomy, which is not uncommon in cancer. More complex FISH approaches, 
representing different combinations of the above described , sign ificantly improve the specificity of the 
method , 123 however, they may result in complex patterns that in some instances are very d ifficult to analyze. 
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Chromosomal breakpoints in fixed, archived material  can be studied by interphase F ISH using 
routine paraffin tissue sections or nuclear preparations, isolated from paraffin tissue blocks. The major 
advantages of FISH on paraffin tissue sections are that the translocation carrying cel ls can be analyzed in 
their h istological context and that the method needs less patients' material .  I n  contrast, the use of isolated 
nuclear preparations 1 35· 136 avoids the artifacts generated by truncation and overlapping of the cel l  nuclei in 
tissue sections. 
Therefore, the scoring and interpretation of the hybridization signals is less complex and the method 
is preferable for detection of numerical aberrations or in  case of a combination of structural and numerical 
abnormalities of the targets. However, there is l ittle control on the d istribution and number of tumor nuclei in 
1 3  
the specimen during the procedure of isolating nuclei from tissue blocks, whi le F ISH on intact paraffin tissue 
sections allows a more supervised analysis of chromosomal aberrations.  
There are few data avai lable about possible procedures for evaluation and interpretation of the F ISH 
results in paraffin embedded tissue samples . One option is to adopt the scoring procedures and statistical 
methods regularly used for fresh or frozen cel l preparations 144 However, in tissue sections, sectioning 
artifacts and nuclear overlap result i n  more complex patterns, which makes the scoring more difficult and 
time consuming and drives the investigator to a certain bias to only score the ful ly interpretable n uclei .  In 
addition, the size of the tumor cel ls and the design of the probe sets may also affect the performance of the 
test on tissue sections much more than on isolated nuclei . For instance, a larger size of the nuclei and a 
longer physical distance between two probes obviously wil l result in more nuclei with an incomplete set of 
signal because of the cutting artifacts. An alternative approach is to use thick sections (15-20 µm) and to 
evaluate hybridization signals by confocal m icroscopy, avoiding section ing artifacts. 1 30•1 3 1  
Current view on the diagnosis and classification of Burkitt's lymphoma 
The eponym Burkitt's lymphoma (BL) underscores the un ique contribution of Denis Burkitt who 
described this tumor in chi ldren in equatorial Africa in 1961, delineated its geographical distribution and 
pioneered its treatment. 145 A few years later, a col laborative meeting of the World Health Organization and 
the I nternational Agency for Research in Cancer defined the characteristic morpholo�j of the tumor and also 
extended this definition to tumors that occasionally occur in all other parts the world. 1 Currently, three forms 
are recognized that occur in completely different cl inical settings: an endemic form (eBL) found in equatorial 
Africa and Papua New Guinea, a sporadic form (sBL) arising in  non-endemic areas, and human 
immunodeficiency virus associated BL (HIV-BL). 1 ' 2 • 40• 1 4 •1 50 Although BL comprises only 1-2% of all 
lymphomas in  Western Europe and USA, it represents 30-50% of childhood lymphomas in the same parts of 
the world, 25-35% of al l HIV related lymphomas and it is the most common childhood malignancy i n  the 
endemic areas. 
From a biological point of view BL is a relatively homo�eneous d isorder, derived from early 
centroblasts, present in the dark zone of normal germinal centers . 1 ·3·4 · 1 37 Correspondingly, BL express CD10 
and BCL6 and lack BCL2. Most cases carry a reciprocal translocation t(8;14)(q24;q32) or one of its variants 
resulting in the deregulation of MYC gene. 1 ·38-41 However, BL subtypes show certain differences in their 
cl in ical presentation , anatomical distribution of the disease, and association with Epstein-Barr virus (EBV) 
infection . 1 •2·1 48· 149 In addition, both the 8q24 and 14q32 chromosomal breakpoints differ at the molecu lar level 
in  endemic and sporadic BL patients 4 1 · 87·88" 90, suggesting that different mechan isms and therefore different 
stages of B-cell development are involved in the generation of chromosomal breakpoints 3·5· 41 (e.g. /GH 
hypermutation and /GH class switch recombination, respectively) . 
The terms Burkitt's l ike lymphoma has been introduced into the REAL classification scheme 2 for the 
cases that lie in this histologic "no man land" between BL and DLBCL, however it caused considerable 
confusion and misunderstanding in the field. 1 50· 1 51 In a key manuscript on the reproducibil ity and cl in ical 
impact of the REAL classification , an unacceptable low inter- and intra-observer agreement existed with 
respect to the histological recognition of Burkitt and Burkitt- l ike lymphoma. 1 51 
The recognition and prompt diagnosis of BL versus DLBCL bear important clin ical implications, as 
BL patients benefit from specific chemotherapeutic regimens. 1 52 · 1 53 The recent World Health Organization 
(WHO) classification took a view that 'atypical Burkitt's/Burkitt's l i ke lymphoma belong to the spectrum of the 
true Burkitt's, however, using more restricted criteria for its diagnosis: CD10+, BCL6+, BCL2-, Ki-67~100%. 1 
Furthermore, due to a certain  level of confusion in l iterature, the term Burkitt's l ike lymphoma was advised to 
be omitted. In addition , the presence of the t(8;14) or its variants is highly recommended for the diagnosis of 
BL and especially its morphological variant aBL . 1 · 1 50 However, to the best of our knowledge, the WHO 
recommendation on the presence of an 8q24/MYC breakpoint for the d ifferential diagnosis of BL versus 
DLBCL has not been validated on a large lymphoma series . Whi le most cases of BL apparently contain an 
Bq24/MYC breakpoint, this aberration is clearly not disease specific as it has been identified in 5-15% of 
DLBCL, in few FL in high-grade transformation, in MM with a cl inically accelerated phase, but also in rare 
case of lymphoblastic lymphoma/ leukemia and MCL in blastic transformation.42-48 • 1 54 
The scope of the thesis 
Chapter 1 of this thesis provides general information upon the chromosomal translocations in B- cel l 
lymphomas and their incorporation i nto current classification scheme. Different approaches for the detection 
of the chromosomal translocation are briefly reviewed with a special emphasis on the interphase FISH as a 
preferable detection strategy. Current idea upon the diagnosis and classification of Burkitt's lymphoma is 
further presented, pointing out possible diagnostic pitfalls and the impact of MYC translocation in this field. 
In chapters 2 and 3 the detection of the translocation breakpoints by segregation interphase FISH, 
using routine, fixed, paraffin-embedded tissue sections is described. Both studies used similar t issue pre­
treatment protocols; in chapter 2 large multi-YAC's constructs, flanking MYC breakpoint region were appl ied 
as a probes, while in chapter 3 three small locus specific probe sets , consisting of cosmids and PACs were 
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tested for the detection of the translocation breakpoints within BLC1, BCL2 and MYC breakpoint regions. 
With all probes we achieved consistent, sufficient FISH signals using various patients' samples. Different 
algorithms for evaluation and interpretation of FISH signals on routine paraffin sections were tested and 
compared. 
Detection of the MYC translocation breakpoints by interphase segregation FISH is the subject of 
chapter 4. Two probes sets, flanking the breakpoint region of more than 1 Mb were tested on 40 cell lines and 
lymphoma samples with 8q24 abnormalities and applied on a series of Burkitt's lymphoma from three 
different geographic regions. The presence of MYC translocation breakpoint is identified in conjunction to the 
morphology, immunophenotype, EBV association and geographical origin of the samples. Further analysis of 
the lymphoma samples that lie into the histological "no man's land" between adult BL and DLBCL is 
presented in chapter 5. Our data indicate that a subset of DLBCL share not only similar (immune-) 
morphology with BL but is also relatively frequently carry MYC translocation breakpoints. 
Four cases of non-endemic, EBV positive BL, associated with unusual florid granulomatous reaction 
are presented in chapter 6. 
Chapter 7 review the data on association of different lg translocation with MM and related plasma 
cell disorders, their impact on the biology of disease and patient's outcome. 
In chapter 8 we report on FISH analysis of the 11q13 breakpoint and the chromosome 11 numerical 
status in conjunction to Cyclin D1 RNA and protein expression in 46 MM samples. In addition in the same 
MM series we evaluate the concurrent expression of another 11q13 oncogene MYEOV. 
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Chapter 2 
MYC translocations in "Burkitt-like" lymphoma: a FISH study of paraffin embedded 
biopsy samples 
Eugenia Haralambieva, Georges Delsol , German Ott , Stefano Pileri , Phil ippe Gaulard , Jonathan A. 
Fletcher, Alison H.Banham , David Y. Mason 
The detection of chromosomal translocations by fluorescent in situ hybridisation (FISH) is widely 
performed, but very few studies have attempted to apply this technique to paraffin embedded routine biopsy 
samples. Here we report a study in which paraffin sections from 36 B cel l  lymphoma biopsies were analysed 
for the presence of MYC translocation breakpoints by means of FISH. The probes consisted of multi-YAC 
constructs that flanked the breakpoint region therefore separate upon a chromosomal translocation and 
generate split signals (rather than a more ambiguous "co-local isation" pattern obtained when the two 
partners in a hybrid gene are detected). Results were assessed by a simple approach that does not require 
counting of signal numbers per nucleus and is hence more appropriate for use in routine practice. A total of 
1 9  of the 36 lymphomas were scored as positive for MYC translocation, and this included 1 6  of the 20 cases 
in which classical cytogenetics had shown the presence of the (8; 1 4) translocation (or one of its two 
variants). We conclude that this two-colour "split signal technique" based on breakpoint flanking probes can 
be readily appl ied to detect chromosomal translocation in paraffin embedded tissue sections. Furthermore, 
our results suggest that the controversial category "Burkitt-like" lymphoma is a heterogeneous disease with 
respect to translocations involving the MYC oncogene, immunophenotype and clin ical features, at least in 
adult patients. 
British Journal of Haematology, 2003, 121: 49-56 
21 
Introduction 
In recent years non-random cytogenetic abnormalities (e.g. chromosomal translocations) have 
been identified in a wide variety of haematological malignancies and solid tumours, and they frequently 
contribute directly to neoplastic transformation (by activating a quiescent oncogene or by creating an 
oncogenic fusion protein). This direct causal role in the malignant process may account for the fact that these 
genetic lesions are often more specific as markers of different tumour categories than are morphological 
features or immunophenotypic profiles. 
Unfortunately cytogenetic analysis requires fresh tissue samples and is a labour intensive 
technique with a relatively low success rate, so that it is not readily applied in the setting of a routine 
pathology laboratory. A simpler alternative is to use fluorescence in situ hybridisation (FISH) on interphase 
nuclei to detect both numerical and known structural aberrations. However, this technique is also 
conventionally performed using fresh or frozen samples, limiting its suitability for the routine diagnostic 
laboratory. 
For this reason, attempts have been made to perform FISH on routine paraffin embedded tissue 
sections, but they have been hampered by technical problems (e.g. high background, weak or inconsistent 
hybridisation signals, ambiguities in interpreting the results), and relatively low success rates have been 
reported (Braziel et al, 2001; Nolte et al, 1996; Nolte et al, 1995). 
In this paper we report FISH analysis on a series of routine human lymphoma biopsies using 
large multi-YAC probe constructs that flank the MYC region on chromosome 8 where translocation 
breakpoints occur in Burkitt's lymphoma. These included lymphoma samples that had been studied 
previously by classical cytogenetic techniques, allowing validation of the FISH results. 
We also analysed 26 lymphoma cases of the controversial "Burkitt-like" category for the 
presence of MYC translocation, and correlated the results with immunophenotypic and clinical data. 
In many in situ hybridisation protocols the final evaluation involves extensive counting 
procedures to identify different signal patterns, followed by statistical analysis. However, in this study we 
adopted a non-numerical approach to reading the results, similar to the "eyeballing" assessment that 
pathologists make of immunohistochemically labelled sections in routine practice. 
Materials and Methods 
Tissue samples: 
Routinely processed formalin or Bouin's fixed paraffin embedded lymphoma samples were obtained 
from the authors' institutions. A total of 20 lymphoma samples (of different morphological subtypes) were 
selected on the basis that the (8;14) translocation (or a variant) had been previously detected by 
conventional cytogenetic analysis (see table1A). 
In addition, 16 samples of the controversial "Burkitt-like" category (BLL) were studied. (Table 1 B). 
These cases shared some of the features of Burkitt's lymphoma (BL), e.g. high proliferative pattern, "starry 
sky" appearance, cohesive growth pattern however differed in their cytomorphology and/or 
immunophenotypic prifile. 
lmmunophenotyping 
lmmunohistochemical labelling of paraffin sections was performed for the following markers: CD20 
(antibody L26), Ki-67 (antibody MIB1), bcl-2 (antibody 124) and CD10 (antibody 56C6). The first three 
antibodies were obtained from DAKO, the last one from Novacastra, Newcastle, UK. 
Cytogenetic studies 
These were performed by conventional methods using G- or R- binding techniques on cells isolated 
from fresh tissue biopsies. 
Fluorescence in situ hybridisation 
MYC probes: The probe sets consisted of two multi-YAC constructs flanking the MYC translocation 
breakpoint region of 1Mb. Their generation and detailed characterisation was described previously (Davison 
et al, 1998). Probes were labelled with either FITC or biotin by random priming (lnvitrogen, Paisley, UK). 
In situ hybridisation of paraffin sections: Dewaxed 4 µm paraffin sections were pressure cooked for 
8 minutes in a microwave oven in TrislEDTA buffer solution (50 mM Tris basel2 mM EDTA, pH9.0) to make 
target DNA accessible to the probes. Additional tissue pre-treatment included RNAase (Sigma, Poole, UK) 
100µm/ml/ 2 X standard citrate saline (SSC) pH 7.0 for 1 hour at 37°C, followed by 30 minutes incubation 
with pepsin (Sigma, Poole, UK), 50 µg/ml in 0.1 mM HCL at 37°C. To end the reaction, the slides were 
placed in a stop buffer (50 mM MgCl2/PBS) for 5 minutes and washed 2 X 5 minutes in PBS (pH 
7.4).Denaturing was performed in 70% formamide (Sigma, Poole, UK) /2 X SSC for 15 minutes at 80°C.The 
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MYC probes, diluted to 100-200 ng/µI in hybridisation mix (50% formamide/10% dextran sulphate / 2 x SSC) 
were denatured at 80°C for 5 minutes and an aliquot (10 µ1-20 µI) was then placed onto denatured slides. 
Hybridisation was performed in a humidified chamber overnight at 37°C. 
Post-hybridization washes and detection: After removing the coverslips, the slides were washed 2 X 
5 minutes in 0.4 X SSC/0.05% Tween 20 at 72°C, followed by 2 X 5 minute washes in 2 x SSC/0.05% 
Tween 20 and a final 5 minute wash in 4 X SSC /0.05% Tween 20. To avoid non-specific labelling, the slides 
were incubated in blocking buffer (5% non-fat milk, 2 X SSC /0.05% Tween 20) at 37°C for 10 minutes. 
Biotinylated probes were detected with Texas Red-Avidin DSC, biotinylated goat-anti-Avidin, and Texas Red­
Avidin DSC (Vector Laboratories, Burlingame, CA, USA). The signals of FITC-labelled probes were amplified 
by mouse anti-FITC and FITC-conjugated goat anti-mouse lg (DAKO). All the reagents were diluted in 
blocking buffer according to the manufacturer's instruction. The incubations were performed for 30 minutes 
at 37°C with intervening 3 X 5 minute washes in 4 X SSC/0.05% Tween 20. After counterstaining with DAPI 
the sections were mounted in DAKO fluorescence maunting medium (DAKO). 
Fluorescence microscopy 
The samples were evaluated on a Zeiss fluorescent microscope, equipped with Texas Red, FITC, 
DAPI and triple filters under 100 X oil objective. Images were recorded as previously described using 
Labvision and Photoshop software (lmprovision and Adobe respectively) running on an Apple Macintosh 
computer (Cheong et al, 1995). The samples were evaluated independently, without knowledge of the 
cytogenetic results. 
Resu lts 
Examples of the patterns observed are shown in Fig. 1. Areas that were suitable for assessment 
(e.g. in which tissue structure was intact) were evaluated, ignoring areas of poor hybridisation or over­
digestion and also areas where the tissue is too dense to give interpretable results. 
A simple approach to assessment of FISH results summarised in Fig. 2 was established. This 
scoring procedure eliminates from consideration cells that are uninterpretable because of artefactual 
phenomena (e.g. partial loss of the nucleus during sectioning, excessive non-specific signals) and lends itself 
to use in a routine diagnostic setting.Translocations involving the MYC gene were identified by this non­
numerical approach when a specific signal pattern (by co-localisation of one pair of signals and segregation 
of the other) was seen. The results from FISH, together with immunohistochemical and clinical data, are 
summarised in Table 1. Cells with a FISH pattern indicative of MYC translocation (Figs. 2 and 8) were 
detected in 16 out of the 20 cases in which the (8;14) translocation or one of its two variants had been 
detected previously by cytogenetics (see Figs. 1c and d). Among the 16 cases selected on the basis of 
"Burkitt-like" morphology, three samples showed evidence of translocation. In addition, one case showed 
amplification of the intact MYC gene, indicated by the presence of multiple co-localised signals (Fig 1 e). 
Twenty six lymphoma samples in this series that shared "Burkitt-like" features were reviewed 
together in relation to the presence or absence of a translocation involving MYC (as detected by classical 
cytogenetics, and/ or by FISH) (see table 1A and B). All but one patient were adults and in half of them 
translocations of MYC gene have been identified. The MYC breakpoint positive patients were slightly 
younger (age 12-80, median 40) than MYC breakpoint negative patients (34-90, median 58) with tendency of 
male prevalence (9 out of 13, MYC breakpoint positive, and 7 out 13, MYC negative) and extranodal site 
involvement (6 out of 13, translocation positive, and 3 out of 13 translocation negative). 
Twenty three of "Burkitt-like" lymphoma samples were immunostained for CD10, which was 
expressed in 9 out of 12 translocation positive cases and in 6 out of 11 translocation negative cases. The 
staining pattern for BCL2 showed the opposite tendency as 10 out of 13 translocation negative samples, 
expressed BCL2 in contrast to 5 out of 13 translocation negative samples. 
Six patients co-expressed CD10 and BCL2 and 1 lacked both markers. 
Discussion 
In recent years fluorescence in situ hybridisation has been used extensively to study genetic 
alterations in interphase cell preparations from smears, cell suspensions of cells isolated from fresh or frozen 
tissue samples. However most of the studies using FISH on routine processed paraffin embedded tissue 
have been restricted to the detection of numerical aberration (e.g. trisomy, chromosome loss), and there 
have been few reports of the detection of chromosome translocations in routine biopsy samples of tumour 
tissue (Biegel et al,995; Nolte et al, 1995, 1996; Davison et al, 1998; Zilmer et al, 1998; Birdsall et al,1999; 
Cataldo et al, 1999; Kumar et al, 1999; Li et al, 1999; Lu et al, 1999; Remstein et al, 2000; Braziel et al, 
2001). 
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Table 1 .  Details of lymphoma cases, investigated in the present study 
A. Cases, previously studied by cytogenetics 
Case Sex Age Site Histology Ki67 
CD10 
no. 
1 M 23 Liver Burkitt's 80% Pos 
2 M 32 Subcutaneous nodule Burkitt's 90% Pos 
3 M 77 Lymph node Burkitt's 90% Pos 
4 M 1 7  Stomach Burkitt-like 95% Pos 
5 M 24 Lymph node Burkitt-like 95% Pos 
6 M 35 Stomach Burkitt-like 95% Pos 
7 M 34 Stomach Burkitt-like 95% Pos 
8 F 70 Lymph node Burkitt-like 90% 
Neg 
9 M 41 Thoracic wall Burkitt-like 90% Pos 
10 M 80 Lymph node Burkitt-like 80% 
Pos 
1 1  F 56 Lymph node Burkitt-like 90% 
Neg 
12 M 56 Lymph node Burkitt-like 80% NA 
13  M 61 Lymph node DLBCL 80% Pos 
14 M 65 Retroperitoneal tumour DLBCL 90% NA 
15  M 57 Lymph node DLBCL 50% Neg 
16 F 47 Lymph node FL grade I l l  90% 
Pos 
17  F 72 Lymph node MCL, blastoid variant <50% 
Neg 
18 M 42 Lymph node MCL, blastoid variant <50% 
Neg 
19 F 63 Lymph node Burkitt-like <50% 
NA 
20 M 66 Lymph node DLBCL <50% 
Pos 
BCL2 FISH Karyotype 
Neg Pos 1(8;1 4) 
Neg Pos 1(8;22) 
Neg Pos 1(8;14) 
Neg Pos 1(8;1 4) 
Neg Pos 1(8;1 4) 
Neg Pos 1(8; 1 4) 
Neg Pos 1(8;1 4) 
Pos Pos 1(8;1 4) 
Neg Pos 1(8;1 4) 
Pos Pos 1(8;1 4) 
Pos Neg 18; 1 4) 
Pos Pos 1(8; 1 4) 
Pos Pos 1(2;8) 
Pos Pos 1(8;22) 
Pos Pos 1(8; 1 4) 
Neg Pos 1(8; 1 4) 
Pos Pos 1(8;22) 
Pos Neg 1(8; 1 4) 
Pos Neg 1(2;8) and t(8; 14) 
Pos Nea t(8;22) 
B. Large B cell lymphomas (not studied by cytogenetics) that showed "Burkitt-like" or "atypical 
Burkitt's" features 
Case Sex Age Site Ki67 CD10 BCL2 
FISH 
no. 
21 F 21 Large intestine 95% Pos Neg 
Pos 
22 F 42 Stomach 95% Pos Neg 
Neg 
23 M 64 Lymph node 50% NA Pos 
Neg * 
24 F 67 Ovary 90% NA Pos 
Neg 
25 F 34 Small intestine 95% Pos Neg 
Neg 
26 F 91 Lymph node 80% Neg Pos 
Neg 
27 M 49 Lymph node 80% Neg Pos 
Neg 
28 F 79 Lymph node 90% Pos Pos 
Neg 
29 M NA Lymph node 90% Neg Pos 
Neg 
30 F NA Lymph node 99% Pos Pos 
Neg 
31 M 62 Lymph node 85% Pos Pos 
Neg 
32 M 34 Lymph node 95% Pos Neg 
Neg 
33 M 55 Lymph node 95% Neg Pos 
Neg 
34 M 23 Lymph node 95% Pos Neg 
Pos 
35 M 12 Tonsil 95% Neg Neg 
Pos 
36 M 62 Lymph node 95% Neg Pos 
Neg 
• - amphficat,on of MYC gene; DLBCL - Diffuse large 8-cell lymphoma; FL - Follicular lym
phoma; 
MCL- Mantle cell lymphoma; NA - Data not available. 
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In the present study we report the use of this approach to detect translocations involving the MYC 
gene in routine lymphoma tissue sections, obtained from several different laboratories. The technique we 
used differed in several respects from previous reports. Firstly, several FISH studies have been performed 
on isolated nuclei obtained by dissociation from paraffin sections (Colleoni et al, 2000; Kumar et al, 1999; Li 
et al, 1999; Poetsch et al, 1999; Remstein et al, 2000). However the application of FISH on routine paraffin 
sections allow to study the translocations in their histological context, needs less patients material and is 
more close to the routine pathology settings. To avoid problems of truncation of the nuclei some studies 
(Aubele et al, 1997; D'Alessandro et al, 1997) report on the use of thick (i.e. 15 - 20µm) sections. Of note, 
this approach hampers hybridisation efficiency in addition and needs special equipment (confocal 
microscope) for evaluation of the results, which would make again the technique of little use in a routine 
context. 
In the present study we evaluated and analysed the results on conventional computer-based 
fluorescence microscopy system, which has already been used extensively in one of the authors' 
laboratories for evaluating and recording immunofluorescent labelling of paraffin embedded tissue sections 
(Mason et al, 2000). 
A scoring system such as the one proposed in this study (see Fig 2) should eliminate from 
consideration nuclei that are truncated or in which hybridisation has been sub-optimal. Evaluation of in situ 
hybridisation frequently involves counting the number of signals associated with a specified number of cells 
(including negative controls to establish threshold values) but in the present study we made a subjective 
assessment of the presence of a translocation involving the MYC gene, comparable to the non-numerical 
evaluation of immunohistological labelling with which pathologists are familiar. As a result of our experience 
we recommend the strategy summarised in Fig. 2, since in situ hybridisation is unlikely to be adopted in 
routine diagnostic practice if its results cannot be rapidly assessed. 
Finally in our study we used breakpoint flanking probes in FISH segregation assay instead of more 
traditional usage of probes that hybridise to the two different translocation partners in the hybrid gene (e.g. 
PML-RARA and BCR-ABL). This technique, in which co-localisation of the two probes indicates the 
presence of a translocation, has been widely used (Biegel et al, 1995; Birdsall et al, 1999; Colleoniet al, 
2000; Kumaret al, 1999; Lief al, 1999; Lu et al, 1999; Nolteet al, 1995; Taniwaki et al, 1995; Zilmer et al, 
1998). However it suffers from relatively high rate of false positivity due to random co-localisation of the 
signals in the interphase nuclei (Chase et al, 1997), and is likely to rise an even higher level of false positivity 
on tissue sections because of the overlapping of the nuclei. 
Of note, many genes involved in translocations (MYC, BCL6, ALK) have more than one 
translocations partners which is again in favour of the use of FISH segregation approach for regular 
detection of translocation breakpoints. 
More complex FISH approaches (e.g. additional probe labelled in a third colour and others) give rise 
to complicated and uninterpretable FISH results in tissue sections and do not seem appropriate for routine 
use. 
However in this study we used breakpoint flanking probes that produced bright contrasting signals 
on paraffin sections and are unlikely to generate false positive results. This FISH segregation approach has 
been used in studies of a number of genes involved in translocations, e.g. ALK (Cataldo et al, 1999), BCL-1 
(Coignet et al, 1996), MYC (Davison et al, 1998), EWS (Davison et al, 1998) and BCL-2 (Vaandrager et al, 
2000)) but its application on routine paraffin sections remained limited. 
The results we obtained in the present study suggest that technical obstacles related to the 
application of FISH technique on paraffin tissue could be avoided by using appropriate tissue pretreatment 
protocol. 
We analysed by means of FISH 36 routinely processed lymphoma samples for presence of MYC 
translocation breakpoint. However in 4 samples with previously proven translocation by conventional 
cytogenetics we fail to detect it by means of FISH. These samples are under further investigations. It is very 
unlikely MYC translocation breakpoint to be located out of the range of the probes as they flank a genomic 
region of more than 1 Mb 5' and 3' of the gene. It is possible the translocation to be confined to a small 
proportion of the tumour cells and to be missed in the process of evaluation of he samples. 
It is of interest that most of the unselected cases categorised as "Burkitt-like" lymphoma for 
which no cytogenetic data were available lacked evidence of MYC translocation. However, MYC breakpoint 
can clearly occur in such cases, since ten of the 20 lymphomas studied because they were known to carry 
an (8;14) translocation (or one of its variants) were classified as "Burkitt-like" tumours. The REAL 
classification took the view that lymphomas with "Burkitt-like" morphology probably belong to the spectrum of 
diffuse large cell lymphoma (Harris et al, 1994). However the category was not reproducible even between 
experienced haematopathologists (<50% agreement in the International Non-Hodgkin's Lymphoma Study). 
Moreover clinical data indicated that at least in children tumours classified as BLL behave as true BL. The 
recently published WHO classification implies more stringent criteria (Ki67 labelling index -100%) and 
categorises ·atypical Burkitt/Burkitt-like" lymphoma with true Burkitt's lymphoma (adding however that this 
term should be "reserved for cases with proven or strong presumptive evidence of MYC translocation").Our 
data on cases with "Burkitt-like" features, and data from Brazial et al (Braziel et al, 2001) who observed MYC 
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translocation in four of five such cases, indicate that some cases carry a breakpoint involving MYC but that 
others may lack this anomaly. Our results also suggest, in keeping with a previous study of Braziel et al 
(Brazielet al, 2001 ), that expression of CD1 O and absence of BCL-2 are features that tend to pick out some 
but not all of translocation-positive "Burkitt-like" neoplasm. However the patients in our series are clearly 
heterogeneous in respect to available clinical data, antigen expression profile and MYC translocation and 
seems not to represents disease entity. In addition high proliferative index shared by the tumours in our 
series could possibly be related to other underlying genetic lesions in cases lacking MYC translocation. Of 
note, MYC translocation is also not strictly disease specific and could occur in different disease entities (see 
table 1A). As the group included mainly adult patients ii would also clearly be of interest to analyse larger 
series including also young patients and to correlate the presence or absence of MYC breakpoint with clinical 
outcome. 
In conclusion, our study suggests that FISH analysis on paraffin embedded sections in 
technically feasible and could be performed in routine pathology settings both for diagnostic and research. 
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Figure 1 .  Dua l colour FISH segregation assay on 
routine paraffin embedded lymphoma biopsies using 
two MYC breakpoint flanking probes. Each part of 
the image (a - e) shows hybridisation signa ls of an 
area with the FITC-labelled probe (hybridising 
te lomeric to the breakpoint region,) with the Texas 
Red-labe lled probe (hybridising centromeric to the 
breakpoint region), and with both probes 
simu ltaneously. Al l images a lso show the DAPI 
nuclear counterstain. (a) Low power of a large B ce ll 
lymphoma. Many ce lls show co-loca lised red and 
green signa ls, indicating norma l cel ls (representative 
examp les arrowed). (b) A B ce l l lymphoma of 
"Burkitt like" morphology at higher power showing 
twe lve ce lls, a ll with coincident signa ls ,  indicating 
that this tumour, despite its morpho logy, probably 
does not carry one of the classical Burkitt's­
associated trans locations. (c and d) Two lymphomas 
showing a pair of segregated and a pair of co­
loca lised (arrowed), signals indicating mono-a l le lic 
translocation breakpoint involving the MYC gene. I n  
one o f  these cases, cytogenetic ana lysis had  been 
performed on fresh tissue and had shown the 
presence of an (8;1 4) trans location. (e) A large B 
cel l lymphoma, showing amplification of MYC, as 
indicated by mu ltiple co-loca lised signa ls. 
Figure 2. Strategy for eva luating FISH resu lts for 
translocation of the MYC gene in paraffin embedded 
tissue biopsies (and approach that shou ld be equa l ly 
app licable to other genes involved in trans locations). 
Step 1: The section is scanned for a nuclei which 
contain two specific, hybridisation signa ls with one of 
the probes (preferably the probe that gives the least 
non-specific background reactivity). This step selects 
nuclei that were likely lo contain both MYC a lle les 
and shou ld e liminate from further consideration 
nuclei in which one of the signa ls has been lost 
during tissue sectioning, or hybridisation was not 
efficient. Nuclei which show on ly one signa l or 
mu ltiple signa ls (1  and 2 respective ly) are not 
considered further. Exception are the nuclei showing 
mu ltiple specific signa ls for both probes were, 
indicating the presence of amplification.(3) 
Step 2: The fluorescent filter set is then changed lo 
view the signals from the other probe on any nuclei 
fu lfilling these criteria, but the resu lt is ignored if there 
is no signa l (4), on ly one signa l (5) or mu ltip le signa ls 
(6) (indicating excessive non-specific hybridisation). 
Step 3: The nucleus can then be assigned to one of 
two categories, representing the absence or 
presence of mono-a llelic MYC translocation 
breakpoint (7 and 8 respectively). 
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Chapter 3 
Detection of three common translocation breakpoints in non-Hodgkin's lymphomas 
by fluorescence in situ 
hybridization on routine paraffin-embedded tissue sections 
Eugenia Haralambieva, Karin Kleiverda, David Y Mason, Ed Schuuring, Philip M Kluin 
Non-random chromosomal translocations are specifically involved in the pathogenesis of many non­
Hodgkin's lymphomas and have clinical implications as diagnostic and/or prognostic markers. Their detection 
is often impaired by technical problems, including the distribution of the breakpoints over large genomic 
areas. This study reports a fluorescence in situ hybridization (FISH) method which allows the detection of 
specific chromosomal breakpoints in tissue sections from routinely fixed, paraffin-embedded samples. 
Hybridization was performed after damasking the DNA. Previously validated locus-specific probes (cosmids, 
PACs) flanking the BCL 1, BCL2 regions and similar new probes for the MYC breakpoint region were used. 
The cases studied were five mantle cell lymphomas (MCL) and five follicular lymphomas (FL), selected on 
the basis of a previously proved t(11 ;14) and t(14;18) and five randomly chosen Burkitt's lymphomas (BL), as 
well as 21 negative control samples. In all samples, hybridization signals of sufficient intensity were obtained. 
Three different algorithms were used to score the hybridization signals in tissue sections, two of them taking 
into account the nuclei and their signal distribution indicative of chromosomal break, and one only 
considering the colocalization or segregation of the signals. 
In control tissues, these algorithms resulted in cut-off levels of 9.1 %, 1.3%, or 10.0%. In the 15 
lymphoma samples the percentages of abnormal cells/signals ranged from 28% to 80%, 13% to 49%, and 
40% to 70%, respectively. The results indicate that small locus-specific probes can be used in FISH for 
regular detection of translocation breakpoints on routine paraffin tissue sections. 
J Pathol 2002; 198: 163-1 70 
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Introduction 
During the past decade the association of distinct types of non-Hodgkin's lymphomas (NHL} with 
certain recurrent genetic abnormalities has been extensively studied. Many of these abnormalities include 
chromosomal translocations which are involved in the pathogenesis of the disease, through mechanisms 
including activation of a proto-oncogene via transcriptional deregulation such as BCL 1/CCND1, BCL2, BCL6, 
MYC [1,2] or the generation of a fusion gene such as NPM-ALK [3]. Apart from their pathogenic relevance, 
many genetic lesions represent molecular markers of the disease and have diagnostic and clinical 
implications [4]. Conventional cytogenetic analysis is feasible in only a few cases, as it requires fresh tissue 
samples and dividing cells. On the other hand, the lack of local clustering of the breakpoints (e.g. 
BCL 1/CCND1 and MYC) and heterogeneity of the translocation partners (e.g. BCL6} make PCR and 
Southern blot less applicable for regular diagnostics [5,6]. In some instances, an abnormally expressed 
protein product, such as cyclin D1 in MCL, strongly indicates the presence of a translocation breakpoint and 
can be detected by immunohistochemistry. However, no such correlation exists in many other cases, such 
as BCL2 and BCL6 in diffuse large B cell lymphoma. Breakpoint analysis, therefore, cannot simply be 
replaced by immunohistochemistry for the respective oncogene products. Fluorescence in situ hybridization 
(FISH} is a relatively simple technique that allows the detection of both numerical and defined structural 
chromosomal abnormalities and also provides reliable information at the single-cell level [5,7]. It has been 
extensively applied on metaphase spreads or intact lnterphase nuclei obtained from imprints, cell 
suspensions, or frozen tissue. However, its application on routine paraffin-embedded tissue sections is 
impaired by technical problems, such as weak and/or inconsistent hybridization signals, low signal-to-noise 
ratio, and ambiguities in interpreting the results [8-14]. 
Here we report on the successful FISH analysis of three common chromosomal translocations on 
routine paraffin-embedded tissue sections. BCL 1, BCL2 (3' of the mbr/mcr region} and MYC translocation 
breakpoints were detected using small locus-specific probes including single PACs and cosmids. The probe 
sets for BCL 1 and BCL2 have already been extensively tested on nuclear suspensions from fresh or frozen 
tissue samples [15-17]. A full contig of MYC probes was mapped using DNA fibre FISH and an appropriate 
probe set was selected on the basis of the available literature on MYC breakpoints in non-endemic BL [18-
20]. Together with an additional probe set covering the far 5'region of MYC involved in endemic BL [18-21], 
it will be the subject of a more detailed study on BL (Haralambieva et al., in preparation}. 
Two-colour FISH breakpoint analysis can be performed using a colocalization assay with probes that 
are specific for the two different loci and that are randomly localized in normal nuclei, but colocalize upon 
chromosomal breakage and juxtaposition of the two loci; or a segregation assay in which two breakpoint 
flanking signals colocalize in normal nuclei, but segregate upon chromosomal breakage. Combinations of 
both assays are also possible. Segregation assays have a number of advantages over colocalization assays. 
Firstly, due to the fortuitous overlap of signals in normal cells, the cut-off levels are generally much higher in 
FISH colocalization assays than in segregation assays [22]. Secondly, some authors described a non­
random distribution in nuclei especially for the genes/loci that are involved in translocations, further 
increasing the chance of colocalization in normal cells [23-25]. Thirdly, some target genes such as MYC and 
ALK have variable partners to which they are juxtaposed and, in the case of a colocalization assay, probes 
for all partners should be used. Finally, in tissue sections, both cutting artefacts and the overlap of nuclei 
generate loss of signals, as well as additional fortuitous overlap. In a colocalization assay, these patterns are 
difficult to recognize and interpret. In contrast, using appropriate nearby probes in a segregation assay, each 
normal cell should be easily recognizable by the presence of one or two sets of overlapping signals and each 
single-coloured signal should indicate a chromosomal breakage. In the present study, a maximal distance of 
approximately 800 kb was chosen to avoid false segregation of signals in normal lnterphase nuclei. 
Several algorithms for the interpretation of the FISH results were tested, two of these taking into 
account the number and distribution of signals in each individual nucleus, and one considering only the 
presence of segregated versus colocalized signals, irrespective of their nuclear distribution. 
Materlals and methods 
Tissue samples 
Routinely processed paraffin-embedded biopsy samples of five patients with MCL, five patients with 
FL, and five non-endemic BL patients were retrieved from the files of the Department of Pathology, Leiden 
University Medical Centre, and the Department of Pathology, University Hospital Groningen, The 
Netherlands. The samples dated from 1986 to 2000 and were fixed in 10% phosphate-buffered formalin 
solution pH 7,0 and routinely processed in multiple pathology laboratories. All MCL and FL samples had 
characteristic morphological and immunophenotypic features [4,26] and were selected on the basis of 
previously demonstrated BCL 11/gH and BCL2llgH translocations, respectively [15-17]. All BL patients were 
children or young adults with an abdominal tumour, showing unambiguous morphological and 
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immunophenotypic characteristics of BL [4,26]. For controls we applied every probe set on paraffin sections 
of three hyperplastic tonsils and on sections of four other lymphomas in which the specific breakpoint was 
not expected; for instance, two MCL and two BL were used as negative tumour controls for the BCL2 probe 
set. 
Probe sets 
Originally, the two probe sets for BCL 1 (5' of CCND1 gene) and BCL2 (mbr/mcr region) were 
designed using a combination of DNA fibre FISH and lnterphase FISH [15-17]. In brief, for mapping of the 
probes and subsequent mapping of all possible breakpoints, DNA fibre FISH was used on normal and 
lymphoma DNA fibres, respectively. Based on these data, optimal probe sets for interphase FISH were 
selected (Figure 1, BCL 1 and BCL2). Subsequently, these sets have been extensively tested on large series 
of clinical material. For detection of the breakpoints in the immediate 5' region and the intron I region of MYC, 
as reported in most sporadic Burkitt's lymphomas [18-20], we selected two pooled cosmids (cos I CS and 
cos II F5) and PAC 11171<22 (Figure 1, MYC) which, according to the published data, should flank the 
breakpoint region in most nonendemic BL. 
All probes were labelled by standard nick translation with biotin-16-aUTP or digoxygenin-11-dUTP 
(Roche, Basel, Switzerland) and dissolved in the hybridization solution consisting of 50% formamide, 10% 
dextran sulphate, 50 mM sodium phosphate, and 2X standard saline citrate (SSC) pH 7.0. 
Sample preparation 
Approximately 4 µm thick tissue sections were placed on aminopropyltriethoxysilane (APES, Sigma­
Aldrich, Chemie, Steinheim, Germany) coated slides, dewaxed and rehydrated. The target demasking 
protocol consisted of 10 min pressure cooking in 50 mM Tris/2 mM EDTA buffer solution, pH 9.0, after which 
the slides were washed in 2X SSC. RNase treatment using 100 µg/ml RNase (Roche, Basel, Switzerland) 
was performed at 37°C for 1 h followed by enzymatic digestion with 0.1% pepsin (Sigma-Aldrich) pH 2.0 at 
37°C for 10 min. The tissue samples were then washed with phosphate-buffered saline (PBS) pH 7.4 and 
dehydrated in 70%, 90%, and 100% ethanol. Denaturing was performed on a slidewarmer at 80°C for 12 min 
in a solution containing 70% formamide, 50 mM sodium phosphate, 2X SSC, pH 7.0, under a coverslip. 
Slides were washed in ice-cold 2X SSC for 2 min, dehydrated in 70% (-20°C), 90%, and 100% ethanol and 
then airdried. 
Hybridization and detection 
Aliquots of labelled DNA of each probe were diluted to a final concentration of 3 ng/µI in 50-fold 
excess Human Cot 1 DNA (lnvitrogen Life Technologies, Paisley, UK) in hybridization solution, denatured at 
80°C for 8 min and annealed at 37°C for 30 min. Probe mixtures, 10-20 µI per section, were placed onto 
denatured slides and covered with glass coverslips. The hybridization was carried out in a humidified 
chamber at 37°C overnight. Excess of the probe was washed in 2X SSC/0.1%Tween (3 XS min at 37°C), 
0.1X SSC (3 X 5 min at 60°C) followed by Tris/NaCl/0.05% Tween, pH 7.5 for 5 min at room temperature. 
lmmunodetection was performed as previously described [27]. 
Evaluation 
Slides were analysed with a Leica DMRXA fluorescence microscope equipped with PL Fluotar 10x, 
40x and 100x objectives and triple band-pass filter for FITC, Texas Red and DAPI (Leica). For 
documentation, images were captured using a COHU 4910 series monochrome CCD camera (COHU, San 
Diego, CA) attached to the fluorescence microscope and Leica QFISH software (Leica Imaging Systems, 
Cambridge, UK). Images were processed with Adobe Photoshop (version 4.0; Adobe Systems, Mountain 
View, CA). 
Hybridization signals were enumerated in 200 morphologically intact nuclei for each sample. To 
avoid detection of signals in overlapping nuclei, an inherent problem in tissue sections, nuclei were counted 
mainly at the periphery of the section and/or at the places where a lower density enabled recognition of 
individual cells. Alternatively, 200 hybridization signals (single against colocalized) were counted in tissue 
sections without looking at the individual nuclei. Signals were considered colocalized when the distance 
between them was equal to or smaller than the size of one hybridization signal. 
Statistical analysis of the results was performed using the Mann-Whitney test for comparison of two 
independent groups. 
Results 
Hybridization efficiency and analysis In negative controls: For all probes, hybridization signals 
of sufficient intensity were obtained (Figure 2). No cases were excluded because of a weak signal. Of note, 
we observed no significant variation in hybridization efficiency related to the date and origin of the sample. 
Furthermore, the DNA damasking protocol allowed us to use a fixed pepsin concentration and digestion time. 
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Although in a pilot study a readable hybridization signal was obtained using probe sets consisting of 
two single cosmids, we used a single PAC and/or two pooled cosmids to obtain a comparable intensity of 
signals (Figures 1 and 2). As seen in Figure 1, the three probe sets had a separation of 250 kb for the BCL2 
mbr/mcr breakpoints, 400 kb for the MYC breakpoints, and 800 kb for BCL 1 breakpoints. In the 21 negative 
controls (for each breakpoint three tonsils and four lymphomas without a breakpoint) hybridized with these 
probe sets, segregated signals (see Figure 3, patterns C-H) were found in 1-7% of the nuclei (mean 4.0%, 
standard deviation 1. 7% ). Therefore, the cut-off level was set up at 9.1 % (mean plus three times standard 
deviation; see also Figure 4, BCL 1, BCL2, and MYC). There were minor differences between the three probe 
sets: with the BCL 1 probe set, single segregated signals were detected in 1-7% (mean 4.9%, standard 
deviation 1.9%) of the nuclei, with the BCL2 probe set in 1-4% (mean 3.0%, standard deviation 1.2%), and 
with the MYC probe set in 1-5% (mean 4.2%, standard deviation 1.5%) of the cells. These differences 
paralleled the different distances between the flanking probes for each probe set (Figure 1 ). Nuclei with two 
colocalized and two segregated signals (Figure 3, pattern C), recognized as the most stringent indication for 
a mono-allelic breakpoint, were exceedingly rare (0-1 %, mean 0.15%, standard deviation 0.37%; see also 
Figure 4, pattern C) in negative control tissue samples. A third option for evaluation of the FISH results is to 
score only the type of signal (colocalized against separated) without looking at individual cells and assuming 
that the presence of any single signal indicates a true breakpoint. In negative control tissues, 1-9% (mean 
3.7%, standard deviation 2.1%) single signals were counted and the threshold level was set at 10.1%. 
One follicular lymphoma, which initially was used as a negative control for assessment of MYC 
breakpoints, showed segregated MYC signals in 43% of the nuclei and segregated BCL2 signals in 68% of 
the nuclei. This case probably represented an FL with bi-allelic BCL2 and MYC breakpoints [28) and was 
therefore excluded from the control group for MYC. 
Detection of BCL1, BCL2 and MYC breakpoints In lymphomas: Breakage within the BCL1, 
BCL2, and MYC breakpoint region should result in segregation of one red and one green signal. However, 
due to the cutting artefacts and the admixture of normal cells, this will result in at least eight different signal 
patterns (Figure 3, patterns A-H, Figure 2B and C). In aneuploid tumours, even more patterns may be 
envisaged. 
The scoring results for five FL, BL, and MCL are presented in Figure 4. In all 15 tumour samples 
hybridized with the appropriate probe sets, segregated signals (patterns C-H) were detected in 28-80% 
(mean 55.7%, standard deviation 15.3%) of the counted nuclei. The highest percentages (58-80%, mean 
69.2%, standard deviation 8.9%) were found in five BL samples hybridized with the MYC breakpoint probe 
set, while in FL and MCL the segregation was found in 34-67% (mean 48.0%, standard deviation 14.6%) 
and 28-60% (mean 50.0%, standard deviation 13.5%) of the nuclei, respectively. For all probe sets, the 
counts were significantly higher than in control tissues (p < 0.001).The percentage of nuclei with the most 
stringent pattern indicative of a breakpoint, namely two colocalized and two segregated signals (Figure 4, 
BCL 1, BCL2, and MYC, pattern C), varied from 13% to 49% (mean 28.0%, standard deviation 9.0%) in the 
15 tumour samples. It was significantly higher than the threshold level (1.2%) observed in the negative 
controls (p < 0.001 ). Using the third algorithm, in which only the type of signal is evaluated (percentage of 
single and double, colocalized signals), without taking into account the distribution of signals in the cells), 
40-70% (mean 53.9%, standard deviation 8.3%) single signals were detected in the tumour samples, as 
opposed to the threshold of 10.1 % in the control samples (p < 0.001 ). 
Discussion 
We describe the successful application of interphase FISH detection of three common chromosomal 
translocations in routine paraffin tissue sections. Small locus-specific probes were used, two of three probe 
sets already having been extensively tested by conventional interphase FISH analysis on fresh nuclei. 
Currently, various FISH methods are used for the detection of chromosomal translocations in 
lnterphase nuclei obtained from cell suspensions, imprints, or frozen tissue. Some studies have reported the 
successful application of this technique either on nuclei isolated from paraffin tissue blocks or on tissue 
sections of paraffin-embedded samples [8-14,29,30). The major advantages of FISH on paraffin tissue 
sections are that the cells carrying the translocation can be analysed in a histological context and that less 
patients' material, including already available routine sections sent from elsewhere, can be used. There is a 
little control on the presence and number of tumour nuclei in the specimen during the procedure of isolating 
nuclei from tissue blocks, while paraffin tissue sections allow more supervised analysis. However, to the best 
of our knowledge, very few groups have been able to apply this technique in a routine diagnostic setting. The 
relatively low rate of success [8,9) may be related to a combination of factors including the small size of the 
targets, their degradation and/or masking during the fixation and further processing of the sample, and the 
use of relatively insensitive detection systems and fluorescence microscope equipment. Alternatively, large 
insert clones such as multi-yeast artificial chromosome (YAC) constructs (with a total length of hundreds of 
kb's) have been applied as locus-specific probes [13,14). Another option is the implementation of probes 
against repetitive DNA targets, as they result in strong and easily detectable signals. Indeed, probes for 
32 
repetitive 6-satellite peri-centromeric DNA targets have been used both in combination with and without a 
locus-specific probe to detect chromosomal breakpoints in paraffin-embedded tissue (11, 12]. Both the use of 
the large multi-YAC probes and the use of peri-centromeric probes have important disadvantages. Apart 
from the labour to deplete the YACs from repetitive DNA sequences to obtain relatively clean hybridization 
signals, the segregation and colocalization of such distant probes might be relatively fortuitous in interphase 
nuclei and g ive rise to ambiguous interpretation. Furthermore, neither of these approaches allows exact 
localization of the breakpoint, which is increasingly important since some genomic areas contain a high 
density of genes that might all be involved in a translocation. In contrast, the currently selected locus-specific 
probes allow detailed mapping of the breakpoints, as well as detection of small interstitial insertions and 
deletions (data not shown). 
Individual optimization of the protease digestion time and/or enzyme concentration is often 
necessary to obtain relatively good results in paraffin tissue sections (11,29]. This is a time-consuming 
procedure and needs relatively large amounts of patient material. In contrast, in almost all samples tested so 
far, the currently used simple DNA demasking protocol resulted in reproducible signals, i rrespective of the 
probe combinations or tissue samples. Some difficulties were encountered for Burkitt's lymphoma samples 
received from Africa, which might be due to excessively long fixation times or the use of other fixatives (data 
not shown) .  As the technique does not require special skills, consumables or equipment, and so far has been 
successfully applied to all three breakpoint regions on a consecutive series of more than 150 lymphoma and 
myeloma samples (Haralambieva et al. ,  in preparation), we believe that it can also be successfully applied to 
any other breakpoint. 
Theoretically, the most informative approach to evaluating the interphase FISH results is to count all 
nuclei with all different patterns of signals. However, this is a very complex and time-consuming approach, 
since there are at least eight different patterns (Figure 3) to be scored and even more in the event of there 
being additional numerical chromosomal aberrations. Another disadvantage is that, in seeking to recognize 
all patterns in single nuclei ,  the observer tends to score at places where the tissue is less dense, such as at 
the edges of tissue sections. A second approach is to evaluate only the most stringent pattern (Figure 3, 
pattern C) and to omit the nuclei with an incomplete set of signals. This results in a very low cut-off level 
(1.2%) but the procedure remains time consuming and difficult, driving the investigator to a certain bias. 
Additionally, possible aneusomy must be considered. The third approach is to count the type of signals 
(colocalized against single) without assessing the nuclei .  This is the most easy, non-selective approach, as it 
can be applied on the whole tissue section, even in areas with nuclear overlap, and since it is not influenced 
by aneusomy or other factors. In addition, the size of the tumour cells may also affect the performance of the 
test on tissue section; larger size obviously will result in more nuclei with an incomplete set of signals, 
because of the cutting artefacts. However, a high level of single split signals should promptly indicate the 
presence of translocation breakpoint. Single signals may also be caused by structural abnormalities different 
from translocation breakpoints, such as deletions in the target region). Obviously, these single signals must 
be discerned from single background signals, which indicates that the level of background signals must be 
assessed before counting.  
In conclusion, we have shown that the detection of chromosomal breakpoints on paraffin tissue 
sections by interphase FISH can be reliably performed in a diagnostic setting. We did not, however, 
investigate samples with focal involvement of tumour cells, for instance trephine biopsies with foci of MCL or 
FL ,  nor did we test the sensitivity of our assays in samples involved by minimal residual disease. 
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Figure 1. Schematic representation of the FISH probe sets for detection of the 
BCL 1 /CCNO/, BCL2 and MYC breakpoints. The probe sets were designed to flank the 
possible breakpoint regions as closely as possible, and their approximate positions are 
indicated on the map. They consist of differently labelled, in green (open bars) and red 
(dark bars), pooled cosmids and PACs . 
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Figure 2. (A and B) Comparison of the distribution of FISH signals in paraffin sections of a negative control tissue 
sample and Burkitt's lymphoma, respectively, using alternatively labelled (red and green) MYC flanking probes in a 
FISH segregation assay. Only colocalized green and red signals are identified in the negative control samples (A), 
representing the intact MYC loci. In contrast, a MYC translocation breakpoint in a Burkitt's lymphoma is easily 
recognized by the presence of scattered single red and green signals (8). (C) Composite picture of cell nuclei, 
displaying different patterns of hybridization signals. 1 :  nucleus with 2 intact MYC loci, representing a reactive cell in 
the lymphoma sample; 2: nucleus with mono-allelic breakpoint, recognized by segregated red and green signals and 
a normal set of colocalized signals; 3-5: examples of the cutting artefacts resulting in nuclei with other signal 
patterns 
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Figure 3. Schematic presentation of nuclei with different patterns of hybridization signals in 
tissue sections. Due to cutting artefacts, there are at least six more hybridization signal 
patterns to be evaluated in tissue sections than in intact lnterphase nuclei. (A-H) Different 
signal patterns in control tissue and in tumour samples with a mono-allelic chromosomal 
break. In tumour samples, pattern A represents the reactive cell compartment. Of note, more 
options must be considered in the event of numerical chromosomal aberrations 
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Figure 4. Scoring results in 
tumour samples and negative 
controls when hybridized with 
BCL 1 ,  BCL2, and MYC probe 
sets, as indicated in the boxes. 
(A-H) Different patterns as 
explained in Figure 3. The open 
and black bars represent the 
percentage of nuclei with a 
certain signal pattern in the 
tumour samples and negative 
controls, respectively. MCL: 
mantie cell lymphoma; FL: 
follicular lymphoma; BL: Burkitt's 
lymphoma. • A case of follicular 
lymphoma with both a BCL2 and 
a MYC breakpoint 
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Chapter 4 
lnterphase Fluorescence In Situ Hybridization for Detection of 8q24/MYC 
Breakpoints on Routine 
Histologic Sections: Validation in Burkitt Lymphomas from Three Geographic 
Regions 
Eugenia Haralambieva, Ed Schuuring, Stefano Rosati, Carel van Noesel,Patty Jansen, Inge Appel, Jeroen 
Guikema, Henry Wabinga, Luiz Fernando Bleggi-Torres, King Lam, Eva van den Berg, Clemens Mellink, 
Shams van Zelderen-Bhola, Philip Kluin 
A chromosomal translocation involving the MYC gene is characteristic of Burkitt lymphoma (BL) and 
represents a molecular disease marker with diagnostic and clinical implications. The detection of MYC 
breakpoints is hampered by technical problems, including the distribution of the breakpoints over a very large 
genomic region of approximately 1,000 kb. In this article, we report on the testing and validation of a 
segregation fluorescence in situ hybridization (FISH) assay for MYC breakpoints on a large series of BLs. A 
contig of overlapping genomic clones was generated, and two probe sets flanking the MYC gene were 
selected. Both probe sets were tested in an interphase FISH segregation assay on 8 B-cell lymphoma cell 
lines and 32 lymphoma samples with proved 8q24/MYC abnormalities and validated in 47 BLs from The 
Netherlands, Brazil, and Uganda. MYC translocation breakpoints were identified in 98% of the tumors of the 
test series and in 89% of the cases of the validation series. In 89% of all positive samples, the breakpoints 
were located between 190 kb 5' and 50 kb 3' of MYC. Nine cases had more distant breakpoints, and in one 
patient an insertion of MYC into the IGH region was detected. In two of the three BLs lacking CD10 
expression, no breakpoint could be detected, suggesting that CD10 is a discriminative marker of BL. We did 
not find consistent differences between BL and atypical BL in incidence of an MYC breakpoint. 
Genes Chromosomes Cancer. 2004;40:10-18 
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Introduction 
The eponym Burkitt lymphoma (BL) recognizes the unique contribution of Dennis Burkitt in  
describing the cl inical features of th is  tumor found in  children in equatorial Africa, del ineating its geographical 
distribution, and pioneering its treatment (Burkitt, 1958). Currently, BL is believed to occur in  three cl inical 
settings: an endemic form (eBL), found in equatorial Africa and New Guinea; a sporadic (sBL), or "non­
African," form, arising in nonendemic areas and a human immunodeficiency virus -associated form (HIV-BL; 
Wright, 1997; Diebold et al., 2001 ). Recognition and prompt diagnosis of BL are of cl in ical importance 
because it is a highly aggressive tumor that responds best to specific chemotherapeutic regimens that are 
different from those used for other aggressive B-cell lymphomas such as diffuse large B-cel l  lymphoma 
(DLBCL; Magrath et a l . ,  1996; Harris et al . ,  1999; Mead et al. , 2002). However, especially in (adult) patients 
outside Africa, the diagnosis of BL is not highly reproducible, even among experienced hematopathologists 
(Non-Hodgkin's Lymphoma Classification Project, 1997; Magrath et al . ,  2000). This is caused by the 
continuous histologic spectrum on which BL and DLBCL lie and by the partial ly overlapping histogenesis of 
both tumors. Ideally, the diagnosis of BL is based on cl in ical ,  morphologic, immunophenotypic, and 
cytogenetic criteria (Harris et al., 1 994, 1999; Diebold et al., 200 1 ). Indeed, the recent World Health 
Organization (WHO) classification recommended the presence of the t(8;14) or its variants t(2;8) and t(8;22) 
or of a MYC rearrangement as prerequisites for the diagnosis of BL and the morphologic variant, atypical 
Burkitt lymphoma (aBL; Diebold et a l . ,  2001 ). 
The translocations involving 8q24/MYC, which are a cytogenetic hal lmark of BL (Zech et a l . ,  1976; 
Dalla-Favera et al., 1982; Traub et al., 1982), resu lt in deregulation of the MYC gene by juxtaposition to 
immunoglobul in regulatory sequences and loss or disruption of its 5' regulatory sequences. In about 85% of 
cases of BL, the translocation partner of MYC is the immunoglobul in heavy-chain ( IGH) locus on 
chromosome 14, whereas, in the remaining 15%, the K and >. l ight-chain loci on chromosomes 2 and 22, 
respectively, are involved. Furthermore, the position of the breakpoints in both the 8q24/MYC and the IGH 
loci varies with the geographic origin of the tumor (Pelicci et al . ,  1986; Shiramizu et al . ,  1990, 1991 ). In  most 
non-African BLs, MYC breakpoints are within  intron I or the region immediately 5' of MYC, whereas in non­
African cases, they are d ispersed over a large genomic area 5' of MYC (Joos et al . ,  1992a, b). Variant 
translocations usually involve the 3' region of MYC and also are dispersed over a large genomic area of 
approximately 300 kb (Henglein et a l . ,  1989; Zeidler et al . ,  1994; Caria et a l . ,  2000). Burkitt lymphomas in 
South American patients harbor a mixed pattern of chromosomal breakpoints (Gutierrez et a l . ,  1992). 
Although cytogenetic analysis certainly has the advantage of detecting not only t(8; 14) and its 
variants but any other chromosomal aberration as wel l ,  this method is feasible only in  a l imited number of 
cases because it requ ires fresh tissue samples. Because of the variabil ity of the breakpoints, polymerase 
chain reaction (PCR) is difficult to apply for regular diagnostic purposes. Long-distance PCR assays can 
detect t(8;14) in sporadic BL (Akasaka et al . ,  1996; Basso et al . ,  1 999), but because of the position of the 
breakpoints, not in African BL. 
Fluorescence in s itu hybridization (FISH) is a preferable technique for detection of chromosomal 
breakpoints because this method al lows the detection of widely dispersed breakpoints. Additionally, it can be 
applied on routinely processed tissue sections of a formalin-fixed, paraffin-embedded specimen and 
therefore allows studying large series of unselected cases (Haralambieva et a l . ,  2002). 
Several groups reported on the detection of MYC translocations in BL using FISH (Ried et al., 1992; 
Veronese et al . ,  1995; Davison et al., 1998; Rack et al., 1998; Siebert et a l . ,  1 998). However, the method 
has been tested on a l imited number of cell l ines and/or primary BL samples, and its appl ication in the 
regular diagnosis of BL remains uncommon. 
Here we report on a FISH segregation assay for detection of MYC translocation breakpoints in a 
genomic region from 900 kb 5' to 450 kb 3' of the gene. Two probe sets were selected on the basis of the 
available literature on MYC breakpoints (Pel icci et a l . ,  1986; Henglein et a l . ,  1 989; Shiramizu et a l . ,  1991 ;  
Gutierrez et  al . ,  1992; Joos et  a l . ,  1992a, b; Zeidler et  al . ,  1994; Caria et  a l . ,  2000) and designed for a FISH 
segregation assay. Both probe sets were tested on 8 B-cell lymphoma-derived cel l l ines and 32 lymphoma 
samples with cytogenetically or molecularly proved 8q24/MYC abnormal ities and were validated on routinely 
processed tissue sections of 47 BUaBLs collected from The Netherlands, Brazil ,  and Uganda, being 
representative of sporadic, South American, and equatorial African Burkitt lymphomas, respectively. 
Materials and Methods 
Test Series: cell lines and B NHL patients with an Bq24/MYC abnormality: Seven B-cell 
lymphoma-derived cel l l ines with a previously cytogenetically identified t(8 ;14)  and the Namalwa cell l ine 
with a 8q24/MYC breakpoint that was detected by pulsed-field gel electrophoresis (Joos et al 1992b) were 
included. Daudi ,  Raj i ,  Namalwa, Jijoye, and BL65 were derived from African BL patients, Ramos and BL41 
were established from non-African BL patients ,  and Napi originated from a transformed fol l icular lymphoma 
(FL). All cell l ines were grown in RPMl-1640 medium supplemented with 10% calf serum (In Vitrogen Life 
Technologies, Paisley, UK). BL65 was provided by Dr. G. M. Lenoir (IARC, Lyon ,  France). Ramos and Jijoye 
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were purchased from the American Type Culture Collection (Manassas, VA) and BL41, Daudi, and Raji from 
the German Collection of Microorganisms and Cell Culture (Braunschweig, Germany). Napi was established 
at the Department of Hematology, Leiden University Medical Center (LUMC), Leiden, The Netherlands. 
Routinely processed paraffin-embedded biopsy samples from 32 lymphoma patients were selected 
on the basis of previously cytogenetically proved 8q24 abnormalities and retrieved from the files of the 
Department of Pathology, LUMC, Leiden; the Department of Pathology & Laboratory Medicine, University 
Hospital Groningen (AZG); and the Department of Pathology, University Medical Center (AMC), Amsterdam, 
The Netherlands. The samples were classified according to the WHO classification scheme (Diebold et al., 
2001) as BL (N = 14), aBL (N = 6), DLBCL (N = 8), FL (N = 3), or NHL not otherwise specified (N = 1). One 
aBL and one DLBCL presented in HIV-positive patients. All cases had a (8;14)(q24;q32) except for 2 cases 
with a variant t(8;22)(q24;q11 ), one with t(2;8)(p12;q24), one with del(8)(q24), and one with add(8)(q24). 
Validation Series: Burkitt and atypical Burkitt Lymphomas: Routinely processed, paraffin­
embedded biopsy samples from 47 BLs and aBLs were retrieved from the files of the Departments of 
Pathology of the LUMC, AZG, and AMC, as well as from the Dutch Childhood Oncology Group, The Hague, 
The Netherlands; the Department of Pathology, Mekerere University, Kampala, Uganda; and the Division of 
Anatomic Pathology, Hospital Nossa Senhora das Gracas, Curitiba, Brazil. All samples were reviewed and 
classified according to the recent WHO classification (E.H., S.R., and P.K.). Only lymphoma samples with a 
high proliferative rate (Ki67 labeling index > 95%) were studied. Samples with centroblastic and/or 
immunoblastic morphology were classified as DLBCL and subsequently excluded. Four patients (N11, N32, 
N36, N38; Table 1) were HIV-positive. 
Fluorescence in situ hybridization: To obtain appropriate FISH probes for the detection of 
breakpoints in the MYC region, we constructed a physical map by generating a contig of partially overlapping 
genomic clones in and around the MYC gene, using DNA fiber FISH (Fig. 1 ). 
Clone pHM-1 (3129) represents a 10-kb EcoRI/EcoRI fragment in pBR322 and contains the whole 
MYC gene (kindly provided by Dr. I. Laird, Leiden University Medical Center, Leiden, The Netherlands). The 
P1 clones ICRF7000G569 (8034) and ICRF7000G2350 (8035), which were reported to cover and flank the 
MYC gene (Feo et al., 1994), were purchased from the Reference Library Database (Berlin, Germany). 
Cosmid clone K880 (4540; Mautner et al., 1995) covers the MYC gene and its 3' region; it was provided by 
Dr. J. Mautner, Institute of Clinical Molecular Biology and Tumor Genetics, Munich, Germany. PAC103G5 
(4745), PAC117K22 (8071 ), and PAC124B14 (8072) were obtained from the RPCl-1 Human PAC Library of 
the Roswell Park Cancer Institute (available at the Leiden Genome Technology Center, Leiden, The 
Netherlands). PAC103G5 (4745) was identified by screening with the p8q290 probe from the MYC/BVR1 
region, and both PAC117K22 (8071) and PAC124B14 (8072) with p8q373/550 probes from the MYC/PVT1 
region (Henglein et al., 1989); probes were provided by Dr. M. Lipp, Ludwig-Maximilians-University, Munich, 
Germany. The cosmid clones cos-B11-I (4663), C11-I (4665), AS-II (4673), G11-1 (4666), B10- 1 1 1  (4674), A7-1 
(4662), A12-II (4669), C10-II (4676), G12-I (4667), 012-1 1 (4670), A1-I (4661), F9-II (4672), CB-I (4664), FS-11 
(4671), A7-1 1  (4668), and C4-III (4675) were obtained by subcloning of partially digested DNA from YAC 
clone yP72 (8045), provided by Dr. C. Croce (Jefferson Cancer Institute, Philadelphia, PA; Veronese et al., 
1995) in sCOGH6. The cosmid clones cos-H4.1, cos-P380J9, and cos-MYC72 (Siebert et al., 1998) were 
kindly provided by Dr. S. Joos (Deutsches Krebsforschungszentrum, Heidelberg, Germany). The BAC clones 
RP11-414A9 and RP11-351C8 were selected according to their location in the minimal tiling path 5' of MYC 
by use of MapViewer at www.ncbi.nih.gov (build 33) and purchased from BACPAC, Children's Hospital 
Oakland (Oakland, CA). 
DNA fiber FISH was used to map all genomic clones relative to pHM-1 (3129), K880 (4540), 
ICRF7000G569 (8034), and ICRF7000G2350 (8035). By comparing them with the already-established size 
markers for the 11q13 region (clones cos 6.22, cos 3.62, and cos 3.91, with a total length of 113.4 kb; 
Janssen et al., 2000) ascertained in cohybridization experiments, we determined the length of the combined 
signals of clones ICRF7000G2350 (8035), pHM-1 (3129), and PAC103G5 (4745) as 198.6 kb. These 3 
clones were subsequently used as internal size markers for assessment of the length of the entire region. 
Two probes for the IGH locus were selected for the MYC/IGH colocalization FISH assay. Cosmid 
cos lg6 covers the constant region of the immunoglobulin heavy-chain locus (Vaandrager et al., 1998) and 
was provided by Dr. T. Rabbits (MRC Center, Cambridge, UK). PAC27M16 (5093), located immediately 3' of 
the immunoglobulin heavy-chain locus (manuscript in preparation), was provided by Dr. D. Cox (Research 
Institute, Hospital for Sick Children, Toronto, Ontario, Canada). 
To achieve easily interpretable results on tissue sections, a two-color FISH segregation assay was 
designed, using breakpoint flanking probes that were labeled differently (Fig. 1) by standard nick translation 
with biotin-16-dUTP or digoxigenin-11-dUTP (Roche, Basel, Switzerland). Hybridization on DNA fibers, on 
interphase nuclei from frozen samples, and on routine paraffin tissue sections was performed as described 
previously (Vaandrager et al., 1996, 2000; Haralambieva et al., 2002). To obtain sufficient hybridization 
efficiency on some of the paraffin-embedded samples from Uganda, additional digestion by increasing the 
pepsin concentration (up to 5.0%) and incubation time (up to 1 hr) was necessary. 
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Three hyperplastic tonsils, 2 mantle cell lymphomas, and 2 FLs without a MYC breakpoint were used 
as negative controls. The cut off level for every probe set was determined for the percentage of cell nuclei 
with at least a single segregated signal (Haralambieva et al., 2002, method 1) in these 7 negative controls 
and inferred from the mean + 3 standard deviations. For this purpose, 200 nuclei were counted. Samples 
with a segregated signal level above the cut off level were considered positive for a breakpoint. 
EBER in situ hybridization: In situ hybridization was performed for detection of EBER 1-2 mRNAs 
using a fluorescein-conjugated EBV (EBER) peptide nucleic acid probe (Dako, Glostrup, Denmark) on 
paraffin tissue sections. Alkaline phosphatase- conjugated anti-FITC sheep lgG Fab fragments (Roche) 
were used in a second step. The visualization was performed with 5-bromo-4-chloro-3-indolyl-phosphatase, 
4-nitroblue tetrazolium (Roche, Mannheim, Germany), and MgCl2. 
lmmunohistochemistry: lmmunohistochemistry was performed on formalin-fixed, paraffin­
embedded tissue samples. Briefly, 4-µm sections were heat-retrieved for antigen in a buffer solution of 50 
mM Tris and 2 mM EDTA, pH 9, for 30 min in a microwave oven. The following markers were analyzed: CD 
20 (clone L26, dilution 1:100; Dako), Ki-67 (clone MIB-1, dilution 1:100; Dako), CD10 (clone 56C6, dilution 
1:20; Novocastra, Newcastle upon Tyne, UK), BCL2 (clone 124, dilution 1:25; Dako), and BCL6 (PG-B6p, 
dilution 1 :20; Dako). lmmunostaining was performed in a Nexes automated immunostaining machine 
(Ventana Medical Systems, Tucson, AZ) according to the manufacturer's instructions. 
For BCL6, an additional amplification step was incorporated into the standard immunostaining 
protocol. A tumor was considered positive for expression of specific antigen if more than 10% of the tumor 
cells showed appropriate immune reactivity. 
A percentage of the Ki-67-positive cells was determined as the actual percentage of tumor cells, thus 
excluding reactive macrophages and small lymphocytes. 
Results 
Selection of probes for detection of breakpoints In MYC region by interphase FISH: All clones 
were mapped relative to each other by FISH on DNA fiber preparations of reactive tonsils. The total area 
covered by the contig was estimated to be more than 1.3 Mb, ranging from 900 kb 5' to 450 kb 3' of MYC 
(Fig. 1A; see Materials and Methods section). 
For detection of the breakpoints in the immediate 5' region (intron I of MYCJ and in the 3' region, we 
selected two pooled cosmids, [CB-I & F5-II] and PAC 1117K22 (Fig. 1A). According to published data, this 
probe set should detect most breakpoints of non-African BL and BL with a variant translocation. To detect 
the breakpoints in the far 5' region as reported in African BL, we selected an additional probe set (cosmids 
[B11-I & C11-I) and PAC 103G5; Fig. 1A). All breakpoints within a region from 190 kb 5' to 50 kb 3' of MYC 
should be detected by both probe sets (Fig. 1A). In the 7 negative control tissues, segregated signals were 
detected in 1 %-5% (mean 4.2%; SD 1.5) and 1 %-7% (mean 3.3%; SO 1.9) of nuclei when hybridized with 
the 3' and 5' probe sets, respectively. The cut off level for both probe sets was set at 9.0%. 
Using two selected probe sets in a FISH segregation assay to detect MYC breakpoints in a 
series with proved 8q24/MYC abnormalities :  MYC breakpoints were identified in 39 of 40 (98%) samples 
with a cytogenetically or molecularly proved 8q24/MYC breakpoint. In 36 of 39 (92%) of the positive samples, 
including all BL cell lines, the breakpoint was identified by segregation of both probe sets; therefore, the 
breakpoints were in a region that went from 190 kb 5' to 50 kb 3' of MYC. Three cases (one with a 1(8;14) 
and two with a 1(8;22)) had a breakpoint more than 50 kb 3' of MYC. In case 26, a DLBCL with a 
cytogenetically proved 1(8;14), no breakpoint was detected with either FISH probe set. Because the 
breakpoint might have been outside the range of the probe sets, we used an additional probe, BAC RP11-
351 C8, which maps 900 kb 5' of MYC, in combination with the pooled cosmids [B11-I & C11-I). Again, no 
breakpoint was detected. In addition, two probes for /GH at 14q32 (coslg6 and PAC27M16) did not 
colocalize with any of the MYC probes. 
Detection of MYC breakpoints by segregation FISH In randomly selected Bls: We validated 
both probe sets on 47 BLs: 15 BLs from Uganda, 10 BLs from Brazil, and 22 BLs from The Netherlands. No 
cytogenetic data were available for these patients. A MYC breakpoint was identified in 41 of the 47 BLs, 
which represented 86% of the Dutch cases, 70% of the BLs from Brazil, and 100% of the BLs from Uganda 
(Table 1, Fig. 1 B). In 35 of the 41 breakpoint-positive cases (85%), the translocation breakpoints were in a 
genomic region that ranged from 190 kb 5' to 50 kb 3' of MYC. Three far-3' and 3 far-5' breakpoints were 
detected in 1 case from The Netherlands, 2 cases from Brazil, and 3 cases from Uganda. 
In 6 cases, no breakpoint was detected either with both FISH segregation assays or with the above­
mentioned additional far-5' probe, BAC RP11-351 CB (Table 1 ). Unfortunately, case 16 could not be studied 
further because of lack of available tissue. In the 5 remaining cases, we used an additional probe, 
ICRF7000G569, which covers the MYC gene, in combination with the MYC region flanking probes. In 1 of 
40 
the 5 cases - a BL from The Netherlands (case 1 4, Table 1 )  - we observed colocal ization of the MYC flanking 
probes (PAC1 1 7K22 and the pooled [C8-I & FS-1 1 1 ) ,  but 3 signals for probe ICRF7000G569. As assessed in 
i ndependent F ISH experiments, one of these 3 signals did not colocal ize with either 1 1 7K22 or [C8-I & FS-1 1 ) .  
This ind icates that a part of the region, including the MYC gene itself, was excised from its original location at 
8q24. An additional F ISH assay using probe ICRF7000G569 and two lgH probes (cos lg6 and PAC27M 1 6) 
showed colocal ization of this third ICRF7000G569 signal with both IGH signals, ind icating that MYC was 
inserted in the IGH reg ion at 1 4q32. 
Presence of MYC breakpoints in the context of histopathologic, epidemiologic, and clin ical 
data : The results of immunostain ing,  EBER in situ hybridization, FISH analysis of MYC breakpoints, and the 
patients' data are summarized in Table 1 .  
The patients were between 3 and 52 years old,  with a median age of 8 years. Most BLs (71 %) 
presented at extranodal s ites, especially the i leocecum/abdomen. In 4 patients from Uganda, the tumors 
were in the head and neck reg ion. Ten cases were classified as aBL. As compared to the findings in 
classical BL, aBL did not show any significant difference in cl in ical presentation,  immunophenotype, EBV 
association, or MYC breakpoints (Table 1 ). All BLs were BCL6-positive, 93% stained for CD10, and 98% 
were BCL2-negative.  EBER in situ hybridization for EBV was positive in 52% of a l l  tumors: 38% of the Dutch , 
93% of the Ugandian ,  and 50% of the Brazil ian cases . We did not find any association of the incidence and 
location of MYC breakpoints with age (ch i ld vs. adult) ,  EBV status, and site of presentation (extranodal vs. 
nodal) .  However, 2 of 3 CD10-negative BLs, both from Brazi l ,  did not harbor any MYC breakpoint. Al l  5 BL 
cases without a detectable MYC breakpoint represented children: 2 from The Netherlands and 3 from Brazi l .  
Only 2 of these patients had an extranodal tumor, and none had an i leocecal tumor. The single EBV-positive 
BL without an MYC breakpoint was from an H IV-positive patient from Brazil (Table 1 ,  case 32). As ind icated 
above, 2 of the BLs without a detectable MYC breakpoint showed an aberrant immunophenotype with 
absence of CD10 expression. 
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Figure 1 .  A: Schematic presentation of the MYC gene region. The arrows indicate the position of MYC, PVT1 (plasmocytoma 
variant translocation 1 ) , BVR1 (Burkitt variants' rearranging region 1 ) , and the approximate positions of most of the reported 
breakpoints (which we located relatively far from the MYC gene). All genomic clones (bars) were mapped by DNA fiber FISH 
relative to pHM-1 , K880, ICRF7000G569, and ICRF7000G2350, which all cover the MYC gene. Subsequently, two probe sets 
were selected for interphase FISH segregation assay: ( 1 )  cosmids CB-I and F5-I I  (pooled) and PAC 1 1 1 7K22, also indicated by a 
blue connection line; and (2) cosmids B1 1 -I and C1 1- I  (pooled) and PAC 103G5, indicated by an orange connection line. The 
green and red bars represent the probes labeled with digoxigenin and biotin, respectively. In the upper part of the figure, probes 
previously used in interphase FISH are indicated (Ried et a l . ,  1 992; Veronese at a l . ,  1 995; Rack et a l . ,  1 998; Siebert et al . ,  1 998). 
The bars with an interrupted outline represent the probes not mapped by us by fiber FISH but located according to the reported 
data. The multi-YAC constructs (Davison et al . ,  1 998, Zymed) and LSI MYC dual-color break-apart rearrangement probes (Vysis) 
are not shown in this figure because they map to a very large genomic region on both sides of MYC (Zymed) or have been 
incompletely mapped accurately (Vysis). B: Example of FISH signal patterns in paraffin tissue section of a Burkitt lymphoma, using 
the B1 1- I  and C 1 1 -I probe set and 103G5, as indicated in A. The translocation breakpoint is easily recognized by the presence of 
single red and green signals. The arrow indicates a cell with a set of colocalizing signals (yellow spot), representing the normal 
allele, and one single red and one green signal, indicating the presence of a monoallelic break. Note that because of the 
sectioning artifacts, many cells have incomplete sets of FISH signals. 
TA!ll.E I .  ASH fer 8q2◄1MYC Brmlcpolnts In Random ly Seleaed BlslaSI.! 
Number D&!lgnosl! Source Age s .. CDI0 Bd2 EBY MYC l ' MYC 5 '  
I BL Netherlands l l  omenwm + + + 
2 BL Netherlands 9 mesientery + + + + 
3 BL Netherland, l l  alxfomen NA + + 
◄ BL Netherlands 5 abdomen + + + 
5 aBL Netherlands 1 0  lleocerum + + + 
6 BL Netherland, l l  Ileum + + + 
7 BL Netherlands 7 lleocerum + + + 
8 BL Netherlands 6 promm + + + 
9 BL Netherlands ]9 lymph node + + + + 
1 0  BL Netherlands 52 lymph node + + + + 
I I '  BL Netherlands 26 lymph node + + + + 
1 2  BL Netherland, 1 5  1JeoceCJm NA NA NA + + 
l l  BL Netherlands NA NA NA NA NA + + 
I◄ BL Netherland, 1 2  alxfomen + + - ins - 111' 
IS BL Nethertmm 8 1leocerum + + + 
1 6  BL  Netherland, 6 lymph node + 
1 7  BL Netherland, 8 lleoceam NA + + 
1 8  aBL Netherland, 9 oroplmynx + NA 
1 9  aBL Netherland, 9 1looceaJm + NA + 
20 BL Netherland, 7 atxlomen + + + + + 
21  aBL Netherland, 7 tons:11 + NA + + 
u BL Netherland, 5 mnsll + + + 
2] aBL BraJI I 4 perlcrbltal 
24 BL BriUII 5 atxlomen + + + + 
25 BL BriUII 2 1  abdomen + + + 
26 aBL BriUII 3 retrcperltoneum + + + + 
27 BL BriUII 10 lymph node 
28 aBL BraJII 4 alxfomen + + + + 
29 aBL BriUI I 3 lymph node + + 
30 aBL BriUII 3 retrcperrmneum + + + 
3 1  B L  BriUII 8 lymph node + + + 
32• BL BriUII 5 lymph node + + 
33 BL U,anda NA NA + NA + 
3◄ BL U,anda l l  mandible + + + + 
]5 BL Upnda 9 abdomen + + + + 
36' BL Upnda 7 NA + + + + 
37 BL Upnda 22 lymph node + + + + 
38' BL Upnda 2] lymph node + + + 
]9 BL U,anda 7 atxlomen + + + + 
40 BL U,anda 4 mandible, maxilla + + + + 
◄I BL U,anda 5 NA NA NA + + + 
42 aBL Upnda 35 lymph node + + + + 
43 BL UJPnda 1 5  lymph node + + + + 
4◄ BL U,anda 20 mandible NA NA + + 
45 BL U,anda 3 orbit NA NA + + + 
46 BL U,anda 6 NA + + + 
47 BL U,anda 1 5  abdomen + + + + 
BL-6umtt t,m� 111BL---matpgo1i: nrim,utypial Burkittlymphom11; •HfV-positiwe patients;, NA-du.a ;:are not.11Ylil111t:le; ins-insertion d MYC 
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The- data an I-cell mrrlu:rs., BCL& and Ki&7 are not induded 1n the: ab� because .d tllll"ICf"I had :a 1-mll p-lCnoqpc, expn:SR!d BCL.&. and the 
MIB- IIKi.&7 l:lbe:lrli il"IZx ·win > � 
Discussion 
In  the present study, a novel interphase segregation FISH assay for the detection of 8q24/MYC 
translocation breakpoints was appl ied , and it could detect an 8q24/MYC breakpoint in 98% of the cases in 
the test series and 89% of the cases in the val idation series. Therefore, this assay provides a rapid and 
reliable tool for detection of MYC breakpoints on routine paraffin sections of BL samples. Moreover, the 
assay appears to be valuable for cases from different geographic regions known to harbor differently 
positioned 8q24/MYC breakpoints . 
Various F ISH strategies have been used to detect MYC translocation breakpoints. One approach is 
to use an IGH probe in combination with a single 8q24 probe that spans the breakpoint region . In a 
translocation , the 8q24 probe wil l  split, and one signal wi l l  colocal ize with the IGH probe (Veronese et a l . ,  
1 995; Siebert et  a l . ,  1 998). However, the size of  the additional 8q24 signal depends on the position of  the 
breakpoint; i n  some instances, it can be too small to be visual ized . In addition, cutting artifacts and the 
overlap of nuclei in tissue sections generate both loss of signals and fortuitous overlap, resulting in patterns 
that are d ifficult to recognize and interpret. We used a more appropriate assay, a simple segregation assay 
in which differently colored breakpoint-flanking signals segregate upon chromosomal breakage .  
Accord ing to  the l im ited data available from DNA pulsed-field and FISH mapping stud ies {Joos et  a l . ,  
1 992a, b) ,  most t(8 ; 1 4 )  breakpoints in African Bls are spread over a reg ion of  55-340 kb 5'of MYC. 
Breakpoints 3'of MYC involved in the variant translocations have been mapped from 1 6  to 250 kb 3' of MYC 
within the B VR1 and PVT1 reg ions {Henglein et a l . ,  1 989; Carie et a l . ,  2000). 
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However, previously reported FISH assays were designed to detect breakpoints in specific 5' or 3' 
regions, not to detect all possible breakpoints (see Fig. 1; Ried et al., 1992; Veronese et al., 1995; Rack et 
al., 1998; Siebert et al. , 1998). Two FISH assays for the detection of MYC breakpoints are commercially 
available through Zymed (Zymed Laboratories, South San Francisco, CA) and Vysis (Vysis, Inc., Downers 
Grove, IL). The Zymed assay consists of six yeast artificial chromosome (YAC) constructs flanking the MYC 
region that have been depleted of repetitive DNA sequences by subtraction technology (Davison et al., 1998; 
Haralambieva et al., 2003). The three centromeric and three telomeric YACs cover a region of approximately 
1.5 and 4.5 Mb, respectively, and leave a gap of approximately 1 Mb around MYC. Because of this design, 
breakpoints can only be detected but not mapped by this assay. In the assay from Vysis, the 3' probe starts 
approximately 1 Mb 3' of MYC and covers a region of 400 kb. However, the exact location of the 5' probe is 
not known, and according to the manufacturer, it starts not farther than 140 kb 5' of MYC. Consequently, the 
assay may miss breakpoints within the far-5'area (cases 30, 33, and 44, as well as additional cases of non­
African BL with such far-5' breakpoints; see Table 1; Haralambieva et al., in preparation). Furthermore, in 
other BLs (e.g., the Daudi cell line), the break might be within the region covered by the probe itself and 
therefore would give rise to a complex signal pattern. In contrast to both commercially available probe sets, 
our small locus-specific probes (cosmids and PACs) are relatively simple to handle and allow a relatively 
exact mapping of the breakpoints, as well as detection of small interstitial insertions and deletions. 
Thus far, all of the methods of detecting MYC breakpoints, including the commercially available 
assay from Vysis, have been validated in relatively few BL cell lines and primary BL specimens (Ried et al., 
1992; Veronese et al., 1995; Davison et al., 1998; Rack et al., 1998; Siebert et al., 1998; Basso et al., 1999). 
According to our results in the current test and validation series, the majority (89%) of all 8q24/MYC 
breakpoints are within a region from 190 kb 5' to 50 kb 3' of MYC, whereas 11 % of the breakpoints are far-5' 
or -3' breakpoints. In keeping with previous reports (Henglein et al. , 1989; Joos et al., 1992a,b; Cario et al., 
2000), the latter may be relatively more common in African BL patients and BL with a variant breakpoint 
(Table 1). Of interest is the position of the breakpoint in one Dutch BL with a cytogenetically proved 1(8;14) 
that was located between 50 and 350 kb 3' of MYC. This configuration indicates that not only the variant 
translocations but also 1(8;14) breakpoints can be localized far-3' of MYC. 
Six cases (in the test and validation series) did not show a breakpoint using our FISH assay. 
Recently, Fabris et al. (2003) reported on 8q24/MYC breakpoints in multiple myeloma cell lines and primary 
myeloma samples. Interestingly, 5 of the 11 cell lines had a breakpoint more than 2. 7 Mb from MYC; 
however, ii is not clear whether MYC or other genes were affected in these cases. In addition to the 
possibility of such distant breakpoints, MYC can also be deregulated by other mechanisms, such as 
mutations, small insertions of lg regulatory elements into the MYC locus, and insertion of MYC into the lg 
loci. Indeed, we encountered one BL with an insertion of MYC into the lgH region, which, to our knowledge, 
has not been described previously. Of note, such small insertions will remain undetected by conventional 
cytogenetics and most FISH assays and can only be detected by specifically designed FISH assays. 
Although 8q24/MYC translocation breakpoints are considered a cytogenetic hallmark of BL, some early 
cytogenetic studies (Zech et al., 1976; Komblau et al., 1991) included a considerable number of BLs 
negative for 1(8;14) or its variants. Further analysis of such MYC breakpoint-negative cases is necessary, 
especially to investigate whether they are true BLs or belong to a "gray zone" between BL and diffuse large 
B-cell lymphoma. Our data suggest that the absence of CD10 expression, a bona fide marker of germinal­
center B cells, is associated with the absence of an 8q24/MYC breakpoint, indicating that these CD10-
negative tumors do not belong to the category of BL. Atypical BLs did not differ from classical BL in any 
aspect. Thus, in keeping with the current WHO classification (Diebold et al., 2001), these aBLs probably 
belong to the entity of true BL. 
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Clinical, lmmunophenotypic, and Genetic Analysis of Adult Lymphomas with 
Morphologic Features of Burkitt Lymphoma 
Eugenia Haralambieva, Evert-Jan Boerma, Gustaaf W. van Imhoff, Stefano Rosati, Ed Schuuring, Hans 
Konrad Milller-Hermelink, Philip M. Kluin, German Ott 
A prompt distinction of Burkitt lymphoma (BL) versus diffuse large B cell lymphomas (DLBCL) has 
important clinical implications; however, this distinction can be difficult. We analyzed 74 adult gray zone and 
1 0  reference pediatric BL using immunohistochemistry (Ki-67, CD10, bcl2, bcl6) and fluorescence in situ 
hybridization (FISH) for MYC, BCL2, and BCL6 breakpoints. Two algorithms for classification were followed: 
algorithm A used a two-step review by four hematopathologists and algorithm B a set of only biologic 
markers (Ki-67 <! 90%, CD10+, bcl6+, bcl22, MYC breakpoint+, BCL2 and BCL6 breakpoint -). Both 
algorithms categorized all reference cases as BL. In the adult group, algorithm A resulted in 21adult BL and 
52 DLBCL and algorithm B in 23 BL and 51 "non-Burkitt" lymphomas (nBL); 9 cases (12%) contained two 
different translocations and were categorized as nBL in algorithm B. Fifteen cases (20%) fulfilled the BL 
criteria of both algorithms. Although not considered as BL according to both algorithms, many other 
lymphomas showed nonetheless a phenotypic and/or genetic shift to BL. BL according to algorithm B was 
more homogeneous with respect to clinical presentation (gender and localization) than BL defined by 
algorithm A. Our data suggest that only a few cases of these gray zone lymphomas represent true de novo 
BL. lmmunohistochemistry for Ki-67, CD10, and bcl2 with analysis of MYC and preferably also BCL2 and 
BCL6 may be advised as a marker panel for this diagnostic dilemma. 
Am J Surg Pathol 2005;29:1086-1094 
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Introduction 
The REAL and WHO classifications introduced the concept of clinicopatholo�ic entities in which 
histology, immunophenotype, genetic data, as well as clinical features are integrated.1 6• This led to a major 
increase in interobserver and intraobserver agreement, as well as in a worldwide high level of acceptance by 
hematologists and oncologists.1 7  However, a few problems remained, one being the differential diagnosis of 
Burkitt (BL), atypical BL (aBL), Burkitt-like lymphoma (REAL classification), and a subset of diffuse large B­
eel! lymphomas (DLBCL) with features of BL. Indeed, this is a long-standing problem, already starting with 
the introduction of the term "undifferentiated non-Burkitt's lymphoma" in the Rappaport classification and 
"small non-cleaved non-Burkitt's lymphoma" in the Lukes' classification.25•33 In a key manuscript on the 
reproducibility and clinical impact of the REAL classification, an unacceptable low interobserver and 
intraobserver agreement existed with respect to the histologic distinction between Burkitt-like lymphoma and 
DLBCL, which did not improve by integration of immunohistology or clinical data. 42 
From a biologic point of view, BL seems to be a relatively homogeneous disorder characterized by 
the expansion of early germinal center blasts in the so-called dark zone of normal germinal centers.29 In 
parallel to their normal counterparts, BL cells almost invariably express CD10 and bcl6 but lack bcl2.1 1  
Genetically, BLs carry a reciprocal translocation t(8;14)(q24;q32) o r  one o f  its variants resulting in 
deregulation of MYC. Three subtypes of BL have been described: endemic (equatorial Africa and parts of 
New Guinea), sporadic, and HIV-associated BL, which differ in their clinical presentation and association with 
Epstein-Barr virus (EBV) infection.6•1 8•27•38 These subtypes, although uniformly characterized by MYC 
translocations, occasionally show subtle to marked cytomorphologic variation (eg, plasmacytoid 
differentiation in some HIV-associated BLs).19 In addition, although cytogenetically indistinguishable, both the 
8q24 and 14�32 chromosomal breakpoints differ at the molecular level in endemic and sporadic BL 
patients.27•31 •32• 4 This suggests that different mechanisms are involved in the generation of chromosomal 
breakpoints (eg, IGH hypermutation and IGH class switch recombination, respectively) and therefore that 
endemic and sporadic subtypes probably originate from different stages of B-cell development. 
DLBCL is much more heterogeneous and can be molecularly divided in at least two subtypes: 
lymphomas with a germinal center B cell-like profile of gene exi:iression (GCB profile) and lymphomas that 
express genes more related to activated B cells (ABC profile).2•1 0•1 2  Also from a cytomorphologic point of 
view, DLBCL is highly heterogeneous with a range from Hodgkin-like features in T-cell-rich B-cell lymphoma 
to cases composed of relatively small- to medium-sized cells that mimic BL.1 6•1 9  At the cytogenetic and 
molecular genetic level, a large number of chromosomal translocations can be found, including BCL6 
breakpoints in approximately 20% to 35%, BCL2 breakpoints in 15% to 20%, and MYC breakpoints in 5% to 
10% of the tumors. Furthermore, many tumors have complex karyotypes with multiple structural 
abnormalities. 9•20•22 
The presence of a diagnostic overlap between BL and DLBCL resulted in the introduction of poorly 
defined borderline categories such as undifferentiated non-BL, small noncleaved non-BL, Burkitt-like 
lymphoma (BLL), and aBL.3•1 6• 1 9•39 These terms generated considerable confusion and were differently used 
by various hematopathologists. However, a prompt diagnosis and distinction of BL versus DLBCL bear 
important clinical implications since treatment of BL often differs from treatment of DLBCL patients.28 The 
present WHO classification recommends the presence of 8q24 breakpoints and/or MYC rearrangement as a 
prerequisite to the diagnosis of BL and its morphologic variants. Unfortunately, genetic aberrations involving 
MYC are not strictly disease specific and, to the best of our knowledge, this WHO recommendation has not 
been validated in a large lymphoma series. 
Here, we describe the clinical, phenotypic, and molecular features of 74 lymphomas obtained from 
adult patients with either a typical BL or a gray-zone BUDLBCL as well as 10 pediatric reference BL cases. 
All cases were analyzed for cytomorphology, phenotype, and translocation breakpoints within the 8q24/MYC, 
18q21/BCL2, and 3q27/BCL6 breakpoint regions (further called MYC, BCL2, and BCL6). Two different 
algorithms for classification were followed, one conventional algorithm accomplished through a two-step 
review procedure by four hematopathologists and the other by means of application of exclusively a 
combination of immunophenotypic and genetic markers. 
Material and methods 
Selection of cases: Seventy-four cases collected between 1990 and 2003 (Table 1) were retrieved 
from the archives of the Departments of Pathology of the University Medical Center Groningen (N = 23) and 
the Department of Pathology of the University of W0rzburg (N = 33) as well as from a review of two clinical 
trials on aggressive NHL in The Netherlands (HOVON 27 and HOVON 40; N = 18). All cases were 
lymphomas from adult patients (age>16 years); all tumors included as Burkitt lymphoma were non-endemic 
cases; AIDS-related lymphomas were excluded. The following criteria were used to include cases in the 
present study: 
• Cases diagnosed as BL with a typical growth pattern and a high proliferation rate as 
established by staining for Ki-67/MIB-1 (in general, >90% positive nuclei), however, occasionally with 
a relatively high degree of nuclear polymorphism (BL and aBL in the WHO classification) 
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• Cases submitted as DLBCL with features of BL, in particular a composition of 
relatively small- to medium-sized blasts, a high degree of monomorphism, a cohesive growth 
pattern, a high proliferation rate, and/or a starry-sky appearance. Classic DLBCL were not included 
in the study. 
• Cases for which the hematopathologist could not decide upon the differential 
diagnosis of BL and DLBCL. 
Ten cases of unambiguous pediatric BL (Table 1, cases A-J) were included as a reference group. 
lmmunohlstochemlstry: lmmunohistochemistry was performed on formalin-fixed, paraffin-
embedded tissue sections, after 30 minutes antigen heat-retrieval in 50 mM Tris/2 mM EDTA buffer solution, 
pH 9.0 in a microwave oven. The following markers were analyzed: Ki-67 {clone MIB-1, dilution 1 :100; 
DAKO, Glostrup, Denmark), CD10 {clone 56C6, dilution 1:20, Novocastra, Newcastle upon Tyne, United 
Kingdom), bcl2 {clone 124, dilution 1:25, DAKO), and bcl6 {PG-B6p, dilution 1:20, DAKO). lmmunostaining 
was performed in the Nexes automated immunostaining machine {Ventana Medical systems, Tucson, AZ) 
according to the manufacturer's instructions. For Bcl6 an additional amplification step was incorporated into 
the standard immunostaining protocol. A tumor was considered to be positive for expression of a specific 
antigen if more than 10% of the tumor cells showed appropriate immune reactivity. A percentage of the Ki-
67-positive cells was determined as an actual percentage of the tumor cells, thus excluding reactive 
background cells. 
Fluorescence in situ hybridization: All cases were studied by segregation FISH on paraffin tissue 
sections for the presence of translocation breakpoints within three breakpoint regions, MYC, BCL2, and 
BCL6. 
For detection of M YC translocation breakpoints, three probe sets were used15 as follows: all cases 
were tested with the probes flanking the region from 190 kbs 5'to 450 kbs 3' of MYC. Samples that did not 
show any breakpoint were studied with an additional probe set covering the far (700 kbs) area upstream of 
MYC. The remaining negative cases were tested with a probe combination designed to detect a possible 
excision of MYC from 8q24 and subsequent insertion elsewhere in the genome.1 5  
BCL2 breakpoints were studied using two previously reported probe sets, for detection of mbr/mcr 
and 5'/FVT1 breakpoints, as well as excision of BCL2.37 
The FISH segregation assay for detection of 3q27/BCL6 region breakpoints will be described in 
detail elsewhere. Briefly, one probe set flanks the MBR in the 5' noncoding region of BCL6 {PAC 133M19 
and PAC 165121, kindly provided by Dr. R. Dalla Favera, Columbia University, NY). The second probe set 
consists of PAC 133M19 and BAC RP11-137K3 and detects the ABR breakpoint region located between 
245 and 285 kbs 5' of BCL6.6 BAC RP11-137K3 was selected on basis of its location in the minimal tiling 
path 5' of BCL6 {MapViewer at www.ncbi.nih.gov; build 33) and obtained from BACPAC Resources, 
Oakland, CA). 
The probes were labeled using Kreatech's ULS nonenzymatic labeling method {Kreatech 
Diagnostics, Amsterdam, The Netherlands, BCL2 and MYC probes) or by standard nick-translation (BCL6 
probes) with biotin-16-dUTP or digoxygenin-11-dUTP {Roche, Basel, Switzerland). The conditions for the 
hybridization and the evaluation of FISH results on routine tissue sections have been described recently.1 3  
Hfstopathologic classification: To reach a diagnosis according algorithm A, all samples, including 
the 10 reference BL cases, were reviewed by four hematopathologists {H.K.M.-H., G.O., P.M.K., and E.H.) in 
a two-step procedure {Tables 1 and 2). First, each pathologist evaluated the samples independently, based 
on the histology, immunohistochemistry, age, and site of the involvement, but without knowledge of 
molecular data, the original diagnosis, and/or the opinion of other reviewers. All cases were categorized 
according to the WHO classification scheme; however, the interpretation of the weight of the individual 
morphologic and immunophenotypic features was left to the judgment of the individual reviewer. aBL referred 
to the cases with atypical cytomorphologic features, mostly a considerable variation in nuclear and nucleolar 
size, irregularities of the nuclear contour, or plasmacytoid differentiation, nevertheless considered to belong 
to the BL entity. As a second step, all four reviewers discussed the discordantly classified cases using a 
multiheaded microscope, and this resulted in a final diagnosis further called "algorithm A diagnosis." After 
this review, individual cases were discussed with knowledge of the molecular data, but the algorithm A 
diagnosis was not altered. 
The second approach {algorithm 8) included direct application of a combination of markers, 
recommended by the WHO classification for the diagnosis of BL. Since the primary selection of the cases 
was based on morphology {see selection of cases) and, therefore, all cases were considered to represent 
gray zone lymphomas, any additional histopathology review was omitted. According to this algorithm, BL 
referred only to these cases that had a Ki-67 labeling rate of>90%, that were bcl6+, CD10+, and bcl2-, and 
carried a MYC breakpoint. All cases that did not fulfill these criteria, but also the cases that harbored 
additional BCL2 and/or BCL6 breakpoints and therefore might represent transformed lymphomas, were 
excluded from the category of BL and denoted as non-Burkitt lymphoma {nBL). 
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Statistical analysis: For comparison of the various parameters the Fisher exact test was applied. 
Results 
The classification of all the samples together with the patients' data, immunophenotype, and the 
molecular data (presence of breakpoints in MYC, BCL2, and BCL6) are listed in Table 1 and summarized in 
Table 3. 
TABLE 1 .  DATA OF ALL PATIENTS 
case Sex age site Algorithm A Algorithm B Ki67 CD10 bcl2 bcl6 FMYC FBCL2 FBCL6 
A m 1 0  ileocecum BL BL 99% + + + 
B m 9 parapharynx BL BL 99% + + + 
C m 4 ileocecum BL BL 99% + + + 
D m 5 ileocecum BL BL 99% + + + 
E m 6 prostate BL BL 99% + + + 
F m 7 ileocecum aBL BL 99% + + + 
G f 9 retrop., mediastinum BL BL 99% + + + 
H m 1 3  ileocecum, mesentery BL BL 99% + + + 
I m 1 3  intestine, retrop., pleural c .  BL BL 97% NE + + 
J m 1 3  ileocecum BL BL 99% + + + 
39 nasal cavity BL BL 99% + + + 
2 m 71 liver, lymph node aBL BL 95% + + + 
3 20 lymph node BL BL 99% + + + 
4 m 18  stomach, lymph node aBL BL 99% + + + 
5 f 71 thyroid aBL BL 95% + + + 
6* f 33 ovary aBL BL 97% + + + 
7* m 34 mediastinum BL BL 99% + + + 
8 m 39 lymph node BL BL 95% + + + 
9 m 52 lymph node aBL BL 99% + + + 
1 0  m 68 lymph node BL BL 95% + + + 
1 1  m 68 mesenteric lymh node aBL BL 99% + + + 
1 2  m 62 ileocecum BL BL 99% + + + 
1 3  m 22 lymph node, waldeyer aBL BL 95% + + + 
1 4* m 40 ileum BL BL 99% + + + 
1 5  m 34 ileocecum BL BL 99% + + + 
1 6  m 52 oral cavity DLBCL BL 99% + + + 
17 m 24 soft tissues, BM DLBCL BL 95% + + + 
1 8  m 32 ileocecum DLBCL BL 99% + + + 
1 9* m 43 stomach DLBCL BL 99% + + + 
20 f 46 breast, BM DLBCL BL 99% + + + 
21 f 67 stomach DLBCL BL 90% + + + 
22 m 74 lymph node DLBCL BL 99% + + + 
23* Im 42 stomach DLBCL BL 99% + + + 
24 f 65 lymph node BL nBL 90% + + + 
25 m 63 omentum majus BL nBL 99% + + + + 
26* m 65 omentum aBL nBL 95% + + 
27 m 33 lymph node DLBCL nBL 99% + + 
28 f 61 stomach DLBCL nBL 80% + + 
29 m 79 lymph node DLBCL nBL 95% + + 
30 m 38 stomach DLBCL nBL 99% + + 
31 m 76 colon DLBCL nBL 99% + + 
32 m 78 lymph node DLBCL nBL 99% + + + 
33 f 71 soft tissues DLBCL nBL 99% + 
34 f 48 lymph node DLBCL nBL 99% + + 
35 m 29 lymph node DLBCL nBL 99% + + 
36* m 36 ileum DLBCL nBL 50-99% + + 
37 f 65 pancreas, peritoneum, In DLBCL nBL 50-99% + + NE + 
38* 65 spleen DLBCL nBL 80% + NE + 
39 90 lymph node DLBCL nBL 90% + + 
40* 58 lymph node DLBCL nBL 97% + + +ABR 
41*  60 ovary DLBCL nBL 90% + + + 
42* m 60 skin DLBCL nBL 99% + + 
43* m 44 lymph node DLBCL nBL 95% + + NE 
44 m 52 lymph node DLBCL nBL 95% + + + 
45 f 63 breast DLBCL nBL 95% + + + 
46 65 lymph node DLBCL nBL 99% + + + 
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case Sex age site Algorithm A Algorithm B Ki67 CD1 0 bcl2 bcl6 FMYC FBCL2 FBCL6 
47 m 66 lymph node DLBCL nBL 70% + + + 
48 m 67 small bowel DLBCL nBL 95% + + 
49 m 69 nasopharynx DLBCL nBL 90% + NE -
50 69 cecum DLBCL nBL 90% + + + + 
51 72 lymph node DLBCL nBL 90% + + 
52 80 lymph node DLBCL nBL 90% + + NE + 
53 m 84 lymph node DLBCL nBL 99% + + 
54 m 89 skin DLBCL nBL 95% -CD5+ + + 
55 m 62 lymph node DLBCL nBL 95% + + 
56 m ? bone DLBCL nBL 80% + + - amp + 
57 f 52 lymph node DLBCL nBL 90% + + + 
58 f 53 lymph node DLBCL nBL 95% + + + 
59 ? 41 stomach DLBCL nBL 90% + + NE 
60 m 47 ileum DLBCL nBL 90% + + + 
61*  f 1 9  ovary DLBCL nBL 98% + + 
62 m 48 tonsil DLBCL nBL 99% + + 
63* m 64 lymph node DLBCL nBL 99% + + 
64 m 1 3  lymph node DLBCL nBL 90% + + + 
65 f 63 abdominal DLBCL nBL 95% + + + + 
66* 58 lymph node aBL nBL 99% + + + + +ABR 
67* m 36 abdomen aBL nBL 95% + + + + + 
68 43 ovaries, small bowel, CNS aBL nBL 99% + + + + 
69 56 mesentery DLBCL nBL 90% + + + + 
70 50 lymph node DLBCL nBL 90% + + + + + 
7 1 •  m 44 omentum DLBCL nBL 50-90% + + + + + 
72 f 52 ovary DLBCL nBL 85% + + + + + 
73• m 64 abdomen DLBCL nBL 97% + + + + + 
74 33 lymph node DLBCL&foll nBL 99% + + + +ABR 
•: cases included in HOVON clinical trials. NE: not evaluable; Case 56 represented an adult patient (>1 6  yr) without known date of birth; 
ABR: breakpoint in the ABR of BCL6. 'cases 36, 37 and 71 showed heterogeneous Ki 67 labeling pattern ranging from 50 to 99% in 
different part of the sample 
Two diagnostic algorithms to diagnose Burkitt lymphoma 
Algorithm A diagnosis: as a result of the conventional histopathology review procedure that included 
the multihead review session, all 10 reference pediatric BL and 21 adult cases (28%) were diagnosed as BL 
(typical BL, n = 1 O; a BL, n = 11 ); 52 adult cases were classified as DLBCL (70% ). One DLBCL harbored foci 
of follicular lymphoma grade 3B and was classified as "other" (Tables 1 and 3). In 58% of the cases, a 
consensus diagnosis was reached independently by all four pathologists and in 80% by three of four 
pathologists. As shown in Table 2, the individual pathologists differed in their preference to use or avoid the 
diagnosis BL: reviewer 2 diagnosed BL in 81 % of the cases finally diagnosed as such but showed a 
concomitant trend to overdiagnose it in the DLBCL cases (7 of 52 cases; 11 %, data not shown), whereas 
reviewer 4 was relatively reluctant to diagnose BL at all. A consensus diagnosis by all four pathologists was 
reached independently in only 24% (5 of 21) of the adult BL and in 69% (36 of 52) of the DLBCL. As 
expected, a complete consensus was much more easily to achieve in the pediatric BL (80%). 
Classification according to the algorithm B resulted in 23 BL and 51 nBL. Applying the algorithm A 
diagnosis on these 23 BL cases, 8 of had been classified as BL, 7 as aBL, and 8 as DLBCL. Therefore, 71 % 
of these exclusively phenotypically and genetically defined BL presented with an atypical morphology, and 
even 35% would have been placed in a different lymphoma category using conventional microscopy. In 
reverse, 6 cases (29%) that had been classified as BL or aBL according to algorithm A did not fulfill the BL 
criteria of algorithm B. In 2 cases, this was caused by a weak bcl2 expression of the tumor cells, in 1 case by 
the lack of a detectable 8q24/MYC breakpoint and in 3 cases (50%) by the presence of a second 
translocation (see below). 
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Table 2. Consensus in histopathological diagnosis (algorithm A) 
consensus N Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 Consensus by Consensus by 
diagnosis 3/4 pathologists 4/4 pathologists 
(%) (%) (%) (%) (%) (%) 
(a)BL pediatric 10 1 00 1 00 90 90 90 80 
(a)BL adult 21 62 81  52 48 48 24 
DLBCL 52 88 84 88 98 94 69 
Other 1 00 1 00 0 0 0 0 
Total adult 74 81 84 77 82 79 55 
Clinical and lmmunohistologlc data: 
All data available on the patients and their tumors, categorized according to the two algorithms, are 
listed in Table 1 and summarized in Table 3. Both algorithms showed a male predominance, which tended to 
be more pronounced in the BL group according to algorithm B than any other category (difference between 
both algorithms, not significant). BL patients were significantly younger than DLBCL and nBL patients, and 
especially according to algorithm B, BL patients more often presented with extranodal disease (P < 0.05). All 
BLs but also the majority of the DLBCLs and nBLs were CD10 and bcl6 positive, indicating the limited value 
of these markers in this gray zone area. Most of all BLs showed a strong uniform bcl6 expression pattern 
resembling that of a normal germinal center, while nBLs/DLBCLs tended to label more heterogeneously, with 
variation of the intensity and percentage of positive tumor cells (data not shown). In contrast to the BLs in 
which bcl2 protein expression was infrequent (24% according to algorithm A and by definition absent 
according to algorithm B}, 62% of the DLBCLs and 73% of the nBLs expressed bcl2 protein at an extent of 
10% or more tumor cells (Table 3). 
Molecular data 
A MYC breakpoint was detected in a high proportion (57%} of the tumors, ie, by definition of 
algorithm B in all BL, but also in 29% of the nBL (difference significant, P < 0.001; Tables 1 and 3). Using 
algorithm A, differences in translocation frequencies were less explicit but still significantly different (Table 3). 
Most MYC breakpoints were detected with the probe set covering breakpoints in a region of 190 kb 5' to 450 
kb 3'of MYC, and only three additional breakpoints were exclusively detected with the second probe set for 
breakpoints more 5' of MYC (data not shown). In 2 cases, additional FISH studies with a third probe set 
supported the presence of an insertion of MYC instead of a translocation (data not shown). 
BCL2 breakpoints were detected in 9 samples: 3 nBLs (algorithm B) carried this breakpoint as a 
single genetic abnormality, whereas in 5 other nBLs it was combined with a MYC breakpoint (see below). In 
one nBL with foci of follicular lymphoma grade 3B, it was combined with a BCL6 breakpoint (Table 1 ). 
BCL6 breakpoints were identified in 10 tumors: in 6 nBLs it was the only genetic lesion, in 3 nBLs it 
was combined with a MYC breakpoint, and in the above mentioned "composite" nBL it was combined with a 
BCL2 breakpoint. 
Further analysis showed a significant positive association between CD10 expression and the 
presence of a MYC translocation breakpoint (P < 0.001 ), whereas BCL6 breakpoint-positive samples tended 
to lack CD10 (P = 0.05) and to express bcl2 (P < 0.05). Bcl2 expression did not correlate with a BCL2 
breakpoint since only 7 of the 37 cases (19%} that expressed the protein contained a BCL2 breakpoint. 
Neither was bcl2 expression a strong predictor for the absence of a MYC breakpoint: 14 of 37 cases (38%} 
with expression of bcl2 contained a MYC breakpoint. Since almost all cases in this series were bcl6 positive, 
no correlation of antigen expression with any genetic lesion could be recognized. 
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Table 3. lmmunophenotype, molecular genetic results and cl inical data according to the different 
classification algorithms 
Algorithm A Algorithm B 
BL pediatric 
N=1 0 
(a)BL DLBCL (a)BL nBL 
N=21 N=52 N=23 N=51 
age range (yrs) 4-1 3 1 8-71 1 3-90 1 8-74 1 3-90 
median 9 43 60 42 63 
m/f ratio 9,0/1 ,0 2,0/1 ,0 1 ,3/1 ,0  2,8/1 ,0 1 ,  1 /1 ,0  
extranodal presentation (%) 10 ( 100) 9 (43) 25 (48) 15 (65) 19 (37) 
consensus pathologists (%) 8 (80) 5 (24) 36 (69) 
range Ki67 labeling (%) 97-99 95-99 50-99 95-99 50-99 
CD1 0+ (%) 1 0  (1 00) 20 (95) 35 (67) 23 (100) 33 (65) 
bcl6+ (%) 10 ( 100) 20 (95) 43/47 (91 )  2 3  (1 00) 40/46 (89) 
bcl2+ (%) 0 (0) 5 (24) 32 (62) 0 (0) 37 (73) 
CD1 0+,bcl6+,bcl2- (%) 1 0  (1 00) 15 (71 )  8 (1 5) 23 (1 00) 0 (0) 
any MYC breakpoint (%) 1 0  ( 1 00) 20 (95) 18 (35) 23 (1 00) 15 (29) 
MYC breakpoint alone (%) 10 (1 00) 18 (86) 13 (25) 23 (1 00) 7 ( 14) 
BCL2 breakpoint (%) 0 (0) 1 (5) MYC 7 ( 13) ;  4 MYC 0 (0) 9 ( 18) ;  5 MYC 
BCL6 breakpoint (%) 0 (0) 2 ( 10); 2 MYC 8 (1 6); 1 MYC 0 (0) 1 1 /50 (22); 3 
MYC 
One case of composite lymphoma (DLBCL and follicular lymphoma grade 1 1 18) was omitted from DLBC (algorithm A) but included in the 
nBL group (algorithm B) 
Samples with double translocation 
Nine samples carried a combination of translocation breakpoints in MYC, BCL2, and/or BCL6 (Table 
1 ) .  In keeping with the classification criteria of algorithm B, all cases were categorized as nBL ;  however, the 
group was heterogeneous according to algorithm A: one tumor with a MYC and BCL2 breakpoint was 
classified as BL and 4 as DLBCL, 2 lymphomas with a combination of a MYC and BCL6 breakpoint were 
diagnosed as BL and one as DLBCL (Fig. 1 C) ,  and finally one lymphoma with a BCL2 and BCL6 breakpoint 
was diagnosed as a composite DLBCL and follicular lymphoma, grade 3B. The majority (6 of 9 )  of these 
patients were female and 6 of 9 tumors coexpressed CD1 0, bcl2 , and bcl6 . Of interest, in 2 of 3 cases with a 
MYC and BCL6 breakpoint, the BCL6 breakpoint was located with in the alternative breakpoint reg ion (ABR) 
of BCL6, while in 5 of 6 DLBCLs with a single BCL6 breakpoint, it was located in the major breakpoint reg ion 
(MBR) .  Furthermore, all cases with this double breakpoint expressed bcl2 protein. 
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FIGURE 1 .  Morphology of Burkitt lymphomas and DLBCL. 
A, A low power overview at 40x magn ification. B-E, The 
detai led morphologic spectrum of various cases at a 
magn ification of 1 OOX (oil immersion) . Details on clinical 
presentation are presented in Table 1 .  A, Tumor no. 16 (51 
years , oral cavity) , algorithm A DLBCL, algorithm B BL, with 
a "starry sky" appearance, relatively small cell composition, 
and high degree of monomorphism, features shared by 
most of the cases included in this study. The tumor showed 
expression of CD10  and bcl6 without bcl2 and with 
exclusively a breakpoint in the MYC reg ion. B, Tumor no. 4 
( 1 8  years , tumor stomach), algorithm A aBL, algorithm B 
BL , with a subtle degree of nuclear polymorphism , 
expression of CD10  and bcl6 without bcl2 and with 
exclus ively a breakpoint in  the MYC region. C, Case no. 68 
(43 years, tumor of both ovaries) algorithm A aBL, algorithm 
B nBL ,  with an even higher degree of nuclear 
polymorphism, that co-expressed bcl6 and bcl2 protein but 
lacked C D 1 0  and contained a double translocation in the 
MYC and BCL6 regions. D, Case no. 18 (32 years , 
ileocecum),  algorithm A DLBCL, algorithm B BL, containing 
tumor cells with abundant cytoplasm, and large nuclei with 
prominent eosinophilic nucleoli and an "open" chromatin 
pattern reminiscent of centroblasts and immunoblasts; this 
case showed the immunophenotype and genotype of BL: 
CD1 0 and bcl6 expression, with lack of bcl2 and a 
breakpoint in MYC with no other breakpoints. Note that this 
tumor presented as an ileocecal mass reminiscent of BL. E, 
Case no. 62 (48 years , tumor of the tonsi l) ,  algorithm A 
DLBCL, algorithm B nBL, with nuclei that are neither typical 
of BL nor DLBCL, that co-expressed CD1 0 and bcl6, without 
bcl2, but did not contain any detectable MYC or other 
breakpoint . F ,  One example of fluorescent in situ 
hybridization with MYC probes with colocalization of one set 
of probes and segregation of the other set of probes 
ind icating a monoallelic MYC/8q24 breakpoint. 
Discussion 
We report on the combined molecu lar and immunohistochemical analysis of lymphomas that 
represent a histologic gray zone area between classic BL and DLBCL. Since we could not relate our data to 
any establ ished gold standard , two algorithms for classification of the samples were compared . One 
algorithm attempted to make the d istinction between BL and DLBCL with conventional morphologic and 
immunohistochemical means, including a careful two-step pathology review procedure. The second 
algorithm aimed at separating BL from al l other lymphomas (collectively labeled as nBL)  and made use of 
purely immunophenotypic and genetic criteria . S ince submission of the cases to the study was already based 
on a primary morphologic selection (see Materials and Methods), the second algorithm omitted any further 
pathology review. 
In general ,  the great majority of DLBCL can be rel iably d isti ngu ished from BL, and the diagnostic 
problem on ly represents relatively rare borderl ine cases composed of small to medium-sized tumor cel ls with 
a high p rol iferation rate, a "starry-sky" appearance, and a cohesive growth pattern . 
Most l ikely due to a lack of firm histologic and phenotypic criteria and ubiquitously applicable 
molecu lar markers, the lack of a rea l gold standard as well as the continuous!� changing and confusing 
nomenclature, few informative publ ications are avai lable on this issue. 1 ·3 ·7 · 1 4· 1 6-1 8· 8·3° Certain stud ies made 
an attempt to link the borderl ine categories of "Burkitt- l ike lymphoma" and "smal l  non-cleaved, non-Burkitt's 
lymphoma" to DLBCL or BL and/or generated data on their biologic and cl in ical heterogeneity.7• 14·30 A recent 
report on 1 3  Burkitt- l ike lymphomas suggested that they represent a subcategory of classic BL and differ 
both biolog ica l ly and clin ically from DLBCL .7 However, the DLBCL samples of this study were randomly 
chosen while our DLBCL specimens were selected on the basis of morphologic simi larities with BL. I n  
keeping with previous reports, o u r  study confirms the lack of robust histologic criteria since a l l  fou r  
hematopathologists independently reached the same final d iagnosis in only 55% o f  a l l  submitted cases 
(algorithm A). 
Using algorithm B ,  31  % of the adult lymphomas were classified as BL. Interestingly, 8 of these 23 BL 
cases (35%) had been assigned DLBCL accord ing to algorithm A. Their exclusion from BL was mainly based 
on the nuclear pleomorphism with the presence of centroblasts and/or immunoblasts among smal ler more 
classic BL blasts . Vice versa, 6 of 2 1  (29%) lymphomas categorized as (a)BL by algorithm A should have 
been removed to the nBL category using algorithm B. This was due to the presence of a double (MYC and 
BCL2 or BCL6) breakpoint (3 cases) ,  lack of a detectable MYC breakpoint ( 1  case), and/or an 
immunophenotype thought to be incompatible with BL (5 cases) .  In  particu lar, bcl2 expression (>1 0% of 
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tumor cells positive) was frequently seen in these cases (5 of 6 cases). The combined application of both 
algorithms on the total group of adult gray-zone lymphomas resulted in a group of only 15 cases (20%; case 
N 1-15, Table 1) that, similar to the 10 pediatric cases, fulfilled all morphologic, phenotypic, and genetic 
criteria of aBL. Apart from the more robustness of the criteria, also some clinical data suggest that the 
definition of BL according to algorithm B might be slightly superior to that of algorithm A. 
In particular, more patients were male and presented with extranodal disease, both characteristics of 
pediatric and endemic BL as well. Since our study is retrospective in nature and obviously consisted of a 
mixture of patients who not only differed in treatment but also in clinical factors with well known independent 
prognostic impact on outcome in either BL and DLBCL, we could not use clinical outcome, eg, overall 
survival, to compare the different groups as defined by both algorithms. This was also impossible for the 18 
patients who were retrieved from two clinical trials with high-dose, short duration chemotherapy. Such an 
analysis would have required a much larger group of patients. 
A breakpoint within the MYC region was detected in all but one aBL as defined by algorithm A, 
indicating that the t(8;14) or variant translocation is associated with a certain morphology and phenotype. 
However, we frequently encountered this breakpoint in the remaining lymphomas as well (35% in our subset 
of DLBCLs according to algorithm A and 29% in the nBL group of algorithm B). Therefore, this marker should 
not be used alone but only in combination with other meaningful markers. Similarly, Au et al reported on a 
large spectrum of B-cell tumors carrying cytogenetically proven 8q24 aberrations, including BL, BLL, and 
(transformed) lymphomas such as follicular and mantle cell lymphomas as well.3 
Apparently, even in the cases not diagnosed as BL by both algorithms, our primary selection of 
lymphoma cases had already resulted in a biased shift of phenotypic and genetic characteristics toward BL. 
For instance, nBL diagnosed according to algorithm B expressed CD10 in 65% of the cases instead of the 
expected 20% to 45% in regular DLBCL. Similarly, almost all cases expressed bcl6 protein. This shift was 
also evident by the relatively low frequency of BCL6 breakpoints (22% instead of 30%�0% as expected on 
basis of literature data for regular DLBCL) and the high incidence of MYC breakpoints. The reported 
frequencies of MYC breakpoints in DLBCL vary between 4% and 15% depending on the methods used 
(cytogenetics, FISH, Southern blot, or long distance PCR).1 •5•9• 1 9•22•24•26•36 The FISH probes we used flank a 
large genomic region as compared with Southern blot or long distance PCR; however, this cannot fully 
explain the current high frequency of MYC breakpoints in DLBCL or nBL. In a separate study on 62 
International Prognostic Index (IPI) high risk but further unambiguous DLBCL in which we applied the same 
(FISH) methods, 18% had a MYC breakpoint, 18% a BCL2 breakpoint, and 27% a BCL6 breakpoint (Boerma 
EJ, personal communication). 
Eight tumors in adult patients contained a combination of MYC and BCL2 and/or BCL6 breakpoints. 
The combination of MYC and BCL2 breakpoints has been extensively described.21 •26•35•40 Lymphomas and 
leukemias carrying both breakpoints probably develop by a two-step transformation with first the generation 
of the 1(14;18) in a precursor B-cell and thereafter a break at 8q24/MYC that mostly occurs at the mature B­
cell stage. Although sometimes morphologically similar to aBL, these tumors should be distinguished from 
true BL with a sole break in MYC as they often represent a very aggressive disease with a poor clinical 
outcome. Tumors with a concomitant MYC and BCL6 breakpoint have been reported occasionally; however, 
the clinical and biologic significance of these alterations has not been established.1 •26•36 In the present series, 
the 3 cases with a MYC and BCL6 breakpoint shared morphologic and immunophenotypic similarities with 
lymphomas carrying double breakpoints in MYC and BCL2, including expression of bcl2 protein. 
Interestingly, in 2 of the 3 samples, the 3q27 breakpoint was located within the ABR of 3q27/BCL6 that is 
predominantly involved in follicular lymphoma.8 Whether such tumors represent transformed (follicular) 
lymphomas or are part of true BL remains to be established. 
Partly based on the expression of CD10 and bcl6, Burkitt lymphoma is considered as a neoplastic 
proliferation of (early) germinal center B cells. Since many DLBCL and nBL of our study also expressed 
CD10 and bcl6, also these lymphomas might be supposed to be derived from germinal center B cells. 
However, the frequent expression of bcl2 protein in 62% of the DLBCL and 73% of the nBL cases without a 
concomitant underlying t(14;18) is not compatible with a germinal center B-cell phenotype. Our data indicate 
that immunohistochemistry of bcl2 protein expression may be a surrogate marker for BCL2 and BCL6 
breakpoints. Based on this observation and the fact that bcl6 protein analysis has little additional value to 
CD10, we suggest that immunohistochemistry for Ki-67, CD10, and bcl2 in combination with FISH analysis 
for MYC breakpoints could be a minimum marker panel to be used for the diagnosis of BL in adult patients. 
Additional FISH analysis for BCL2 and BCL6 breakpoints might be advisable as well. Future, more extensive 
gene expression studies,2·4•23 but also genome-wide genetic studies such as comparative genomic 
hybridization or array comparative genomic hybridization, in combination with well-controlled clinical trials are 
indispensable to define the exact entity of adult BL and to learn which adult patients might benefit from 
specific therapeutic regimens. 
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Chapter 6 
Florid Granulomatous Reaction in Epstein-Barr Virus-positive Nonendemic Burkitt 
Lymphomas 
Report of Four Cases 
Eugenia Haralambieva, Stefano Rosati, Carel van Noesel, Evan Boers, 
Marinus van Marwijk Kooy, Ed Schuuring, Phi l ip Kluin 
Epithelioid cell granulomas have been reported in association with a wide range of neoplasms 
including malignant lymphomas. In lymphoma, this refers mainly to Hodgkin disease and T-cell derived non­
Hodgkin lymphomas where a granulomatous reaction is probably evoked by aberrant cytokine production in 
the tumor cel ls or other cells composing the tumor background. Here we report on four  cases of sporadic 
Burkitt lymphoma with unusual florid granulomatous reaction. In  all samples, the tumor cells were admixed 
with numerous epithelioid cells that formed clusters and granulomatous lesions. 
No microorganisms could be detected at the tissue level ,  and there were no cl in ical or laboratory 
indications of an underlying immunodeficiency. The lymphomas harbored a specific morphology and 
immunophenotype of Burkitt lymphoma, and the presence of translocation breakpoint in MYC gene was 
confirmed by lnterphase fluorescence in situ hybridization. In all four patients, the lymphoma was associated 
with Epstein-Barr virus infection, detected by EBER in situ hybridization and the latency I phenotype as 
defined by lack of expression of LMP1 . All four patients were treated with polychemotherapy, achieved a 
complete remission, and are alive without evidence of disease. We draw attention to this unusual 
phenomenon as ii caused difficulties in interpretation and delayed diagnosis and hypothesize on the possible 
role of Epstein-Barr virus products. 
Am J Surg Pathol 2004;28:379-383 
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Introduction 
In rare tumors, including malignant lymphomas, epithelioid granulomas may be encountered.4---8 The 
mechanism underlying this phenomenon remains poorly understood; however, some authors favor a view 
that it represents some form of local response to the tumor.6 
Clusters of epithelioid cells are not uncommon in peripheral T-cell non-Hodgkin lymphomas 20--23 and 
may be related to an aberrant cytokine production. For some categories, such as the lymphoepithelioid cell 
lymphoma (Lennert's lymphoma), they represent a characteristic histologic feature of the tumor.8•1 7  This 
phenomenon is relatively. common in Hodgkin lymphoma, both in the primary tumor and at sites that are not 
involved by the tumor. ·7· 1 4'2 2  Several reports suggested that the granulomatous reaction represents a 
nonspecific host response to the tumor and therefore it might account for a more favorable clinical outcome 
of these patients.22 In some instances, epithelioid granulomas may also be evoked by an associated infection 
(eg, mycobacteria but also other bacteria, viruses, fungi, or protozoa),4•6 which is not uncommon in states of 
an underlying, tumor-associated, or therapy-related immunodeficiency. Of note, local irritants may evoke a 
similar tissue reaction and also sarcoidosis can coexist with the lymphoma.4•5·7 
Occasionally a wanulomatous reaction was noted in B cell lymphomas,
3'9'1 5  with two reports on 
Burkitt lymphoma (BL). •1 3 Here we report on four cases of sporadic BL associated with an extensive 
granulomatous reaction. All four cases contained Epstein-Barr virus (EBV), which suggest a pathogenic role 
of this virus in the formation of the granulomatous lesion. 
Material and Methods 
All four samples were retrieved from the pathology files of the Department of Pathology and 
Laboratory Medicine, University Hospital Groningen, Department of Pathology, lsala Clinics, Zwolle and 
Department of Pathology, University Medical Center Amsterdam, Amsterdam, The Netherlands. All four 
cases have been collected during the histologic revision of the samples included in a separate study on BL 
(N = 67) from Europe, South America, and equatorial Africa (Haralambieva at al, in press). 
All samples were fixed in 4% buffered formalin and processed for routine histopathologic 
examination. Ziehl-Neelsen, periodic acid-Schiff, and Grocott stainings were performed for identification of 
acid fast bacteria, yeast and fungi in all tissue specimens. 
lmmunohistochemical labeling for molecules of relevance to the diagnosis of BL was performed on 
4-µm paraffin sections after antigen heat retrieval in 50 mM Tris/2 mM EDTA buffer solution, pH 9.0, for 30 
minutes in a microwave oven. The following markers were analyzed: CD20 (clone L26, dilution 1 :100; DAKO, 
Glostrup, Denmark), Ki-67 (MIB-1, dilution 1 :100; DAKO), CD10 (56C6, dilution 1 :20, Novocastra, Newcastle 
upon Tyne, United Kingdom), BCL2 (124, dilution 1:25, DAKO), BCL6 (PG-B6p, dilution 1:20, DAKO), and 
LMP1 (CS1-4, dilution 1:20, DAKO). lmmunostaining was performed in an automated Ventana NeXes 
staining machine (Ventana Medical System, Inc., Tucson, AZ) according to the manufacturers' instructions. 
The detection of EBER1-2 mRNAs was carried out by in situ hybridization on 4-µm paraffin tissue 
sections using a fluorescein-conjugated EBV (EBER) peptide nucleic acid probe (DAKO). The reaction was 
visualized with alkaline phosphatase conjugated anti-FITC sheep lgG Fab fragments (Roche, Mannheim, 
Germany) followed by 5-bromo-4-chloro-3-indolyl-phosphatase, 4-nitrobluetetrazolium (Roche) and MgCl2 
incubation. 
Fluorescence in situ hybridization (FISH) for detection of the breakpoints in MYC locus was 
performed on routine paraffin sections as described previously. 1 2  Two flanking probe sets were selected to 
detect most of the breakpoints reported in both endemic and nonendemic BL and designed for FISH 
segregation assay. Their selection and detailed characterization are described elsewhere (Haralambieva et 
al, in press). 
Case reports 
Case No. 1 
A 39-year-old Dutch, HIV-negative and previously healthy male patient presented with right axillar 
lymphadenopathy. A fine-needle aspiration cytology of the enlarged lymph node was interpreted as reactive 
due to the extensive presence of histiocytes. However, flow cytometric analysis of the aspirate suggested a 
clonal B-cell proliferation. Histologic examination of a removed lymph node indicated BL combined with 
epithelioid cell granulomas. Since the extensive epithelioid granulomatous reaction caused difficulties in 
interpretation, the case was referred for consultation where the diagnosis of BL was confirmed. The patient 
had no B symptoms. Computed tomography of the abdomen revealed an infiltration of the small intestine by 
the malignancy, but no other sites of involvement were detected by the routine staging procedure (stage 
IIIE). The patient was treated with intensive chemotherapy according to the HOVON 27 protocol, consisting 
of doxorubicin, cyclophosphamide, Uromitexan, and prednisone, followed by a second course of prednisone, 
etoposide, and mitoxantrone and autologous stem cell transplantation. The patient received also central 
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nervous system prophylaxis with intrathecal application of methotrexate and prednisone. He remained in a 
complete remission without evidence of active disease (1-year follow-up). 
Case No. 2 
A 52-year-old and previously healthy male patient presented with a swelling in the left submandibular 
area. No H IV test was performed. Physical examination indicated a lymph node with a diameter of 2 cm. 
H istologic examination showed partial involvement by BL together with an extensive granulomatous reaction. 
The sample was referred for consultation, and the diagnosis of BL was confirmed. The staging procedure 
revealed no other localization of the tumor and no B symptoms were reported (stage IA). The patient was 
treated with standard chemotherapy (CHOP) and rad iotherapy of the involved area. Since then he remained 
in complete remission (1-year follow-up). 
Case No. 3 
An 8-year-old , previously healthy Dutch girl presented with severe abdominal pain. The ultrasound 
and computed tomography procedures showed bulky mesenteric and mediastinal masses. A surgical sample 
from the mesenteric tumor showed morphologic and immunophenotypic features of BL. In the periphery of 
the sample, florid aggregates of epithelioid histiocytes were noted. The H IV status of the patient was not 
assessed. Serological investigations showed for EBV the following pattern: lgM anti-viral capside antigen < 
32, lgG antiviral capside antigen >10240, lgG anti early antigen (EA) >256, lgG anti Nuclear antigen >150. 
The patient was diagnosed as BL stage Ill and was treated with an intensive chemotherapy regimen 
according to the NHL-94 Dutch Childhood Oncology Group protocol, consisting of induction by vincristine, 
cyclophosphamide, prednisone, and intrathecal polychemotherapy followed by maintenance 
polychemotherapy consisting of vincristine, cyclophosphamide, adriamycin, high-dose methotrexate, 
prednisone and intrathecal polychemotherapy. After chemotherapy the patient remained in complete 
remission (8-year follow-up). 
Case No. 4 
A 4-year-old, previously healthy and H IV-negative, Dutch boy presented in the emergency unit with 
episodes of severe abdominal pain. An ileocecal invagination was diagnosed and initially treated 
conservatively. However, an ultrasound examination revealed an ileocecal mass of 5 >< 3 >< 3 cm, and the 
patient underwent an explorative laparotomy. Microscopic examination of the specimen revealed infiltration 
of the intestinal wall by BL.  At the periphery of the tumor and also admixed with the tumor cells, a prominent 
epithelioid histiocytic reaction was noted. The examined lymph nodes showed florid follicular hyperplasia and 
focal lymphoma involvement again accompanied by the epithelioid histiocytic reaction. A staging procedure 
revealed stage II and the patient was treated accord ing to the LMB-96 protocol with vincristine, 
yclophosphamide, adriamycin, and prednisone. After 2 courses of chemotherapy, complete remission was 
achieved and the patient showed no evidence of disease after completion of chemotherapy (3-year follow­
up ). 
Results 
The clinical data and the results of immunostaining, EBER in situ hybridization, and FISH are 
presented in Table 1. 
In all four samples, histologic examination revealed total or partial involvement of tumor composed of 
small- to medium sized cells with round nuclei and 2 to 5 non prominent nucleoli (Fig.1A). Numerous mitotic 
figures and apoptotic bodies accounted for the high proliferation rate of the tumor. A variable number of 
tingible body macrophages was admixed with the neoplastic cells giving rise to a starry sky appearance. In 
all the samples, there was a prominent infiltration of epithelioid histiocytes, forming small clusters and 
granulomas of different size. In 3 of 4 cases, they were intermingled with the tumor, replacing its usual 
monomorphic appearance (Fig. 1 B ,  C). Occasionally, granulomas did also spread in the reactive areas of the 
samples. The granulomas showed no central necrosis (Fig. 1C), although in case no. 4 they were closely 
related to the small area of tumor necrosis. In case nos. 2 and 4, occasional giant cells were identified within 
the granulomas (Fig. 10). 
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TABLE 1 .Main Cl inical and Pathological Findings 
patient age stte HIV stage histochemistry immunohistochemistry EBER FISH Outcome 
status m C 
39 right axillar I I IE  ZN - no acid CD20+, CD3-, CDS-, + + Complete 
lymph node, fast bacteria CD79a+, CD10+, remission 
small intestine PAS, Grocott BCL2-, BCLS+, ( 1 year follow 
- no microorg Ki67:95% up) 
2 52 submandibular Not IA ZN - no acid CD20+. CD3-, CDS-, + + Complete 
lymph node tested fast bacteria CD79a+, CD10+, remission 
PAS, Grocott BCL2-, BCLS+, ( 1 year follow 
- no microorg Ki67:99% up) 
3 8 mesenteric Not IVB ZN - no acid CD20+, CD3-, CD1 0+, + + Complete 
tumor tested fast bacteria BCL2-, BCLS+, remission 
PAS, Grocott lgM+/kappa+, Ki67:98% (8 years follow 
- no microorg up) 
4 4 lleocaecal tumor 1 1 8  ZN - no acid CD20+, CD3-, CD1 0+, + + Complete 
fast bacteria BCL2-, BCLS+ remission 
PAS, Grocott lgM/lgD+/kappa+, (3 years follow 
- no microor Ki67:99%, u 
In all 4 cases, the Ziehl-Neelsen, period ic acid-Schiff and Grocott stainings did not reveal any acid­
fast bacteria, yeasts, or fung i .  In addition, PCR performed on DNA preparations from case nos. 1 to 3 did not 
identify Mycobacterium tuberculosis (data not shown) .  Furthermore, no Schaumann crystals, asteroid bodies, 
or foreign bodies were observed within the granulomas. 
In 3 cases, the pronounced granulomatous reaction caused difficulties in i nterpretation and delay in 
diagnosis. Two of the samples were referred for consultation, and the aspiration cytology was false negative 
in one of them. In all cases, immunohistochemistry confirmed the presence of a highly proliferative B cell 
tumor (Ki67 index >95%) of germinal center phenotype (CD10 and BCL6 positive, BCL2 negative; Table 1). 
In all four samples, EBER in situ hybridization was positive for the tumor cells indicating EBV infection (Fig . 
1 E). All samples lacked expression of LMP1, indicating a latency I phenotype. In add ition, in all four samples, 
a translocation breakpoint in the region of 50-kb 3' to 170-kb 5' of MYC, including MYC itself was identified 





FIGURE 1. A composite picture, 
representing the details of the four 
described cases. A: Classic picture 
of BL, composed of small to 
medium size cells with round nuclei 
and scant cytoplasm . B: Numerous 
granulomas that obscure the 
presence of BL lymphoma. C: A 
small granuloma composed of 
epithelioid histiocytes, lacking 
central necrosis; note the Burkitt 
lymphoma at the right site of the 
picture. D: An occasional giant cell 
that may be found in the 
granulomas. E: All four BL cases 
are strongly positive for EBER 1 -2 m 
RNA by in situ hybridization. 
Here we report on an unusual combination of BL with an extensive epithelioid cell granulomatous 
reaction. Although well recognized in T-cell NHL  and Hodgkin disease, 1 ·7 ·8·1 7·20·2 1  this phenomenon has been 
rarely reported in B-cell lymphomas.3·9 ·1 1 •1 3 •1 5 ·23 We observed this phenomenon in four cases that were 
retrieved from the revision of a series of 67 BL from Europe, South America, and equatorial Africa 
(Haralambieva at al, in press), but we think that this phenomenon is overrepresented in our series since 2 of 
the 4 cases were sent to us for consultation and a third case was sent because the referring pathologist did 
know that we were interested in this particular phenomenon. 
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Previously, Halls et al 1 1  reported on 2 cases of BL with extensive necrosis surrounded by epithelioid 
cell granulomas mimicking tuberculosis. In contrast, necrotic areas were found in only one sample of our 
study and the granulomas did not contain central necrosis. A similar phenomenon has been described in 
seven patients with a small noncleaved lymphoma, 13 and probably at least part of them represented BL. In 
keeping with these two reports, the presence of a florid granulomatous reaction in our samples led to 
difficulties in the cytologic and histopathologic interpretation. In addition, Hollingsworth et al described an 
important clinical implication of this phenomenon, correlating the presence of the granulomas to a favourable 
clinical outcome of the patients.1 3  All patients in our series achieved a complete remission and remained 
without evidence of disease; however, the follow-up period for especially the adult patients is too short to 
draw any firm conclusions. The agents that provoke a granulomatous reaction in malignant lymphomas 
remain unclear. Hall et al 11 suggested that the extensive tumor necrosis itself leads to the granulomatous 
response. Indeed, BL is a tumor with an especially high rate of proliferation and apoptosis; however, in our 
cases, we did not find large necrotic areas as reported by Hall et al.1 1 Moreover, necrosis as observed in 
lymph node infarcts due to non-Hodgkin lymphoma involvement are often demarcated by a fibrohistiocytic 
wall but generally does not evoke a granulomatous reaction. In addition, necrosis can not explain the 
presence of a granulomatous reaction in other tumors nor its presence at distant uninvolved sites as can 
occur in Hodgkin lymphoma. 
A granulomatous reaction may also be caused by a concomitant infection by tuberculosis, yeast, 
fungi, or other microorganisms, or by the presence of inert foreign bodies including fecal contents in cases of 
intestinal perforation, but it might also occur coincidentally without identification of any etiologic agent. In all 4 
cases, we tried to exclude the involvement of any agent at the local tissue level by histochemical stainings 
(all cases) as well as PCR for mycobacteria (3 cases). 
Furthermore, 2 patients tested were HIV-negative, and none of the patients had clinical signs of an 
underlying immunodeficiency, which was supported by the uneventful outcome after the very intensive 
chemotherapy. 
Our observation that all four BL cases were EBV associated while originating from a nonendemic 
area suggests that EBV may have been a causative factor. Our 4 cases were retrieved from a series of 42 
BL from the Netherlands, with EBV being tested in 35 of the 42 cases. Excluding the current 4 (index) cases, 
only 8 of 31 BL (26%) were EBV positive; therefore, we think that this finding is not coincidental (the 
association between EBV and granulomas was highly significant; x2 test and Fisher exact test; P < 0.05). 
However, the current series of BL with a granulomatous reaction is very small, and studies on the EBV status 
in a larger series of lymphomas with a granulomatous reaction, including the already reported cases, 1 1 •1 3  
might clarify this issue. 
What could be the pathogenesis of this granulomatous reaction in EBV-positive BL, and what could 
explain why only very few EBV-positive BL, including none of the 18 EBV positive BL cases from equatorial 
Africa and South America (Haralambieva et al, submitted for publication), showed this phenomenon? EBV 
nuclear antigen 1 (EBNA 1) is the viral protein consistently expressed in all EBV-associated malignancies and 
in fact is the only EBV antigen expressed in BL (latency I phenotype). Whereas other EBV antigens like 
EBNA3A, B, and C are major targets of cytotoxic T lymphocytes, EBNA1 does not appear to be so.1 0• 1 7•1 8 
Recent studies 2• 1 0• 1 9  suggest that CD4+ T helper cells are capable of recognizing EBNA1 in an HLA class II 
restricted way and to develop a TH1 immune response, linked to delayed type hypersensitivity reaction and 
formation of granulomas. Interferon- y, a T H1 cluster cytokine, is a powerful activator of macrophages and the 
most important factor in transforming macrophages into epithelioid and multinucleated giant cells. 
lnterestin��• various CD4+ epitopes within the EBNA1 protein are linked to different HLA class II restricting 
alleles 2'1 • •1 9; therefore, the presence and magnitude of the TH1 response and concomitant production of 
granuloma inducing cytokines may vary dependent on the HLA polymorphism. Thus, this restriction to certain 
HLA alleles might explain why such a florid granulomatous reaction is only seen in very few individuals. 
Finally, it might be hypothesized that this EBV specific TH1 response is also correlated to the relatively 
favorable outcome of these BL patients. 
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Chapter 7 
Multiple myeloma and chromosomal translocations 
Multiple myeloma is a bone-marrow based, multifocal neoplasm derived from a clonal expansion of 
bone marrow plasma cells, representing the immunoglobulin secreting end-stage B-cells. The disease spans 
a spectrum of clinical conditions ranging from asymptotic smoldering and indolent forms to aggressive 
disease with plasma cell infiltration of various organs, severe osteolytic lesions or osteo�orosis with multiple 
bone fractures, plasma cell leukemia or abnormal immunoglobulin tissue deposition,. 1 •2• The presence of a 
monoclonal {-M} protein without any further evidences of multiple myeloma or other related disorder is 
categorized as a monoclonal gammopathy of undetermined significance {MGUS}. The disorder is 
considered to be benign since the clone is stable and the majority of the patients remain asymptomatic, 
however, after many years approximately 25% of them still develop multiple myeloma, light chain deposition 
disease {LCDD}, macroglobulinemia or an other lymphoproliferative disorder.1•3•4 
Recent studies emphasized the importance of genetic abnormalities regarding the biology and 
clinical outcome of MM patients.5•6•7•8•9 More than one-half of MM patients carry translocations involving the 
lgH locus and the remaining patients have hyperdiploidy as the hallmark of their disease.2•9•1 0 Other essential 
genetic aberrations represent chromosome 13 abnormalities, Ras mutations or inactivation of p53 by either 
deletion or mutation. 9'1 1 ' 12' 1 3  
Table 1 Prevalence and clinical importance of lgH translocations 
Abnormality MGUS&SMM (%) MM (%) Oncogenes Effect on prognosis 
lgL translocation <20 <20 c-myc and others Unknown 
lgH translocations 35-50 50-70 
t(4;14)(p16.3;q32) 2-10 15 FGFR3 and MMSET Adverse 
t(1 1 ; 14)(q1 3;q32) 1 5-30 16 eye/in D1 and MYEOV Favorable 
t(14; 16)(q23;q23) 2-5 5 c-maf Adverse 
t(6;14)(p21;q32) Unknown 4 eye/in D3, other Unknown 
Other lgH 1 0-15  1 5-30 mafB, MUM1, others Unknown 
MGUS - monoclonal gammopathy of undetermined significance; MM - multiple myeloma; SMM - smoldering MM 
Interestingly, almost all genetic lesions identified in MM are also present in MGUS 14' 15 and the 
incidence of igH translocation in MGUS is nearly as high as in MM, indicating that they represent an early 
genetic event. FISH studies demonstrate that lgH translocations are detectable in nearly 50% of MGUS and 
SMM, 55-70% of MM, 80% of r.rimary PC leukemia and > 90% of extramedullary plasmacytomas and human 
myeloma cell lines {HMCL} 2•5• •9. As HMCL are usually generated from the more aggressive M M  stages they 
may not precisely reflect the incidence of abnormalities found in vivo in the tumors but rather represent an 
ultimate stage of tumor progression.16 Limited data on translocations involving the light chain genes {lgL} 
indicate the prevalence of lgL ->.. translocations in - 10% in MGUS/SMM and -20% in advanced MM and 
HMCL. lgL-K translocations are relatively infrequent 3•5•6•9 In contrast to the other B-cell neoplasias, MM show 
a marked diversity of the chromosomal partners involved in lg translocations {Table 1 ). Apart from MYC at 
8q24, there are four major lgH translocation partners 11q13/ eye/in D1, 4p16/FGFR3/ MMSET, 6p21/eyelin 
D3 and 16q23/e-maf, with the latter two also involved in lg>.. translocation 1 • 3• 1 7"24• Other recurrent 
translocations that occur less frequently involve 20q11/maf-8 and 6p25//RF-4/MUM-1.25•26 It has been 
proposed that most primary lgH translocations result from errors in B-cell specific DNA remodelinJl 
mechanisms: mostly the lgH switch recombination and less often the somatic hypermutation machinery. 5• 
Since the translocation breakpoints are located within or very near lgH switch regions, lgH enhancers 
segregate into both derivative chromosomes and in consequence one or two potential oncogenes on each 
derivative chromosome can be deregulated. Thus, the t{4;14) results in deregulation in FGFR3 on der14 and 
MMSET on der4.2 1  Similarly, concurrent up-regulation of eye/in D1 and another putative 11q13 oncogene, 
M YEOV has been reported in MM cell lines that carry t{11;14).28 
Of note, the influence of lgH enhancers may extend over a large genomic region as is the case for 
c-maf in the KMS-11 cell line, where the gene is located at -1Mb from the enhancer.23 In such cases 
oncogenes located hundreds of kilobases away can still be transcriptionally up-regulated. In parallel with 
many other translocations, lgH translocations in MM are often unbalanced. For instance the t{4;14) is 
unbalanced in -25% of MM patients , however, these tumors never show loss of der 4 but always of der{14) 
involving FGFR3, indicating that MMSET and not FGFR3 is the target gene of the translocation. This is 
further supported by the observation that some MM cases show retention of der{14} but nevertheless loss of 
FGFR3 expression. 29 
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Translocations that involve MYC represent a paradigm for secondary translocations in MM and their 
incidence is related to disease progression from -3% in MGUS/SMM, 15% in MM and > 90% of HMCL, with 
marked heterogeneity within the tumor cell population 5•30•31 ·32·33• Most karyotypic abnormalities (not 
necessarily involving lgH loci) are complex translocations and insertions that are unbalanced and frequently 
involve more than two chromosomes. They also include amplification, duplication and inversion.31 '32 Simple 
reciprocal translocations involving MYC and the lg loci are less frequent and are usually not mediated by 
somatic hypermutation and/or class switch recombination. 
Current data suggest that specific cytogenetic abnormalities identify subsets of MM patients with 
unique clinical features and therapeutic response 34-38• The t(4;14) is an unfavorable prognostic factor in MM 
patients treated either with conventional or high dose chemotherapy. No difference between patients with or 
without FGFR3 expression have been found, again indicating that MMSET is the target gene of this 
translocation.35'39 This translocation is associated with more aggressive clinical features but also with an lgA 
isotype and A-light chain use.6•35 Limited data indicate that the t(14;16) is associated with similar poor clinical 
outcome.6 Of note, there is a high prevalence of complete or partial deletion of a long arm of the 
chromosome 13q or monosomy 13 (b.13) among patients with t(4;14) and t(14;16) and b.13 on its own 
already represents an adverse prognostic factor, both in patients treated with conventional and high dose 
chemotherapy.37·40•41 Since both genetic aberrations are seen at very early stages of the disease, and the 
order of these events is unknown, it could be discussed which lesion, the translocation or b.13 is most 
relevant. The high prevalence of b.13 in patients with t(4;14) and t(14;16) suggests primacy for a13, however 
it is also possible that these translocations allow a 13 to be "tolerated" by the tumor cells. 
The data on the prognostic value of t(11 ;14) in MM tumors are controversial, however, most recent 
studies indicate that MM patients with t(11;14) have a marginally better survival following conventional 
chemotherapy. 1 8'42 Of note, the outcome significantly improves in patients treated with high dose 
chemotherapy and stem cell support. 35•43 The t(11 ;14) is associated with an oligosecretory and non­
secretory variant, CD20 expression and lymphoplasmocytic morphology. Some cases express lgM instead of 
lgG or lgA 42,44,45 
There are limited data available on MM patients that carry t(6;14)(p21 ;q32) and t(6;14)(p25;q32), 
therefore the clinical implication and prognostic significance of these translocations remain enigmatic. The 
clinical and prognostic implications of MYC abnormalities are also not known, but likely to be negative related 
to overall survival, since MYC aberrations are more frequent in advanced tumors with a high proliferative 
index. 
Genetic lesions in MM have been studied using various methodologies, including conventional 
cytogenetics, metaphase spectral karyotype imaging/multicolor-FISH (SKY/M-FISH), Comparative-Genomic­
Hybridization (CGH), FISH, FICTION and microarray gene expression analysis. Cytogenetic analysis is only 
feasible in advanced MM and plasma cell leukemia. Due to the initially low tumor load and the low 
proliferation rate of the tumor, many cases with less advanced disease (50-70%) reveal normal karyotypes 
that originate from the myeloid elements instead of tumor cells. 34•38•46•47• Even among patients with abnormal 
karyotypes, some of the most important aberrations may be cryptic.20•23 For instance the t(4;14)(p16.3;q32) 
occurs in 15-20% of all MM but can not be recognized in MM karyotypes.20•21 •22 Similarly the 
t(14;16)(q32;q23) is difficult to detect by conventional G-banding, while the detection success rate 
significantly improves by the usage of SKY/M-FISH.23•48•49•50 In contrast, karyotypic analysis is a much more 
sensitive method for the detection of numerical chromosomal abnormalities. Multicolor metaphase FISH (M­
FISH/SKY) is applied to improve the accuracy of conventional cytogenetics, especially for analysis of 
complex karyotypes.48•49•50 FISH represents a preferable technology for screening for various (already 
established) genetic aberrations since it can be performed on non-dividing cells and has a high sensitivity 
and specificity. 10•1 1 • 1 4•1 5•40•41•42 It, therefore, has been successfully used for recognition of numerical 
aberrations (trisomies/monosomies), deletions such as del13q and del17p13.1 but especially of 
translocations involving the lgH , lgL and other loci. To improve the detection of a given genetic aberration, 
especially in patients with a low tumor burden, FISH is preferably combined with cell purification procedures 
(e.g. CD138+ microbead selection) or simultaneous immunofluorescence. Translocations are successfully 
detected using segregation FISH, co-localization FISH or a combination of both techniques. Specific 
problems as VH rearrangement with deletion of DNA template that results in a weak FISH signal and the 
unbalanced nature of some MM translocations should be considered in the evaluation of FISH results. The 
t(4;14)(p16.3;q32) can be also detected by reverse transcription-PCR detection of the lgH-MMSET hybrid 
transcript. 20•21 
Gene expression profiling is also used for the molecular classification of MM and its relation to 
MGUS.51 '52 Recent studies suggest that the majority of the recurrent lgH translocations are also detectable 
by gene expression profiling with spiked expression patterns of the genes involved in the specific 
translocations. 5 1  
Many recent reports emphasize the importance of cr.clin D aenes in the pathogenesis and 
progression of MM and related plasma cell disorders, 1 7' 1 8' 22• 3s--3 • 42"'5•51 ' 5!!'·57 ,however, there are still many 
open questions. For instance, in mantle cell lymphoma the presence of t(11 ;14) strongly correlates with 
cyclin D1 RNA and protein over-expression 58 as a functional endpoint of the genetic lesion. In contrast, in 
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MM cyclin 01 expression and 11q13 aberrations are not that strictly correlated in MM. Thus up to 30% of MM 
patients show Cyclin 01 overexpression as measured by immunohistochemistry or RT-PCR, while the 
incidence of the t(11 ;14) translocation is 15-20% as assessed by FISH studies. Although the discrepancy 
may be partially due to methodological differences and/or patient's selection, it suggests that mechanisms 
other than an 11q13 breakpoint may trigger cyclin 01 overexpression in MM. In chapter 8 we investigated 
this issue by studying a large series of MM with various methods. 
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Chapter 8 
Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed 
by fluorescence in situ hybridization and quantitative analysis of mRNAlevels 
Katja Specht, Eugenia Haralambieva, Karin Bink, Marcus Kremer, Sonja Mandi-Weber, Ina Koch, Raju 
Tomer, Heinz Hofler, Ed Schuuring, Philip M. Kluin, Falko Fend, Leticia Quintanilla-Martinez 
The t(11;14)(q13;q32) is the most common translocation in multiple myeloma (MM), resulting in up­
regulation of cyclin D1. We used a segregation fluorescence in situ hybridization (FISH) assay to detect 
t(11 ;14) breakpoints in primary MM cases and real-time reverse transcriptase-polymerase chain reaction 
(RT-PCR) to quantify cyclin D1 and MYEOV (myeloma overexpressed) expression, another putative 
oncogene located on chromosome 11q13. High levels of cyclin D1 mRNA (cyclin D1/TBP [TATA box binding 
protein] ratio > 95) were found exclusively in the presence of a t(11;14) translocation (11/48 cases; P < 
.00001). In addition, a subgroup of MM cases (15/48) with intermediate to low cyclin D1 mRNA (cyclin 
D1/TBP ratio between 2.3 and 20) was identified. FISH analysis ruled out a t(11 ;14) translocation and 11q13 
amplification in these cases; however, in 13 of 15 patients a chromosome 11 polysomy was demonstrated (P 
< .0001 ). These results indicate an effect of gene dosage as an alternative mechanism of cyclin D1 
deregulation in MM. The absence of chromosome 11 abnormalities in 2 of 15 patients with intermediate 
cyclin D1 expression supports that there are presumably other mechanism(s) of cyclin D1 deregulation in 
MM patients. Our data indicate that deregulation of MYEOV is not favored in MM and further strengthens the 
role of cyclin D1 overexpression in lymphoid malignancies with a t(11 ;14 )(q13;q32) translocation. 
Blood. 2004;104: 1 120-1 126 
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Introduction 
Translocations involving the immunoglobulin heavy chain region (lgH) on chromosome 14q32 are an 
important cytogenetic event in the pathogenesis of various B-cell lymphoid neoplasms such as multiple 
myeloma (MM), mantle cell lymphoma (MCL), Burkitt lymphoma, and follicular lymphoma.1·2 In MM, these 
translocations are thought to be an early event in the pathogenesis, occurring mostly during class switch 
recombination in terminally differentiated B cells and leading to deregulation of translocated genes under the 
influence of the lgH enhancers on 14q32. The lgH locus contains at least 3 different enhancers: the 5' 
intronic µ enhancer (Eµ) located in the intron between the lgH joining (JH) and switch µ �Sµ) sequences and 
two 3'-lgH enhancers located downstream of the constant region genes (Ea1 and Ea2).3• The breakpoints in 
the lgH locus are usually inside switch regions and can result in separating and splitting of 2 different 
enhancers to each derivative chromosome, theoretically leading to deregulation of genes on both derivative 
chromosomes. Occasionally, breaks also occur in the JH region or in the diversity and joining (DJ) region on 
the basis of hypermutations followed by chromosomal breakage. More than 20 different chromosomal 
partner regions that translocate to 14q32 have been identified so far in MM,s-a of which the t(11;14)(q13;q32) 
is the most common translocation with a reported frequenci of 15% to 20% based on fluorescence in situ 
hybridization (FISH) or conventional cytogenetic analysis.a- The 1(11 ;14)(q13;q32) translocation results in 
up-regulation of the cell cycle regulatory proto-oncogene CCND1/cyclin D1, which is normally not expressed 
in plasma cells. In MM the breakpoints are scattered within a 360-kb region between CCND1 and MYEOV.1:i-
15 MYEOV is a putative oncogene previously identified by the application of a NIH3T3 tumorigenicity assay 
with DNA from a gastric carcinoma15 and lacks homology to any known gene. MYEOV is located 360 kb 
centromeric of CCND1 and its activation, concurrent to CCND1 bl juxtaposition of MYEOV to either the 5' 
Eµ or the 3' Ea lgH enhancer, has recently been described.1 However, although MYEOV (myeloma 
overexpressed) was overexpressed in a subset of MM cell lines with 1(11 ;14), it has never been investigated 
in primary MM cases. The aim of this study was, therefore, to investigate both cyclin D1 and MYEOV 
deregulation by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) in a series of 
primary MM cases and to explore its relationship to the presence of a 1(11;14)(q13;q32) translocation, as 
assessed by a FISH assay.16 
Patients, materlals, and methods 
Tissue samples 
Sixty formalin-fixed, paraffin-embedded blocks of 48 patients with MM diagnosed between 1991 and 
2002 were retrieved from the files of the Institute of Pathology, Technical University of Munich (Munich, 
Germany). 
In 9 of these MM cases, 2 or 3 biopsies taken at different time points over a period of up to 5 years 
were available. The biopsies were not decalcified, as most of the material was obtained during surgery from 
large osteolytic lesions. The cases were graded according to the histologic grading criteria described by Bartl 
et al17 and were reviewed by 3 of the authors (L.Q.-M., M.K., and F.F.). Some of the cases have been 
reported previously as part of another study.18 In addition, 14 formalin-fixed, paraffin-embedded blocks of 
non neoplastic lymphoid tissues (6 lymph nodes, 4 tonsils, and 4 decalcified bone marrow biopsies with 
reactive changes) were included as normal tissue controls. 
Cell lines 
In addition to the primary cases, 7 human myeloma cell lines (KMM1, OPM2, U266, KMS5, KMS11, 
KMS12, and KMS18), 2 mantle cell lymphoma cell lines (Granta 519 and NCEB), one anaplastic large cell 
lymphoma cell line (Ki-JK), 2 diffuse large cell lymphoma cell lines (SUDHL-4 and SUDHL-10), and 4 
carcinoma cell lines (HT29, A431, MDA-MB231, and MDA-B468) were used in the study. The carcinoma cell 
lines were acquired from American Type Culture Collection (ATCC; Manassas, VA) and cultured as 
recommended by the supplier. All lymphoid cell lines were cultured in RPMI 1640 medium supplemented 
with 15% fetal calf serum, 2 mM glutamine, 10 U/ml penicillin, and 60 µg/ml streptomycin (lnvitrogen, Life 
Technologies, Karlsruhe, Germany). 
RNA extraction and QRT-PCR 
Tissue preparation, microdissection of pure tumor cell populations, and RNA extraction from 
formalin-fixed tissues were performed as described previously.19 Briefly, approximately 10 000 tumor cells 
were microdissected from each deparaffinized sample. Cells were lysed in 200 µL Tris/EDTA 
(tris(hydroxymethyl)aminomethane/ethylenediaminetetraacetic acid) lysis buffer and 500 µg/ml proteinase 
K. After complete digestion at 60°C, RNA was purified by phenol-chloroform extraction, precipitated, and 
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dissolved in 20 µL H20. Total RNA from cell lines was isolated using the acid-phenol-chloroform 
guanidinium method.20 Extracted RNA was DNase treated by incubating the RNA for 1 hour at 37°C with 
1 0U of DNAse I (Roche, Basel, Switzerland). Reverse transcription was performed with 250 ng of random 
hexamers (Roche) and 200U of Superscript II-reverse transcriptase (lnvitrogen, Life Technologies) in a final 
volume of 20 µL, following the manufacturer's directions. 
QRT-PCR analyses were performed using the ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA). 
MYEOV primers and probe were as follows, yielding a 80-bp product for MYEOV (designated by the 
nucleotide position relative to MYEOV GenBank accession number AJ223366): MYEOV-901 sense, 5'­
CGGTGAGAGGAGCATTTGTGT-3'; MYEOV-980 antisense, 5'-GGCACCCTTGTCTCCCTTGT-3'; and 
MYEOV-930 probe, 5'-FAM TTTGCTGCTGGAGCTGGTGACCG-3'TAMRA. PCR reaction conditions, 
sequences for primers and probes for cyclin 01 and TBP (TATA box binding protein) as housekeeping gene 
control, and quantification procedures have been published.19 The cutoff value for altered cyclin 01 
expression was based on the mean value of cyclin O1/TBP ratios determined in 8 reactive lymphoid tissues 
and bone marrow samples + 5 standard deviations and was 2.33 (mean, 0.84; range, 0.31-1.38). Ratios 
between 2.33 and 20 were arbitrarily considered to represent low (2.33-9.9) to intermediate (10-20) cyclin 01 
overexpression and ratios above 20 or more to represent high cyclin 01 overexpression. Amounts of 
MYEOV and TBP RNA were calculated using linear regression analysis from an external standard curve 
generated from KMS12 RNA. MYEOV/TBP ratios were determined in 14 reactive tissues from lymph nodes 
(LNs), bone marrow (BM), and tonsils (mean, 0.15; range, 0.02-0.5). MYEOV/TBP ratios below 1.0 (mean + 
5 standard deviations) were arbitrarily considered to represent normal or negative MYEOV levels. 
FISH 
B-cell leukemia/lymphoma-1 (BCL-1) breakpoints (5' and 3'of the CCND1 gene) were detected by a 
previously designed interphase FISH segregation assay.13•21 In brief, 2 probe sets were selected after 
mapping of large contigs of probes on normal DNA fibers resulting in a so-called color barcode of the BCL-
1/11 q13 region. Subsequently, a consecutive mapping of all possible breakpoints by applying the same set 
of probes on DNA fibers from tumor material with a putative BCL-1/11q13 breakpoint was performed. A 
schematic representation of the probe sets for detection of the BCL-1 /11q13 breakpoints is shown in Figure 
1A. The pooled cosmids cos6.7/cCl-11-44 were used in combination with the pooled cos6.31/cosH1 .5 to 
detect the breakpoints within an 800-kb region around CCND1. In approximately 8% of MCL cases, we 
previously identified a mono-allelic breakpoint both immediately 3' as well as 5' of the CCND1 gene.24 
Because these mono-allelic double breaks will not be detected with the 800-kb flanking probe set, MM cases 
negative for this latter probe set were studied with cos6.22/CCND1 in combination with the pooled cos6.31 
and cosH1.5 (Figure 1A). 
To determine the position of CCND1 relative to lgH enhancers (Figure 1B), the breakpoint-positive 
cases were analyzed by a colocalization assay using 2 probe sets (Figure 1A-B): (1) cos6.22 (covering 
CCND1) in combination with the pooled cosmid U2-2 (covering the JH and part of the diversity and heavy 
region (DH] gene segments) and cos3/64 (covering the JH, C6, and Cµ gene segments) as described by 
Vaandrager et al 23 and Matsuda et al 22; and (2) cos6.22/CCND1 in combination with PAC27M16 located 
immediately 3' of the immunoglobulin Ca2 region (provided by Dr 0. Cox, Research Institute, Hospital for 
Sick Children, Toronto, ON, Canada). 
Probes were labeled by the Kreatech Universal Linkage System (ULS) nonenzymatic labeling 
method (Kreatech Diagnostics, Amsterdam, the Netherlands) with biotin-16-aUTP or digoxygenin-11-dUTP 
(Roche). The adapted conditions for the hybridization on routine tissue sections from formaldehyde-fixed, 
paraffin-embedded tissue blocks were described recently.16 
Signals were considered colocalized when the distance between them was equal or smaller than the 
size of one hybridization signal. Any breakpoint should result in segregation of one or both probe sets and 
the presence of single red and/or single green hybridization signals in tissue sections.16 In the 7 negative 
control tissues, single signals were detected in 1% to 7% (mean, 4.9%; standard deviation, 1.9%) of the 
nuclei and the cutoff levels for both probe sets were set at 11.0% (mean plus 3 times the standard deviation). 
Samples that showed evidence of increased copy number for CCND1 locus were studied separately 
using the CEP11 probe, labeled with SpectrumGreen, that hybridizes to the alpha satellite DNAsequence 
located at the centromere of chromosome 11 (11p11.1-q11) in combination with CCND1 gene locus 
(11q13}-specific probe labeled with SpectrumOrange (Vysis, Downers Grove, United Kingdom). Tissue 
pretreatment was performed as previously described.25 FISH signals of at least 100 nuclei of each tumor 
area were evaluated by 2 investigators using a laser scanning microscope (LSM 510; Carl Zeiss, Jena, 
Germany) equipped with epifluorescence optics (C-Apochromat X 63/1.2 Wcorr) and an appropriate 
combination of emission filters (BP-500-550 IR, BP-565-615 IR, LP 650). 
Image processing was carried out with Zeiss software (AIM 3.0). Following the criteria of Hopman et 
al,26 each case was classified as amplified for the CCND1 gene locus if there were more than twice as many 
clustered red cyclin 01 signals as green centromere 11 signals (ratio > 2). A polysomy 11 was diagnosed if 
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more than 20% of all nuclei showed more than 2 nuclear red signals accompanied by the same number of 
nuclear green signals (ratio 1 ). 
lmmunohistochemistry 
lmmunohistochemistry was performed on an automated immunostainer (Ventana Medical System, 
Tucson, AZ.) according to previously published procedures.18 The cyclin D1 antibody used in this study was 
from Novocastra (Newcastle, United Kingdom; clone P2D11 F11) and CD20 was from Dako (Glostrup, 
Denmark; clone L26). Images were recorded using a Hitachi camera HW/C20 instal led in a Zeiss Axioplan 
microscope with lntell icam software. Adobe PhotoShop (San Jose, CA) was used for image processing. 
Statistical analysis 
To characterize differences in the mRNA levels between the various MM cases, descriptive statistics 
was used. For continuous variables, the Wilcoxon rank sum test was used to test for differences between 
patients with the t(11 ;14 )(q13;q32) translocation versus other patients. The Fisher exact/chi-square test was 
used for the count data. To correlate between polysomy and nonpolysomy cases, the Wilcoxon rank sum 
test was used. All the tests were performed using functions of ctest package of R libraries for statistical 
computing (www.r-project.org). 
Results 
Quantitation of eye/in D1 mRNA in 48 primary cases of MM 
To establ ish and validate the system for real-time cyclin D1 expression analysis we first analyzed a 
series of well-characterized cel l l ines (Table 1 ). Increased expression of cycl in D1 correlated with both DNA 
amplification in 4 carcinoma cell l ines and with the lymphoid cell l ines carrying t(11 ;14). The results of cyclin 
D1mRNA expression levels in the primary MM tumors are summarized in Table 2. Cyclin D1 mRNA 
transcript levels are clustered in 3 different groups (Figure 2). Group 1 included 11 (23%) cases displaying 
high cyclin D1 mRNA levels (cycl in D1/TBP ratio _ 95; median, 171.3; range, 96. 76-666.25). A second group 
included 15 (31%) cases with low to intermediate cyclin D1 mRNA levels (cyclin D1/TBP ratio between 2.3 
and 20; median, 7.64; range, 2.5-18.72). In 2 patients (cases 12 and 17), follow-up biopsies taken up to 5 
years apart showed simi lar results, indicating that the overexpression of cyclin D1 remains stable over time. 
Final ly, the third group comprised the remaining 22 (46%) cases with normal or negative expression of cyclin 
D1 mRNA (cyclin D1/TBP ratio between O and 2; median, 0.6; range, 0.11-2.03). 
Table 1 Cyclin D1 and MYEOV gene expression levels in lymphoma and carcinoma cell l ines 
Cell Line Origin Q-RT-PCR 11 q 13 status 
CyDI MYEOV 
KMMI Multiple Myeloma absent 0.05 ND 
OPM2 Multiple Myeloma absent 0.05 not amplified KMS5 Multiple Myeloma O.D7 0.42 ND KMSI I  Multiple Myeloma 0.2 2.09 not amplified KMSl2 Multiple Myeloma 29 6.05 t(l l ; l4)(q13;q32) KMSl8  Multiple Myeloma absent 8.33 not amplified U266 Multiple Myeloma 4.2 0.2 Insertion 11 q •, Disomy 
IG-JK Anaplastic Large Cell Lymphoma absent 0.59 ND NCEB Mantle Cell Lymphoma 28.4 2 1 .36 t(l 1 ; 14)(q13;q32) Granta 519 Mantle Cell Lymphoma 79 0.3 t(l l ; 14)(q13;q32) SUDHL-4 DLCL absent 0.06 ND SUDHL-10 DLCL absent 2.84 ND HT29 Gastric Carcinoma 8.8 36. 1 8  amplified A43 1 Squamous Carcinoma 34.6 275 amplified MDA-MB23 1 Breast Carcinoma 7.73 27.5 amplified MDA-MB468 Breast Carcinoma 10. 1 5  2 1 .5 amplified 
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Table 2 FISH and real-time RT-PCR analysls In 48 cases of MM 
Case Age Sex MG Histology Segregation Locus-Specific Q-RT-PCR IHC 
FISH FISH CyDI MYEOV CyDI 
Group 1 :  1(1 1 ; 14) Positive and High Cy01 mRNA and Protein I 64 M G,,c I-LP NF ND 666.25 1 .99 +++ 2a• 78 F G,,c Pos ND 425 9.57 +++ 2b• Pos, i copies ND 571 ND +++ 3 58 M G,,c I-LP Pos ND 408.09 3.3 +++ 4 59 M ... I-LP Pos±, t copies ND 192.9 3.71 +++ 
5 61 F 1C I Pos, i copies ND 175.9 0.55 +++ 6 81  M 1,. I-LP Pos•, icopies ND 166.71 0.03 +++ 7 56 F G,,c I Pos±, t copies ND 163.51 2.71 +++ 8 59 M 1C I-LP Pos, i copies ND 145.22 0.35 +++ 9 76 F 1,. Pos ND 139.24 44.4 +++ 1 0  40 M G,,c Pos±, t copies ND 103.85 1 .98 +++ 1 1 •  76 M 1C I-LP Pos ND 96.76 1 .79 +++ 
Group 2: t(1 1 ;14) Negative and Low to Intermediate Cy01 mRNA and Protein 12a 67 M G,K I-LP Neg, i copies Polysomy 18 .72 7.58 ++ 12b Neg, i copies Polysomy 14.23 ND ++ 12c Neg, icopies Polysomy 17.07 ND + 1 3  78 M ... Neg Disomy 15.44 ND ++ 14 69 F G,K Neg Disomy 15.34 24.28 ++ 1 5§ 32 M G,K Neg, icopies Polysomy 15.36 31 .59 + 16  66 M G,K I-LP Neg, icopies Polysomy 12.42 1 .76 + 17a 59 M G,K I ND Poiysomy 10.49 7.25 + 17b Neg, icopies Polysomy 5.27 ND + 1 7c Neg, i copies Polysomy 6.7 ND + 1 8  74 F G,K Neg, i copies Polysomy 3.78 1 1 .34 ++ 19  74 F G,K I Neg, i copies Polysomy 7.79 10.42 Neg1 20 60 F G,1,. II Neg Polysomy 7.64 1 .59 Neg 2 1  6 1  M ... I Neg, i copies Polysomy 6.6 19.95 Neg1 22• 56 F ... I-LP Neg, i copies Polysomy 4.14 13.94 Neg 23 60 F G,K I Neg, icopies Polysomy 3.63 0.36 Neg 24 68 M ... Neg, icopies Polysomy 3.28 2.34 Neg1 25• 69 F G,K Neg Polysomy 2.56 3.57 Neg 26 73 M G,K I Neg, i copies Polysomy 2.5 3.2 Neg 
Group 3: 1(1 1 ;14) and Cy01 mRNA and Protein Negative 27 76 M A,1,. II Neg ND 2.03 0.36 Neg 28 48 F 1,. II Neg ND 1 .55 0.18 Neg 29 63 F G,K II Neg ND 1 .26 NF Neg 30 79 F ... I Neg ND 1 .23 2.1 3  Neg 3 1  47 F K I Neg ND 1 .0 4.23 Neg 32 71 F G,K I Neg ND 0.87 6.6 ND 33 52 M G,1.. I Neg ND 0.77 Absent Neg 34 72 F ... II Neg ND 0.77 0.44 ND 35 75 M ... II Neg, icopies Polysomy 0.67 0.01 Neg 36 74 F K I Neg ND 0.62 0.8 Neg 37 55 F 1,. I Neg ND 0.57 1 . 14 Neg 38• 63 F A),. I Neg ND 0.46 13.38 Neg 39a 75 F K I Neg ND 0.44 ND Neg 39b Neg ND 0.14 2.48 Neg 40 62 F M,1.. II Neg ND 0.7 2.66 Neg 41 69 M G,1.. I Neg ND 0.38 ND Neg 42a 64 M G,K II Neg ND 0.37 ND Neg 42b Neg ND 0.82 3.42 Neg 42c Neg ND 0.42 ND Neg 43 54 M 1,. I-LP Neg ND 0.27 4. 14 Neg 44§ 64 F G,1.. I Neg ND 0.26 6.8 Neg 45 63 M G,1.. I Neg ND 0.26 6.24 Neg 46 64 E G,1.. I Neg ND 0.2 5.8 Neg 47 76 M G,K II Neg ND 0.13 1 .28 Neg 48 57 M ... I Neg ND 0. 1 1  0.21 Neg 
MG: monoclonal gammopathy; LP: tymphoplasmocytoid morphology; NF not feasible; ND not done; • 
positive for CD20 in a proportion of tumor cells; ... data are not available; ± segregation FISH pattern 
indicative of a translocation with subsequent loss of the derivative chromosome containing MYEOV 
(see Figure 1 0  for a representative example); § multiple biopsies were analyzed; 
I HC score: cyclin 01 +++ _80% tumor cells strongly positive, ++20-50% tumor cells positive, +1 0-
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20% tumor cells positive; ,i cases were considered negative, however, rare bona fide plasma cells were 
positive for cyclin D1 
FISH analysis in primary cases of MM 
Fifty-five routine paraffin samples of 48 MM patients were analyzed by segregation FISH for the 
presence of breakpoints in the CCND1 locus (Table 2). Case 1 was not informative because of the 
consistently weak hybridization signal. Overall, 10 patients (21%) showed evidence of a CCND1 breakpoint 
by the presence of high numbers of segregated FISH signals on tissue sections with the 5' probe set (group 
1; Figure 1 C-E). Further analysis revealed a specific FISH signal pattern in 4 of these patients (cases 4, 6, 7, 
and 10) consisting of 2 co-localized signals representing the normal allele and a single red signal (Figure 
1 E). This pattern and the lack of a single green signal indicated the presence of a mono-allelic translocation 
break in the CCND1 locus with a loss of the derivative chromosome der(11) carrying MYEOV (Figure 1 A,E). 
No additional breakpoints were detected in any of the breakpoint negative cases tested by the 3' 
probe set. 
Colocalization FISH demonstrated that in all evaluable cases in group 1, BCL-1/CCND1 was 
juxtaposed to lgH sequences. In cases 2, 4, 7, and 10, the 6.22/CCND1 probe colocalized with PAC27M16 
but not with cosmids U2-2 and cos3/64, suggesting that the breakpoints were localized either in the gamma 
or alpha switch region of the lgH locus and, thus, CCND1 is only juxtaposed to 3'-Ea enhancers and not to 
the intronic 5'-Eµ enhancer. In cases 5, 6, and 8, the CCND1 signal colocalized with a smaller red signal 
derived from U2-2 and cos3/64 indicating a break at JH or Sµ. 
Since this interphase FISH assay cannot discriminate between a break in JH or Sµ, we cannot 
conclude whether CCND1 is juxtaposed to all 5'-Eµ and the 3'-Ea enhancers (in case of a break within the 
JH region) or only the 3'-Ea enhancers (in case of a Sµ break). In cases 9 and 11, the 6.22/CCND1 probe 
colocalized with PAC27M16, but all signals from cosmids U2-2 and cos3/64 were lost in tumor population 
although they were present in admixed non-MM cells. Consequently, we could not draw any conclusion on 
the exact breakpoint within the lgH locus. Case 3 was not analyzed by colocalization FISH because of lack of 
material. 
In 22 samples of 19 patients, segregation FISH indicated the presence of an increased copy number 
for theCCND11ocus (Figure 1 F). 
In order to confirm this finding and to be able to distinguish between low-level amplification from 
increased chromosome copy numbers (polysomy), these samples and all cases with intermediately elevated 
cyclin D1 levels (cases 12-26 and 35) were further analyzed by FISH with a CCND1 locus-specific probe 
and a chromosome 11 centromeric probe. The results are listed in Table 2. Fourteen cases were scored as 
having an 11q13 polysomy (Figure 1G-H), while only 2 cases with elevation of cyclin D1 levels (13 and 14) 
were disomic (Figure 11). None of the cases showed an 11q13 amplification. 
Histologic findings and immunohlstochemlstry 
Histologically, 39 cases (81%) were composed of well-differentiated plasma cells (Bartl grade I) and 
9 cases (19%) were moderately differentiated (Bartl grade 1 1).17 Ten cases revealed lymphoplasmacytoid 
differentiation (Table 2). Cyclin D1 expression was observed in 18 cases (37.5%). Strong, homogenous 
nuclear staining in the majority of tumor cells (> 80%, +++) was observed in 11 of 18 cases (Figure 3A). 
Intermediate cyclin D1 protein expression (20%-50%, ++) was observed in 4 cases (Figure 3B), and low 
levels of protein expression (10%-20%, +) were observed in 3 cases (Figure 3C). Cases 19, 21, and 24 were 
considered negative (Figure 3D); however, rare bona fide plasma cells were positive for cyclin D1. Four of 48 
cases (8.3%) showed focal expression of CD20. 
Co"elation between the expression of eye/in D1 mRNA and protein with the presence of 
11q13 alterations 
The expression of cyclin D1 (mRNA and protein) together with the presence or absence of the 
t( 11; 14) translocation clearly defined 3 different groups. Group 1 included the 11 (23%) cases displaying high 
cyclin D1 mRNA levels. All 10 evaluable cases showed the t(11;14) translocation by segregation FISH and 
strong nuclear staining for cyclin D1 (+++; Table 2 and Figure 3A). Group 2 contained 15 (31%) cases with 
low to intermediate elevation of cyclin D1 mRNA and no evidence of the t(11 ;14) translocation. 
Thirteen of these 15 cases showed polysomy by the locus-specific probe FISH. The 11q13 
amplification was not identified in any of the cases. In contrast to the previous group, cyclin D1 protein 
expression varied from negative to (++) positive. The correlation between cyclin D1 mRNA and protein 
expression was generally good. Cases with low mRNA levels (cyclin D1/TBP ratio <10) tended to be 
negative or (+) positive for cyclin D1 protein expression, confirming our previous observations that real-time 
RT-PCR is a more sensitive method for the detection and quantitation of cyclin D1 .19  The association of 11 q 
polysomy and low to intermediate cyclin D1 mRNA expression was statistically highly significant (P < .0001 ). 
Group 3 comprised the remaining 22 (46%) cases with normal or negative expression of cyclin D1(mRNA 
and protein) and no alteration of the 11q13 locus. Only in one case (case 35) was a polysomy for 11q 
identified by FISH. 
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Figure 1. Patterns of FISH probes used in this study. (A) Schematic representation of the probe sets used for detection of the 
1(1 1 ;  14)(q1 3;q32) breakpoint in chromosome 1 1 q13 ,  consisting of differentially labeled (green and red) pooled cosmids and P1- derived 
artificial chromosomes (PACs). (Adapted from Haralambieva et al16 with permission.)  (B) Schematic representation of the 
immunoglobulin heavy chain (lgH) gene locus and the lgH FISH probes used in the CCND1 colocalization assay. Cosmid U2-2 covers 
JH and part of DH gene segments and cos3/64 covers the JH, Cµ, and C6 gene segments, as described by Southern blotting analysis 
with segment-specific probes 22 and DNA fiber FISH mapping.23 PAC clone PAC27M16 was mapped by DNA fiber 
FISH and located immediately 3' of the immunoglobulin Ca2 region (J. Guikema, E.S. ,  and P.M.K. ,  unpublished results, May 2003). (C­
F) Segregation FISH analysis. Panels C and D both show a 1( 1 1  ; 14)(q1 3;q32) translocation indicated by the presence of segregated red 
and green signals. Panel E shows a monoallelic translocation break with loss of the derivative chromosome der1 1 ,  as indicated by the 
presence of a single red signal and the lack of a green signal. The colocalized signal (red/green) represents the 
normal allele. (F) Segregation FISH analysis showing increased copy numbers for the CCND1 locus indicated by the presence of 3 
colocalized signals. (G-I) Traditional interphase FISH analysis showing a trisomy (G), a polysomy (H), or a disomy (I) .  Original 
magnification X 630 for panels C-1 . 
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Figure 3. lmmunohistochemical analysis of cyclln D1 in 
48 MMs. (A) Representative case of MM group 1 showing 
strong, homogenous, cyclin D1 nuclear staining in the 
majority of tumor cells (> 80%, +++). lmmunoperoxidase 
staining; original magnification X 400. (B) A representative 
case with intermediate cyclin D1 protein expression (++). 
Nuclear positivity is detected in 20% to 50% of the tumor 
cells. Note that the intensity of the staining varies from cell to 
cell. lmmunoperoxidase staining; original magnification X 
400. (C) MM with nuclear positivity in 1 0% to 20% of tumor 
cells (+) representing low levels of protein expression. 
lmmunoperoxidase staining; original magnification X 640. (D) 
MM negative for cyclin D1 . Note the positivity in endothelial 
cells used as internal control. lmmunoperoxidase staining; 





















Figure 2. QRT-PCR analysis of cyclin D1 mRNA 
levels in MMs. QRT-PCR analysis of cyclin D1 was 
performed relative to the TBP housekeeping gene and 
results are depicted as ratio of cyclin D1 fTBP transcript 
numbers. Three distinct groups of MMs with respect to 
cyclin D1 levels can be identified. Note for comparison 
the cyclin D1 levels in a group of 23 cases of mantle cell 
lymphoma (MCL), the KMS12 MM cell line harboring a 
1(1 1 ;  14)(q1 3;q32) translocation, and the A431 squamous 
cell carcinoma cell line harboring a 1 1 q13  amplification. 
The horizontal line (Tables 1 -2). indicates the cutoff 
value for altered cyclin D1 expression as described in 
"Patients, materials, and methods." 
In this study, we investigated cyclin D1 deregulation in a large series of primary MM cases and 
analyzed a potential correlation with the expression of MYEOV, a proposed oncogene lying in close vicinity 
to the !(11; 14)(q13;q32) breakpoint region. 1 5  In addition, we investigated the influence of distinct 
translocation breakpoints and 11q13 copy numbers on the expression levels of cyclin D1 mRNA. 
We found that high levels of cyclin D1, both at the mRNA and the protein level, occurred exclusively 
in the presence of a !(11 ;14)(q13;q32) translocation. There are only a few thorough studies, so far, 27• 28 that 
correlate cyclin D1 mRNA levels with the presence of a t(11 ;14) translocation. This is largely due to technical 
obstacles, which have now been overcome by the availability of the real-time RT-PCR technique. 1 9 ·29 In this 
study, breakpoints in the 11q13 region were detected in 10 (21 %) of the 47 evaluable cases by our 
segregation F ISH afproach. While the incidence of !(11 ;14) found in our study is similar to that described in 
2 recent reports 1 2 ·3 (17% and 18%, respectively), we provide further evidence that the t(11 ;14) translocation 
is tightly connected with strong cyclin D1 overexpression, as shown by real-time RT-PCR (cyclin D1/TBP 
ratio > 95) and immunohistochemical analysis (+++; Table 2 and Figure 3A). 
The strikingly high levels of cyclin D1 mRNA in MM cases with !(11 ;14) are in contrast with our 
previous find ings in MCL, 1 9 where even though significantly elevated amounts of cyclin D1 mRNA were 
found in all samples (median cyclin D1/TBP ratio 31.9), they were well below the levels of most MM cases 
(Figure 2). The difference is most likely not due to the percentage of tumor cells since we enriched both MCL 
and MM by microdissection. There are 2 possible explanations for the h igher cyclin D1 expression in MM. 
One is the presence of different breakpoints in the lgH locus at 14q32. In MCL, the break occurs in the JH 
region resulting in a d i rect juxtaposition of CCDN1 to the 5'-Eµ enhancer and to the downstream 3'-Ea 
enhancers. The 14q32 breakpoint in MM is usually located in an lgH switch region resulting in the 
juxtaposition of CCND1 onto the 3'-Ea enhancers. Accordingly, our colocalization FISH analysis revealed 
that in the MM cases with a !(11 ;14) translocation, CCND1 expression is triggered by the 3'-Ea enhancers in 
at least 4 of the 7 analyzable cases. A second and more plausible explanation is that due to the higher levels 
of lgH transcription in MM, as opposed to MCL, the enhancers juxtaposed to the CCND1 gene will trigger 
h igher cyclin D1 transcription. 
The second oncogene investigated in this study, MYEOV, lies in close proximity to the CCND1 
locus. For the first time, we demonstrate that MYEOV overexpression occurs in some primary MM cases with 
the !(11 ;14) translocation, presumably as a result of a reciprocal translocation. 1 5  This scenario, where both 
MYEOV and CCND1 come under the separate control of different lgH enhancers seems to be a rare event, 
since high overexpression of MYEOV was found in only 2 of 10 translocated cases, paralleling the findings in 
MM cell lines. 1 5  Because the enhancers are joined to both CCND1 and MYEOV in myelomas with a 
breakpoint in switch y or switch a sites and since MYEOV expression is lost in most of these cases, our data 
strongly suggest that MMs do not favour MYEOV expression. 
An interesting finding is the definition of a subgroup of MM patients with significant correlation 
between low to intermediate cyclin D1 mRNA overexpression and chromosome 11 polysomy (13/14; P < 
.0001). The presence of stable, intermediate cyclin D1 mRNA levels in several follow-up biopsies of 2 
patients with chromosome 11 polysomy, taken up to 5 years apart, supports the notion that polysomy 11 is 
an essential factor related to cyclin D1 overexpression in these patients. Nevertheless, whether polysomy 11 
per se di rectly or ind irectly causes increased cyclin D1 expression in these cases remains to be clarified. The 
influence of the gene dosage effect th rough polysomy on cyclin D1 levels is difficult to explain since, until 
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influence of the gene dosage effect through polysomy on cycl in 01 levels is difficult to explain since, until 
now, it has been considered that cycl in  01 is normally not expressed in lymphoid cells. The frequenct of 
polysomy 1 1  in our study {29%) is in the range of what has been reported previously (1 7%-37%).27' 0-33 
However, the impact of this abnormality on cyclin 01 expression has not been thoroughly addressed. As 
shown in the present study, quantitative RT-PCR and not immunohistochemistry seems to be the method of 
choice to study this possible relationship: we found cyclin 01 staining in only 5 of 1 4  cases with polysomy 1 1 , 
whereas 1 3  of 1 4  cases showed overexpression as determined by RT-PCR {Table 2). Simi larly, in an 
immunohistochemical analysis by Pruneri et al, 30 only 2 of 1 3  cases with trisomy 1 1  showed cyclin 01 
overexpression. 
I n  a recent study, Soverin i  et al ,27 using real-time RT-PCR, showed that MM with trisomy 1 1  
significantly overexpressed cyclin 01 . However, in contrast to our data, where a clear distinction between 
patients harboring the t(1 1 ; 14) translocation and those with trisomy 1 1  was observed, they found some 
overlap between the 2 groups. This discrepancy most probably reflects differences in the methodology. 
Whereas Soverini et al 27 used unpurified mononuclear cell fractions, we analyzed pure tumor cell 
populations obtained by microdissection. 
There is sti l l  a smal l  proportion of MM cases with intermediate overexpression of cycl in 0 1 , lack of 
t{1 1 ; 1 4), and no apparent molecular abnormalities of CCND1 (2 of 1 5  cases, case 1 3  and 14) ,  leaving open 
the possibi l ity of additional deregulating mechanisms. 
One potential explanation, DNA amplification in the 1 1 q 1 3  region, frequently observed in solid 
tumors,34 was not found in any of our MM cases, as shown by FISH and quantitative PCR of cyclin 01 
genomic DNA (data not shown). Other mechanisms include transcriptional regulatory mechanisms or 
insertion of any immunoglobulin regulatory elements, such as the 3'enhancer, as described for the U266 MM 
cell l ine.35 In case of insertion, both breakpoints are located in the region flanked by cos6.7/cCl-1 1 -44 and 
cos6.31 /cosH1 .5, and, therefore, th is aberration will not be detected with the probe sets used in this study. 
In contrast to previous studies, 12•36 it is now accepted that MM with the t� 1 ; 1 4)(q 1 3;q32) 
translocation represents a unique subset of patients with a relatively favorable outcome.37• Future studies 
examining prognosis of MM should take into consideration that cycl in  01 can be up-regulated independently 
of a t(1 1 ; 1 4) translocation, as demonstrated in this study. 
Acknowledgments 
The authors thank Ulrike Reich, Jaqueline Muller, Daniela Angermeier, Elenore Samson, and Nadin 
Kink for their excellent technical assistance. 
References 
1 .  Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2 :1 75-1 87. 
2. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol. 2002;55:273-283. 
3. Chen C, Birshtein BK. Virtually identical enhancers containing a segment of homology to murine 3'IgH-E(hs1 ,2) lie downstream of 
human lg C alpha 1 and C alpha 2 genes. J lmmunol. 1 997; 1 59:1 3 1 0-1318. 
4. Mills FC, Harindranath N, Mitchell M, Max EE. Enhancer complexes located downstream of both human immunoglobulin C alpha 
genes. J Exp Med. 1997; 1 86:845-858. 
5. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001 ;20:561 1 -5622. 
6.  Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple 
myeloma. Blood. 1 998;92:1 743-1748. 
7. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral 
karyotyping. Blood. 1 998;92:4269-4278. 
8. Nishida K, Tamura A, Nakazawa N, et al. The lg heavy chain gene is frequently involved in chromosomal translocations in multiple 
myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1 997;90:526-534. 
9. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cylogenetic studies in 1 00 patients with multiple myeloma, 
plasma cell leukemia, or amyloidosis. Blood. 1 985;66:380-390. 
1 0. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet 
Cytogenet. 1 995;82:41-49. 
1 1 . Smadja NV, Fruchart C, lsnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. 
Leukemia. 1 998; 1 2:960-969. 
1 2. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(1 1 ; 1 4)(q1 3;q32) and t(4; 1 4)(p1 6;q32) in patients with 
plasma cell malignancies. Cancer Res. 1 998;58:5640-5645. 
1 3. Vaandrager JW, Schuuring E, Zwikstra E, et al. Direct visualization of dispersed 1 1 q1 3  chromosomal translocations in mantle cell 
lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood. 1 996;88: 1 1 77-1 1 82. 
1 4. Vaandrager JW, Kluin P, Schuuring E. The t(1 1 ; 14) (q13;q32) in multiple myeloma cell line KMS1 2  has its 1 1 q13 breakpoint 330 kb 
centromeric from the cyclin D1 gene. Blood. 1 997;89: 349-350. 
1 5. Janssen JW, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in 
a subset of multiple myeloma cell lines with 1(1 1 ; 14)(q1 3; q32). Blood. 2000;95:2691-2698. 
1 6. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non­
Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol. 2002; 1 98:1 63-1 70. 
1 7. Barti R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple 
myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol. 1 987;87:342-355. 
1 8. Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in 
multiple myeloma: Stat3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol. 
2003; 1 62:1 449-1461 .  
1 9. Specht K ,  Kremer M,  Muller U ,  e t  al. Identification of  cyclin D1 mRNA overexpression in  B-cell neoplasias by  real-time reverse 
transcription-PCR of microdissected paraffin sections. Clin Cancer Res. 2002;8:2902-291 1 .  
75 
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal 
Biochem. 1987; 1 62:156-1 59. 
21 .  Coignet LJ, Schuuring E, Kibbelaar RE, et al. Detection of 1 1 q13  rearrangements in hematologic neoplasias by double-color 
fiuorescence in situ hybridization. Blood. 1 996;87: 1 512-1 519. 
22. Matsuda F, Shin EK, Hirabayashi Y, et al. Organization of variable region segments of the human immunoglobulin heavy chain: 
duplication of the D5 cluster within the locus and interchromosomal translocation of variable region segments. EMBO 
J. 1990;9:2501 -2506. 
23. Vaandrager JW, Schuuring E, Kluin-Nelemans HC, Dyer MJ, Raap AK, Kluin PM. DNA fiber fluorescence in situ hybridization 
analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center cell lymphoma. 
Blood. 1 998;92:2871-2878. 
24. de Boer CJ, Vaandrager JW, van Krieken JH, Holmes Z, Kluin PM, Schuuring E. Visualization of mono-allelic chromosomal 
aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene. 
1997;15 :1 599-1 603. 
25. Werner M, Mattis A, Aubele M, et al. 20q1 3.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal 
carcinoma of the breast. Virchows Arch. 1 999;435:469-472. 
26. Hopman AH, Ramaekers FC, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid 
bladder tumors. Histochemistry. 1 988;89:307-31 6. 
27. Soverini S, Cava M, Cellini C, et al. Cyclin D1overexpression is a favorable prognostic variable for newly diagnosed multiple 
myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 
2003;102:1588-1594. 
28. Hui P, Howe JG, Crouch J,  et al. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH 
and immunohistochemistry. Leuk Lymphoma. 2003;44:1 385- 1 394. 
29. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur 
J Haematol. 2001 ;67:296-301 .  
30. Pruneri G, Fabris S ,  Baldini L, e t  al. lmmunohistochemical analysis o f  cyclin D 1  shows deregulated expression i n  multiple myeloma 
with the t(1 1 ; 14). Am J Pathol. 2000;1 56:1 505-1 513. 
31 .  Tabemero D, San Miguel JF, Garcia-Sanz M, et al. Incidence of chromosome numerical changes in multiple myeloma: fluorescence 
in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol. 1 996; 149: 1 53-1 61 .  
32. Perez-Simon JA, Garcia-Sanz R, Tabemero MD, e t  al. Prognostic value of  numerical chromosome aberrations in  multiple myeloma: 
a FISH analysis of 15 different chromosomes. Blood. 1998;91 :  3366-3371.  
33.  Nilsson T,  Hoglund M, Lenhoff S, et al .  A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically 
abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age and sex-related differences. 
Br J Haematol. 2003; 1 20:960-969. 
34. Schuuring E. The involvement of the chromosome 1 1 q1 3  region in human malignancies: cyclin D1 and EMS1 are two new 
candidate oncogenes -a review. Gene. 1 995; 1 59:83-96. 
35. Gabrea A, Bergsagel PL, Chesi M, Shau Y, Kuehl WM. Insertion of excised lgH switch sequences causes overexpression of cyclin 
D1 in a myeloma tumor cell. Mal Cell. 1 999;3: 1 1 9-123. 
36. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(1 1 ; 14)(q13;q32); evidence for a biologically defined unique subset of 
patients. Blood. 2002;99:3735-3741 .  
37. Fonseca R ,  Debes-Marun CS, Picken EB, et al. The recurrent lgH translocations are highly associated with non-hyperdiploid variant 
multiple myeloma. Blood. 2003; 1 02:2562-2567. 
38. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in 
patients receiving intensive chemotherapy. Blood. 2002; 100: 1 579- 1583. 
76 
Chapter 9 
Summary and general discussion 
Recent advances in our understanding of NHL biology as wel l  as technical developments promote 
an expanding application of molecular techniques including FISH in research and clinical diagnostics. 
However, the application is hindered by the fact that most clin ical materials are only available as formalin 
fixed and paraffin embedded tissue blocks in which the DNA is relatively degraded and heavily crossl inked. 
In consequence, most efforts were put in the (successful)  development of PCR assays that can detect DNA 
sequence abnormalities in small DNA fragments that can be isolated from these tissue b locks. Another 
possibil ity is FISH but this appl ication was also hampered by the cross l inking and the masking effect of 
proteins on the DNA target. We and others 1 •2 showed that introduction of a tissue pre-treatment step in the 
conventional FISH protocols is an effective solution for this technical problem. As a result multi- Yac 
constructs as wel l  as small locus specific probes (PACs and cosmids) could be successful ly applied for 
detection of chromosomal translocations in paraffin tissue sections (Chapter 2 and 3). All our  subsequent 
FISH studies included in this thesis (Chapters 2, 3, 4, 5, 6 and 8) as well as the published reports by other 
groups 1 •2 indicate that th is approach is appl icable to most of the fixed and routinely processed paraffin tumor 
samples, .  
In  Chapters 1 ,  2 and 3 we point out some intrinsic problems in the evaluation of FISH results in 
tissue sections, mostly related to the cutting artifacts and overlapping of cell nuclei. In addition, we suggested 
several algorithms for scoring of FISH signals, which have been tested on routine tissue sections (Chapter 2 
and 3). Up to now, most investigators tend to adopt the scoring procedures from the cytogenetic laboratories. 
However, the performance of the FISH on routine tissue sections varies depending on the thickness of the 
sections, size of the cel l  nuclei, as wel l as the design of the FISH assay (segregation versus co-local ization 
FISH). I n  addition, the malignant lymphoma clone often is only focally represented in the section and, in  
addition, i i  is often admixed with varying numbers of non-malignant cel ls that harbor normal FISH signal 
patterns. Therefore, various aspects of tissue sectioning and histopathological composition of the sample 
should be taken in consideration when employing FISH on paraffin tissue sections. 
Methodologically, the FISH technique is restricted to a targeted detection of an a l ready known 
abnormality (numerical aberration, translocation or deletion) and the availabil ity of appropriate probes also 
represents an obvious l imitation. However, the current human genome sequencing projects as wel l  as the 
availabil ity of very wel l  characterized large inserts (BAC and PAC) by Internet resources, now enable the 
generation of an almost indefinite number of FISH probes for the identification of genetic abnormal ities in 
lymphoid neoplasias. In parallel, the number of commercially available FISH probes is also steadi ly rising. 
Interestingly, this expanding number of appl ications of the FISH technique in the routine pathology 
setting confronts the pathologists with new responsibil ities that demand additional knowledge of molecular 
cytogenetics and collaboration with molecular biology experts. The individual performance of each FISH 
assay (commercially available or home made) needs to be carefully tested in the pathology laboratory before 
application in clinical diagnostics. In this l ine, in Chapter 4 we present the analysis of a newly generated 
FISH assay for the identification of chromosomal breakpoints in the 8q24 region in and nearby M YC gene. 
This study comprised the detection of MYC translocation breakpoints in a large series of lymphomas and cell 
l ines with a cytogenetically proven 8q24 breakpoint and the subsequent testing of Burkitt lymphomas from 
three different geographic regions (Equatorial Africa, South America and Europe), in context to morphology, 
immunophenotype and EBV status. 
Another important question is how to incorporate the generated molecular genetic data in the 
contemporary diagnostic setting: ( 1 ) are they specific as wel l  as sensitive? (2) are they defining criteria for 
classification?, and (3) for which disease entities?, or (4) do they represent only additional information that 
should be interpreted in the context of the other data available? The wide application of methods l ike FISH in 
cl inical pathology will certainly generate a large number of molecular data that should be closely correlated to 
the morphology, immunophenotype and cl in ical outcome. In consequence, the high scale application of such 
assays might probably revise our understanding or at the end even change our definition of certain 
disorders. 
With respect to specificity of individual markers, ii is already known that certain markers may be 
h ighly characteristic for a certain entity but not always specific. For instance the translocation t(14 ; 1 8) is 
detected in approximately 85% of al l  follicular lymphomas, but also in 1 5-20% of the de novo DLBCL.3'4 
The di lemma how to use these new markers is extensively discussed in Chapter 5, which encloses 
our data on a series of adult 'grey zone' lymphomas encompassing a spectrum of histomorphologies 
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between Burkitt lymphoma and diffuse large B-cell lymphoma, a notoriously difficult area in 
hematopathology. Obviously, the conventionally used panel of immunohistochemical markers (Ki67, bcl2 and 
CD10) helped the morphological diagnosis but was not able to solve the diagnostic dilemma in this field. In 
our study we made an attempt to improve further the histopathological distinction by introduction of FISH for 
MYC, BCL2 and BCL6 breakpoints. All data were compared to those obtained from a set of 'typical' pediatric 
Burkitt lymphomas. In keeping with the WHO recommendations 5 and our data in Chapter 4, the results 
indicate that due to its high sensitivity, FISH for detection of MYC breakpoints (or an equally sensitive 
method) should indeed be used as a prerequisite to the diagnosis of Burkitt lymphoma. However, as 
expected from literature data 6'7'8, this marker alone had a relatively low specificity and was not able to 
delineate any specific subset within this group of grey-zone lymphomas. Only some improvement in the 
recognition of a certain clinicopathologic entity was obtained by the combination with the 
immunohistochemical markers Ki-67, CD1 O and bcl2. FISH for the detection of BCL2 and BCL6 breakpoints 
appeared less helpful, since breakpoints in these genes were less frequent than anticipated. However some 
cases that carry double translocation were identified and they mostly showed an abnormal phenotype. 
Therefore, we concluded that the combination of immunohistochemistry with FISH for MYC breakpoint 
detection certainly improved the diagnostic process, however, even this rather elaborate set of markers is 
insufficient to delineate any solid entity of adult Burkitt lymphoma. Likely, novel data obtained from micro­
array gene expression studies and perhaps also genome wide genetic studies, should be awaited before any 
final conclusions can be drawn. 
Certainly, the presence of a MYC breakpoint as detected in 100% of the pediatric and 57% of the 
grey zone lymphomas as described in chapter 5, confers a distinct morphology and immunophenotype. 
However, in the series of grey zone lymphomas studied by us a MYC breakpoint alone did not recognize 
further any distinct lymphoma subgroup. One explanation is that MYC might be deregulated in far more 
cases than identified by us since other genetic mechanisms (e.g. mutations in essential regulatory sites of 
MYC 9) or epigenetic factors (demethylation and histone acetylation) may result in the same functional 
endpoint. On the other hand, this possibility is implausible since more than 95% of all regular BL as studied 
in chapter 4 and all 10 pediatric BL studied in chapter 5 carried an easily detectable MYC breakpoint. 
Preliminary results from array derived gene expression data indicate that BL is characterized by a 
combination of gene expression patterns, each involving of large number of different genes (EJ Boerma, L 
Staudt, NCI, NIH, Bethesda). Whereas MYC represents an important key regulator of various aspects of the 
cell cycle, and consequently in the control of numerous recognized downstream genes, this MYC associated 
gene expression pattern is not sufficient to characterize BL. For instance, in contrast to DLBCL with a MYC 
breakpoint and overexpression of MYC-related genes, BL show downregulation of NF-kB and many NF-kB 
related genes. Therefore, it will be important to define which other key regulators and concomitant gene 
expression patterns besides MYC and the numerous MYC related genes are characteristic for BL. 
Eight cases from these series (3 BL and 5 DLBC, Chapter 5) carried a combination of MYC and 
BCL2 or BCL6 breakpoints. In tumors with a double translocation involving BCL2 and MYC, it has been 
proven that the translocation involving BCL2 is the first hit (generated during VDJ recombination in a 
precursor B-cell), and the alteration affecting MYC - the second one (mostly generated during lgH 
hypermutation or class switch recombination).6 This suggests that MYC alteration and deregulation confers a 
certain (immuno-) morphology, even if it occurs as a secondary hit. Most tumors with a concomitant MYC 
and BCL2 breakpoint represent a very aggressive disease with a poor clinical outcome which is in 
agreement with the fact that most tumors develop through transformation of a clinically overt follicular 
lymphoma.6•7 Since according to the current view, BL is a primary disease,5•1 0  probably such cases should 
not be classified as BL but separated. 
Lymphomas with a combination of a MYC and BCL6 breakpoint have been reported occasionally, 8' 
11 however, the clinical and biological significance of these alterations has not been established. It is not 
clear which rearrangement occurs first and whether this combination confers a synergistic growth advantage 
on the lymphoma cells. One salient feature of our two BL cases with this dual translocation was the 
overexpression of the bcl2 protein, a feature also seen in cases with a double translocation involving MYC 
and BCL-2 (Chapter 5). Although the selected three genes (MYC, BCL2 and BCL6) are the most commonly 
involved in the pathogenesis of these lymphomas, they by far do not represent the molecular profile of the 
entities. Cytogenetic studies on BL suggest that the 1(8;14) or variant translocations are the sole abnormality 
in almost half of the pediatric BL cases and that adult BL cases have more complex karyotypes with many 
additional alterations (http://cgap.nci.nih.gov/Chromosomes/CytSearchForm). This raises the question 
whether the category of adult BL might contain a proportion of transformed tumors not recognized by the 
more conventional means such as morphology, immunophenotype and the MYC breakpoint analysis. 
Certainly, more genome-wide genetic approaches such as classical karyotyping, CGH and array-CGH in 
combination with gene expression studies are needed to establish the biological relationship between BL 
and DLBCL. 
In chapter 7, we gave a brief introduction to myeloma. Our study on a large series of multiple 
myelomas, presented in chapter 8, in keeping with published data 12• 1 3' 14, indicate that the 11q13 breakpoint 
is associated with high cyclin D1 RNA and protein expression. However, we also identified a subgroup of MM 
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that lack an 11q13 breakpoint and still steadily express cyclin D1 RNA at medium levels. Correspondingly, 
using immunohistochemistry, these samples were labeled for cyclin D1 protein in varying percentages of 
tumor cells and with heterogeneous intensity. Our data indicate an association with a trisomy 11 in these MM 
cases with an intermediate expression. The insertion of lgH enhancer sequences into the 11q13 locus has 
been reported to upregulate cyclin D1 expression in a MM cell line.15  Although we did not exclude a possible 
insertion in our MM series, this activation mechanism seems very unlikely. The high levels of cyclin D1 RNA 
in all cases with 11q13/cyclin D1 breakpoints {e.g. cyclin D1 deregulation upon the juxtaposition to lgH 
enhancer) distinguish them sharply from the other samples. 
In consequence, juxtaposition of enhancer sequences should trigger a similar very high level of 
cyclin D1 RNA expression, but this is not seen in our MM patients. Solely a gene dosage effect by trisomy 11 
is also an unlikely explanation since normal B cells and mature plasma cells entirely lack cyclin D1 
expression. Alternatively epigenetic factors such as demethylation or histone acetylation might play a role as 
well. In cases without any breakpoint or trisomy 11 such a yet undefined epigenetic mechanism might be 
responsible for the basic cyclin D1 upregulation in some cases of MM, and this basic upregulation might be 
incremented to medium levels in MM cases with trisomy 11. In spite of all recent research, it is still not clear 
how cyclin D1 contributes to the pathogenesis of MM, however, apparently certain levels of cyclin D1 are 
necessary for the maintenance of the neoplastic clone.1 6 In addition, it should be noted that MM patients with 
an 11q13 translocation breakpoint and concomitant cyclin D1 deregulation are currently considered to 
represent a biologically and clinically defined group.14•1 6  The relevance of the intermediately elevated cyclin 
D1 RNA levels in the absence of an 11 q 13 breakpoint remains to be identified. 
In keeping with previous reports on MM cell lines, 1 7 our study showed that in a subset of MM 
patients the t{11;14) translocation results in concurrent deregulation of MYEOV, another 11q13 oncogene 
{Chapter 8). In contrast to cyclin D1, the expression levels of MYEOV were not strictly linked to the 11q13 
breakpoint status, however, the lack of sufficient information on MYEOV expression in normal and reactive 
hematopoietic tissues limits the significance of our data. In addition, similar to some other MM translocations 
with activation of two different genes, in a subset of MM cases the der14 with the translocated MYEOV gene 
is lost {Chapter 8). This suggests that deregulation of cyclin D1 and not MYEOV is the critical oncogenic 
event triggered by the 1(11;14){q13;q32) translocation in MM patients. 
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De recente ontwikkelingen in het onderzoek naar de biologie van Non Hodgkin lymfomen (NHL) en 
de gelijktijdige technische ontwikkelingen hebben de toepassing van moleculaire technieken zeals 
fluorescente in situ hybridisatie (FISH) in het wetenschappelijk onderzoek en de klinische diagnostiek in een 
stroomversnelling gebracht. Een van de beperkingen is echter dat heel veel diagnostisch tumor materiaal in 
formaline gefixeerd wordt waardoor het DNA a.a. "gecross-linked" en afgebroken wordt en niet meer 
toegankelijk is voor een aantal van deze technieken. Om dit te omzeilen werd in eerste instantie veel 
aandacht besteed aan de ontwikkeling van op paraffine materiaal toepasbare PCR technieken (waarbij 
kleine stukken DNA vermenigvuldigd en zichtbaar gemaakt kunnen warden). Het alternatief voor een aantal 
vraagstellingen is FISH, maar oak deze techniek heeft te leiden ender de cross-linking van DNA en 
maskering door aanwezige eiwitten. Wij en anderen hebben speciale voorbehandelingsmethodes ontwikkeld 
die het mogelijk maken deze techniek op routine paraffine coupes van formaline gefixeerd materiaal toe te 
passen. Met deze methode konden we heel grate (gist-artificiele chromosomen - YAC) tot heel kleine gen­
specifieke (cosmides) probes gebruiken. De laatste probes zijn uitermate geschikt voor de detectie van 
specifieke chromosomale translocaties (hoofdstuk 2 en 3). In de opeenvolgende hoofdstukken hebben we 
steeds van deze voorbehandelingsmethode en FISH technieken gebruik gemaakt. 
Net als PCR, en in tegenstelling tot klassieke cytogenetica heeft FISH een beperkte toepassing voor 
alleen van tevoren gedefinieerde DNA targets. Echter de nu aanwezige en beschikbare kennis ten aanzien 
van vrijwel de complete DNA structuur en volgorde van baseparen ("het humane genoom"), en de enorme 
hoeveelheid inmiddels (deels commercieel) beschikbare DNA probes heeft de toepassing van FISH sterk 
vereenvoudigd. 
In de hoofdstukken 1 ,  2 en 3 behandelden we de problemen die verbonden zijn met de beoordeling 
van FISH signalen in weefselcoupes waarbij het intrinsieke probleem bestaat dat celkernen, en daarmee oak 
de FISH signalen in de kern, door de aansnijding incompleet zijn. De tot nu toe veel gebruikte 
scoringsmethodes uit de klassieke cytogenetica zijn door de aansnijdingsartefacten in coupes niet adequaat. 
Daarbij hebben we verschillende algoritmes gevonden die geschikt zijn om FISH signalen te kunnen 
kwantificeren en interpreteren (hoofdstuk 2 en 3). 
De vlucht van de moleculaire technieken zeals FISH confronteert de klinisch patholoog met een 
nieuwe verantwoordelijkheid: hoe dient deze de technieken toe te passen en te interpreteren, en welke 
kwaliteitseisen moeten aan de toepassing ervan warden verbonden? In hoofdstuk 4 geven we een 
voorbeeld hoe wij de door ans ontwikkelde FISH test voor de detectie van breuken op chromosoom 8q24 ter 
plaatse van het MYC gen hebben gevalideerd. Dit breukpunt komt met name voor in het Burkitt lymfoom 
(>95% van alle tumoren), een zeldzame maar zeer agressieve vorm van NHL. De aanwezigheid van de 
chromosomale breuk is een voorwaarde om de diagnose te kunnen stellen. Patienten met deze vorm van 
NHL dienen indien oak maar enigszins mogelijk met speciale agressieve chemotherapie schema's 
behandeld te warden. De validatie bestond uit een studie waarin we eerst de technische sensitiviteit en 
specificiteit in een grate serie van tumor samples met bewezen chromosomale 8q24 afwijking alsmede 
controle samples hebben bepaald. Vervolgende besloten wij de performance in de dagelijkse praktijk te 
testen in een grate serie klinische samples waaronder Burkitt lymfomen uit equatoriaal Afrika en Zuid­
Amerika (twee gebieden waar dit lymfoom endemisch voorkomt) en Nederland. Uit deze analyse bleek dat 
de FISH test een hoge specificiteit en sensitiviteit had. 
Daarna resteerde de vraag in hoeverre de FISH test ook behulpzaam is in de dagelijkse praktijk van 
de patholoog, met name in hoeverre deze behulpzaam is in de differentiaal diagnostiek tussen verschillende 
NHL subtypen, en in hoeverre de resultaten op zichzelf staan of alleen gebruikt kunnen warden in 
combinatie met andere aanvullende technieken zeals immuunhistochemie. lnmiddels weten we voor veel 
van dergelijke markers dat een bepaalde afwijking weliswaar kenmerkend, maar niet specifiek hoeft te zijn 
voor een bepaald tumor type. 
Het dilemma hoe deze markers in de afwegingen van de patholoog kunnen warden ge"integreerd, 
wordt in hoofdstuk 5 besproken. In dit hoofdstuk hebben we een groat aantal grijze-zone lymfomen 
onderzocht, dwz lymfomen die lijken op zowel het Burkitt lymfoom als diffuus grootcellige B-cel lymfoom. Dit 
probleem doet zich vooral voor bij volwassen patienten en vormt een notoir dilemma voor oak zeer ervaren 
hematopathologen. Conventionele immuunhistochemie (analyse van het Ki-67 eiwit als maat voor 
proliferatie, het anti-apoptotisch bcl2 eiwit het eiwit CD10, een eiwit met grotendeels onbekende functie) is 
behulpzaam maar lost het differentiaal-diagnostisch probleem tussen beide typen NHL niet op. In hoofdstuk 
5 probeerden wij het onderscheid te verbeteren door aan deze reeds bekende eiwit markers enkele 
genetische markers die met FISH bepaald kunnen warden, toe te voegen. Dat waren de detectie van 
chromosomale breukpunten in 8q24/MYC, 3q27/BCL6 en 18q21/BCL2. In een klassiek Burkitt lymfoom 
verwacht men in 95% van alle gevallen een breuk in 8q24/MYC maar niet in de andere gebieden. 
Daarentegen komen breuken in de andere gebieden vaak (respectievelijk 35% en 20%) voor in de klassieke 
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diffuus grootcellige B-cel lymfomen. Alie gegevens die we verkregen van een serie van 74 grijze-zone 
lymfomen werden vergeleken met die van een serie van klassieke Burkitt lymfomen bij kinderen. Toepassing 
van alleen de FISH voor 8q24/MYC bleek absoluut onvoldoende toevoegende warde te hebben: terwijl de 
sensitiviteit hoog was, was de specificiteit laar: ongeveer eenderde van de grijze-zone lymfomen die wat 
betreft de meer conventionele markers niet voldeden aan de criteria van een Burkitt lymfoom bezaten toch 
een 8q24/MYC breukpunt. Uit deze studie bleek dat de gecombineerde toepassing van immuunhistochemie 
en FISH voor leifst alle drie de genetische afwijkingen vooralsnog absoluut noodzakelijk is om de diagnose 
Burkitt lymfoom met enige zekerheid te kunnen stellen, maar dat oak deze gecombineerde aanpak niet 
optimaal is. Op dit moment zijn dan oak diverse onderzoeksgroepen bezig om de genexpressie patronen en 
genetische afwijkingen van deze lymfomen veel uitgebreider in kaart te brengen. Dit gebeurt o.a. met 
technieken als gen expressie arrays en DNA 'comparative genomic hybridization' (CGH) arrays. 
Waarschijnlijk moeten we eerst de resultaten hiervan afwachten voordat we dit diagnostische probleem 
kunnen oplossen. 
Het MYC gen op chromosoom 8q24, is een uitermate belangrijk gen in de regulatie van o.a. de eel 
cyclus van delende cellen. Activatie van MYC leidt tot de activatie van duizenden andere genen. Een 
interessante wetenschappelijke vraag is daarom in hoeverre de activatie van MYC betrokken is in het 
fenotype en gedrag van Burkitt lymfoom cellen en ook de lymfoom cellen van deze grijze-zone lymfomen. 
Acht lymfomen uit de serie bevatten meerdere translocaties. Uit de literatuur was reeds bekend dat 
de combinatie van een 8q24/MYC en 18q21/8CL2 breukpunt in een tumor geassocieerd is met een Burkitt 
lymfoom morfologie; tumoren met deze afwijkingen gedragen zich vaak zeer agressief en de meeste van 
deze patienten overlijden door progressie van de ziekte. Ook enkele tumoren met een gecombineerde 
8q24/MYC en 3q27/BCL6 breuk zijn wel beschreven, maar de klinische consequenties hiervan zijn tot op 
heden onbekend. 
In hoofdstuk 6 warden 4 Burkitt lymfomen met een opmerkelijke morfologie beschreven. Alie vier 
tumoren werden gekarakteriseerd door de aanwezigheid van niet necrotiserende granulomen tussen de 
tumorcellen. Bij enkele patienten hadden deze granulomen de patholoog misleid wat betreft de diagnose 
Burkitt lymfoom. Wij vonden dat alle tumoren naast het klassiek fenotype en de chromosomale breuk 
8q24/MYC oak het Epstein Barr Virus (EBV) bevatten. Dit werd aangetoond met een andere in situ 
hybridisatie techniek, namelijk ISH voor de EBER RNA moleculen. In dit hoofdstuk speculeerden wij oak 
over de pathogenese van deze granulomen. 
In de hoofdstukken 7 en 8 bestudeerden wij de aanwezigheid en betekenis van een andere 
chromosomale breuk, namelijk die in 11q13/CCND1 bij de hematologische maligniteit multipel myeloom 
(ziekte van Kahler). Dit betreft een tumor van rijpe plasmacellen in het beenmerg en de batten. In deze tumor 
komen diverse chromosomale translocaties voor die met elkaar gemeen hebben dat een breukpunt in de 
constante delen van het immunoglobuline gen complex op chromosoom 14 ligt. Een van de partners is 
cycline 01 op chromosoom 11q13, ook betrokken bij >95% van het mantelcel lymfoom. Dit leidt tot de 
translocatie t(11 ;14)(q13;q32). In hoofdstuk 7 word! een overzicht gegeven van deze chromosomale 
afwijkingen in multipel myeloom. In hoofdstuk 8 onderzochten wij de relatie tussen deze chromosomale 
translocatie en overexpressie van cycline D1 in een grate serie multipel myelomen. FISH, kwantitatieve RT­
PCR en immunohistochemie experimenten lieten zien dat de translocatie gepaard gaat met een hoge cycline 
D1 RNA en eiwit expressie in de tumorcellen. Daarnaast was er een groep myelomen met matig hoge 
expressie zonder translocatie maar met een trisomie van chromosoom 11. Mogelijk draagt "gene-dosage" bij 
aan de overexpressie in deze myelomen. Daamaast was er een categorie myelomen met lage of geen 
expressie. Deze toonden geen translocatie of trisomie 11. Mogelijk spelen epigenetische factoren zeals 
demethylatie of acetylatie een rol bij de cycline D1 expressie in deze myelomen zonder genetische 
afwijkingen. Myelomen met een translocatie t(11 ;14) vertegenwoordigen waarschijnlijk een aparte groep; 
patienten met deze myelomen hebben een wat betere prognose dan andere myeloom patienten. 
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Abbreviations 
ABC activated B cells 
ALK anaplastic large cell kinase 
ALL acute lymphoblastic 
leukemia 
BAC bacterial artificial 
chromosome 
BCR B cell receptor 
BL Burkitt lymphoma 
aBL atypical Burkitt lymphoma 
eBL endemic Burkitt lymphoma 
sBL sporadic Burkitt lymphoma 
BLL Burkitt-like lymphoma 
CGH comparative genomic 
hybridization 
CLL chronic lymphocytic 
leukemia 
CSR class switch recombination 
DLBCL diffuse large cell lymphoma 
EBV Epstein Barr virus 
IG immunoglobulin 




interphase cytogenetics as 
a tool for the investigation of 
neoplasms 
FISH fluorescence in situ 
hybridization 
FL follicular lymphoma 
GC germinal center 
GCB germinal center B cell 
HIV human immunodeficiency 
virus 
HCL hairy cell leukemia 
HMCL human myeloma cell lines 
IGH immunoglobulin heavy 
chain 
IGL immunoglobulin light chain 
M-FISH multicolor fluorescence in 
situ hybridization 
MALT mucosa associated 
lymphoid tissue 
MCL mantle cell lymphoma 
MGUS monoclonal gammopathy of 
undetermined significance 
MM multiple myeloma 
MZL marginal zone lymphoma 
NHL non Hodgkin's lymphoma 
NF-KB nuclear factor -Kappa B 
PAC P1 artificial chromosome 
PCR polymerase chain reaction 
PC plasma cell 
PFGE pulsed-field gel 
electrophoresis 
SKY spectral karyotyping 
SMM smoldering multiple 
myeloma 
WHO World Health Organization 
YAC yeast artificial chromosome 
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